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Abstract 
The eukaryotic translation initiation factor eIF4E is deregulated in many human 
cancers, and its over-expression in cells leads to malignant transformation. 
Oncogenic properties of eIF4E are directly linked to its ability to bind 7-methyl 
guanosine triphosphate (the cap structure) of the 5'mRNA, and initiate translation by 
recruitment of the eIF4F complex and ribosomal apparatus. Antisense mediated 
reduction of eJF4E in transformed cell lines reverted their transformed and 
tumourigenic phenotypes. Over-expression of eIF4E leads to enhanced translation of 
mRNAs with 5'UTR regions containing large amounts of secondary structure that 
encode proto-oncogenes, such as c-rnyc, cyclin Dl, orthinine decarboxylase. The 
cap structure found at the 5' end of mRNA therefore presents itself as a target for 
small molecule inhibitor development targeting eIF4E. 
In this work high resolution crystals were produced of full length human 
eIF4E complexed to m7GTP and the 4E-BPI motif peptide. The interactions of 
eIF4E with the cap structure were also analysed by mass spectrometry, revealing a 
requirement of eIF4E for a guaninie monophosphates derivative with a positive 
delocalised charge on the rn7G ring. The mass spectrometry technique, developed 
for the analysis of eTF4E's interaction with the cap-structure, was then applied to 
screening small molecule cap analogues. Potential inhibitors for screening were 
either isolated using virtual screening techniques or synthesised to produce a series 
of cap mimicking molecules containing a positive delocalised charge. Mass 
spectrometry identified a series of N7 substituted GMP derivatives that bound to 
eIF4E in the gas-phase. These compounds were then used in co-crystallisation trials 
with full length human efF4E complexed with a 4E-BPI motif peptide. The co- 
II 
crystal structures of eIF4E with N7 benzyl derivatives revealed a flipping of the 
tryptophan 102 to accommodate the bulky N7 group and the expulsion of two 
structured waters. It also showed that if a para-fluoro group is located on the benzyl 
modification, then interactions also occur with a structured water and an arginine, 
which explains its increased binding to eIF4E. The flipping of the tryptophan reveals 
the inherent flexibility in the cap-binding site. The structural information, revealing 
that the cap-binding site of eIF4E undergoes a conformational change in binding N7 
derivatives of GMP with large bulky groups, provides us with valuable insight that 
can be used in future drug design efforts. The mass spectrometry assay coupled with 
a clear structure activity relationship, developed on the basis of various "cap-like" 
ligands studied in the work, gives an excellent starting point for the development of 
cap-analogue mimics for anti-cancer therapeutics. 
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Chapter 1: eIF4E a potential therapeutic target for the treatment of cancer. 
1.0 Initiation factor 4E (eIF4E). 
Control of mRNA translation plays a critical role in cell growth, proliferation and 
differentiation. In eukaryotes, most mRNAs are translated in a cap-dependent manner. 
The cap structure m7GpppN (where N is any nucleotide) is found at the 5' terminus of 
all cellular eukaryotic mRNAs (except those in organdies)'. The 7 -in ethyl guanine is 
linked by a 5'-5' tn-phosphate bridge to the first transcribed residue (see figure 1). This 
group known as the 'cap', functions in splicing, polyadenylation, nuclear export, 
stability and recognition of the mRNA for translation 2 . A key player in the regulation of 
translation is the mRNA 5' cap-binding protein eIF4E, which is the rate-limiting 
member of the eIF4F complex 3 . This complex consists of eIF4E, an ATP-dependant 
helicase, and a large scaffolding protein, eIF4G, which acts as a docking site for other 
proteins4 . eIF4E specifically interacts with the cap structure'. 
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An alternative mechanism of translation initiation is cap- and eIF4E independent and 
requires an internal RNA structure termed an Internal Ribosome Entry Site (IRES) to 
which the 40S subunit directly binds. This mode was first identified in picornaviruses 5 '6 , 
but subsequent studies revealed the presence of IRES-dependent cellular translation in 
some mRNA transcripts during mitosis and apoptosis' 79 . 
- 4E-BP 
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Figure 2: (A) Diagrammatic representation of protein interactions in the 48S preinitiation complex. 
Interactions between components of the initiation complex are illustrated. Notably, eIF4E is the only 
factor that specifically recognises the cap structure of mRNA, and so has a crucial role in recruitment of 
the 40S subunit via its interactions with eIF4G, and indirectly via elF3. eIF4A and eIF4B. PABP (not 
shown) interacts with eIF4G and the polyA tail of eukaryotic mRNA (as shown in 213) and causes the 
mRNA to circularise. 
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Protein synthesis is usually the most expensive process in the cell and translation rates 
are tightly regulated'°" . In mammals, regulation mainly operates at a level of initiation, 
rather than elongation or termination. The first step in the initiation process is the 
binding of the small ribosomal subunit (40s) to the mRNA. Since this is the rate- 
11,1 
limiting step in initiation, it is often the target of regulation 2 . In prokaryotes, base 
pairing between rRNA and the 'Shine-Delgarno' sequence preceding the initiation 
codon of each open reading frame plays a dominant role in the ribosome-binding 
step' 3 " 4 . In eukaryotes the binding step is much more complex. The model (as shown 
in figure 2) that best represents this binding step shows that the multi-subunit eukaryotic 
initiation factor 3 (eIF3), which is associated with the 40S ribosomal unit, also binds to 
the mRNA associated eIF4G protein and thereby links the ribosome to the mRNA' 3 " 4 . 
The initiation process consists of three steps: (1) formation of the 43S complex, 
composed of a 40S ribosomal subunit and the initiation factors eIF-2, elF-3, Met-tRNA 
and mRNA, (2) formation of the 48S complex containing mRNA, which is mediated by 
the eIF4 group of factors; and (3) joining of the 60S subunit to form the complete 80S 
13,14 complex 	. In most circumstances, the second step is rate limiting and hence, a major 
point of regulation. This step also discriminates between the mRNAs that are to be 
recruited by the ribosome and remain in the untranslated pool of mRNAs' 2 . This 
process is mediated by the eIF4 group of factors, for which eIF4E is rate limiting 3 . 
Evidence also showing that the role of eIF4E is rate limiting was obtained 
experimentally with the application of antisense RNA technology. Antisense RNA- 
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mediated reduction in eIF4E expression suppressed protein synthesis rates and the 
spectrum of expressed proteins in direct proportion to the level of eIF4E' 5 
In most cases, eIF4G does not only bind directly to mRNA, it also associates with the 
cap structure at the 5' end and the poly(A) tail at the 3' end". Initiation factor eIF4G 
binds the cap and the poly(A) tail indirectly through its interaction with the cap-binding 
protein eIF4E and the poly(A) binding protein Pabip, respectively. The simultaneous 
interaction of these two proteins apart from placing eIF4G on the mRNA also leads to 
the circularisation of the rnRNA 17 . 
Translation initiation and cell viability depends upon eIF4G binding to eIF4E at the 5' 
end of the mRNA. Initiation factor eIF4E binds the methylated guanosine cap of mRNA 
with sub-micromolar ability, and binds non-methylated precursors at least five-fold less 
efficiently". Thus, the eIF4G-eIF4E complex binds to the 5' end of mRNA because 
eIF4E specifically recognises the cap. The association of eIF4G with eIF4E increases 
eIF4E affinity for the cap ten-fold' 9  This allosteric regulation provides a selective 
advantage for the complex over apo eIF4E in binding to the mRNA. The eIF4E cap 
interaction in mammals is regulated by the phosphorylation of eIF4E (at Ser 209) via the 
eIF4G —associated Mnkl kinase20 . 
The phosphorylation state of eIF4E is, in general correlated with the translation rate and 
growth status of the cell 21 . Stimulation of cell growth activates the ras-ERK signaling 
pathway, which leads to the direct phosphorylation of eIF4E at Ser 209. 
ri 
Phosphorylation at Ser 209 by the MAP kinases integration kinases (MNK1/2) is a 
controversial issue as to whether it increases the cap-affinity of eIF4E elevating 
translation rates or not 21 . It has been demonstrated that the mitogens-stimulated 
pathway acting through ERKs, and the stress-activated pathway acting through the p38 
MAPKs, appear to converge on MNK1 (as shown in figure 3)22. 
Mammalian 4E-BP], 4E-BP2 and 4E-BP3 and yeast p20 inhibit cap-dependent protein 
synthesis by binding to eIF4E without affecting cap recognition. Experimental work 
using point mutants showed that human eIF4G1 and the 4E-BP have shared but non-
identical binding sites on human and yeast eIF4E 2325 . eIF4E inhibition is caused by the 
blocking of eIF4G binding by the 4E-BPs. Sequence of the 4E-BPs and the eIF4Gs 
suggest that these two protein families have converged on the same eIF4E binding 
strategy that employs a Y-X-X-X-X-L-0 eIF4E recognition motif (where X is variable and 
çbisL, MorE) 26 . 
Under normal cellular conditions, eIF4E is bound by the inhibitory 4E-BPs, which 
sequester eIF4E from interaction with eIF4G, the scaffolding protein of the eIF4E 
translation initiation complex. Upon mitogenic stimulation, the 4E-BPs become 
phosphorylated at multiple sites as a consequence of both the ras-ERK and P13 
kinase/AKT signalling pathways 
27 (see figure 3). These phosphorylation events 
dislodge the 4E-BPs from eIF4E, thereby freeing eIF4E and enabling eIF4E to deliver 
mRNAs effectively to the eIF4F complex. 4E-BPI phosphorylation is also dependent 
WN 
upon the FKBP-rapamycin associated protein/mammalian target of rapamycin 
(FRAP/mTOR) kinase (as shown in figure 3). Once bound to the scaffolding protein 
eIF4G, eIF4E may become phosphorylated at S209 by the kinase MNK. This 
phosphorylation event may play a key regulatory role for eTF4E binding however it is 
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Figure 3: The intracellular signalling pathways impinging upon the translation initiation factors eIF4E 
and 4E-BPs. The Ras pathway, leading to eIF4E phosphoiylation, and the P13K pathway, leading to 4E-
BP and p70S6K phosphorylation, are depicted. Also shown are the targets of several inhibitors used in 
studying these pathways. 
1.1 Disregulation of protein synthesis is a step in malignant progression. 
It is well established that defective processes of cellular homeostasis, like functions 
involved in DNA repair and genomic stability, result in a predisposition toward 
malignant trans format] on 28 . Disregulation of protein synthesis is also a major step in 
malignant progression. A decade ago, studies aimed at understanding the regulation and 
function of eIF4E revealed that a moderate over-expression of this translation initiation 
factor results in dramatic phenotype changes, including rapid proliferation, suppression 
of apoptosis and malignant transformation 29 . Conversely, the tumorigenic properties of 
cancer cells can be strongly inhibited by anti-sense RNA-mediated reduction of eTF4E 
expression or by over expression of the inhibitory eIF4E binding proteins, the 4E-BPs 30 . 
eIF4E expression was subsequently found to be elevated in carcinomas of the breast, 
head and neck, bladder, cervical, lung and prostate, when compared with normal tissues 
and benign lesions29 . These data firmly implicate elevated eIF4E expression in 
malignant progression. 
Establishing a greater protein synthesis output may be critical for cancer cells to sustain 
rapid rates of cell division. However, analysis of cells transformed by eIF4E revealed 
that the synthesis of only select protein were greatly enhanced, while synthesis of most 
were only minimally increased 31 . These studies indicate that eIF4E specifically 
stimulates translation of several oncogenic transcripts that, under normal cellular 
conditions, are translationally repressed. The concerted upregulation of these key 
malignancy related proteins (e.g. vascular endothelial growth factor (VEGF), cyclin Dl, 
matrix metalloprotease 9 (MMP-9)) may enable tumour cells to override normal growth 
constraints, stimulate angiogenesis, invade surrounding tissue and establish the autocrine 
stimulatory growth and survival signals necessary for the successful establishment of 
mesatases 29 
7 
1.1.1 Protein synthesis and mRNA discrimination. 
Protein synthesis plays a fundamental role in nearly every aspect of metabolism. It also 
constitutes a critical step in the control of gene expression' ° as rnRNAs must be 
recruited for translation. The synthesis of each protein ultimately depends on the 
relative abundance of its mRNA and its capacity of that mRNA to interact with 
components of the translation initiation machinery. This property of the translation 
initiation process establishes a hierarchy among the different mRNAs to be translated 
because the initiation capacity of protein synthesis is limiting. In eukaryotes, the flow of 
information from genes to proteins is too slow to accommodate for rapid changes in the 
environment. Eukaryotes compensate for this problem by maintaining a pool of mRNAs 
that are not immediately utilised. Examples could include transcripts that encode growth 
factors that can be rapidly produced under conditions that require the cells to re-enter 
cell division rapidly 12 . 
In metozoans, mRNAs vary over a 100-fold range in their translational efficiencies 32 . 
Also their transcription is dependent on the particular growth conditions of the cell. A 
theoretical treatment of mRNA competition 10
"
9"' hypothesise that the spectrum of 
translated mRNAs changes with the overall rate of protein synthesis. Weak mRNAs are 
out competed by strong mRNAs when the rate of translation initiation is reduced, as in 
quiescent cells 34 , whereas weak and strong mRNAs are translated when protein 
synthesis becomes disregulated. A disproportionate number of mRNAs that would be 
characterised as weak are those encoding oncoproteins and growth and survival factors, 
these have 5' UTRs that contain secondary structure elements. Several of these genes 
also share the property of being cell-cycle regulated and, in turn, their protein products 
affect cell-cycle progression 29,34  
1.1.2 Paradigm of strong and weak mRNAs. 
By specifically binding the 5'-terrninal cap containing end of mRNA, eIF4E, following 
its release from 4E-BPs, can deliver the mRNA to the eIF4F complex. The eIF4F 
complex then scans 5'-3' unwinding secondary structure in the 5' untranslated region 
(5'-UTR) of the rnRNA to reveal the initiation codon, trigger ribosome binding and 
facilitate translation of the mRNA" The abundance of the active eIF4F complex is 
normally limiting due to the limited expression of eIF4E as well as its binding to the 
inhibitory 4E-BPs. Therefore, cellular mRNAs must compete with each other for access 
to the eIF4F complex and for subsequent delivery to the ribosomes. The short, 
unstructured 5'-UTRs of most cellular mRNAs (e.g. house keeping genes) enable the 
eIF4E complex to scan readily for the translation initiation codon. These mRNAs are 
translated efficiently, even when the active eIF4F complex is limiting, and are termed 
strong rnRNAs (see figure 6). By contrast, the lengthy, G + C rich, highly structured 5'-
UTRs, typical of growth factor and proto-oncogene mRNAs (termed weak mRNAs) 
hinder efficient scanning and start codon recognition (see figure 6). This leads to the 
mRNAs being inefficiently translated, which is further attenuated when the active eIF4F 
complex is lirniting 1 ' 10 ' 13 ' 29 ' 3537 . 
Translation of strong mRNAs (see figure 4) will quickly reach a maximum in the 
presence of low levels of free eIF4E (i.e. active eIF4F complex), even in quiescent cells. 
Weak mRNAs are poorly translated when free eIF4E is limiting. With increased free 
eIF4E (i.e. increased levels of active eIF4F), the translation of these weak mRNAs (e.g. 
growth regulators) is disproportionately enhanced. The levels of free eIF4E can be 
increased substantially by one or all of the following mechanisms: (1) increased eIF4E 
expression; (2) decreased 4E-BP expression; or (3) increased phosphorylation of 4E-BP 
resulting from hyperactivation of intracellular signalling pathways. Cancer cells 
routinely show activation of the signalling pathways that phosphorylate 4E-BPs and may 
also reduce expression of the 4E-BPs 35 . Cancer cells also frequently display increased 
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Figure 4: mRNA competition for translation initiation ' 0293339 . The products of weak mRNAs become 
selectively increased with increased e1F4E concentration, which results in higher amounts of eJF4F 
complex. Disproportionate increased translation of these weak mRNAs would increase with malignant 
progression in relation to increased flee eIF4E. Figure derived from Dc Benedetti and Graff 12 . 
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Consistent high levels of free eIF4E would selectively and disproportionately enhance 
the translation of weak rnRNAs. As these weak mRNAs almost universally encode 
growth regulatory proteins, the concerted upregulation of these gene products may 
profoundly influence the biology of these cells, enabling tumourigenesis and ultimately 
metastatic progression. There is strong experimental evidence that now supports the 
model that increasing levels of free eIF4E preferentially enhances the translation of the 
weak mRNAs driving transformation and malignancy 29 . 
1.2 Role of eIF4E in malignancy. 
Over-expression of eIF4E resulted in cellular transformation and tumourigenesis in the 
immortalised but nontransformed cell lines, NIH3T3, CREF or MM3MG 3941 . eIF4E 
also acts as a potent enhancer of transformation in cooperation with v-myc or E1A 42 . It 
was then discovered that eIF4E expression is elevated in many malignant cell lines 43 ' 44 . 
In CREF cells, eIF4E over-expression not only induced transformation and tumour 
formation but also induced metastatic capacity. Further evidence of a role for eIF4E in 
malignancy has been provided by studies wherein eIF4E expression was suppressed by 
antisense RNA expression or eIF4E function was blocked by the expression of 4E-BPs. 
Ectopic expression of 4E-BPI reverted the transformed and tumourigenic phenotype of 
cells transformed by eIF4E or v-src 45 . Expression of antisense RNA to eIF4E in HeLa 
cells suppressed proliferation and altered cellular morphology 15 . Antisense RNA 
mediated reduction of eIF4E by 60% in ras-transformed CREF cells suppressed soft-
agar colonisation as well as tumour formation and growth 30 . Also the ability of these 
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suppressed46 . Similarly, in human breast and head and neck cancer cell lines, antisense-
RNA-mediated reduction of eIF4E suppressed tumour formation and angiogenesis 4749 . 
Translation of model mRNAs engineered to have excessive secondary structure in their 
5'-UTRs (i.e. model weak mRNAs, see figure 6) were specifically stimulated in cells 
over-expressing eIF4E 31 ' °  Further work has shown that eIF4E controls the translation 
of endogenous rnRNAs whose protein products are well recognised to contribute to 
malignancy (see figure 5). These mRNAs encode proto-oncoproteins such as c-myC, 
cyclin Dl and ornithine decarboxylase (ODC), angiogenesis factors such as FGF-2 and 















Figure 5: Transciption of eIF4E is controlled by c-myc and leads to increased levels of active eIF4E 
complex. This causes increased translation of mRNAs with highly structured 5' UTRs, whose protein 
products are well recognised to contribute to malignancy. These mRNAs encode proto-oncOprOteins 
such as c-myc, cyclin Dl and ornithine decarhoxylasc (ODC). angiogefleSis factors such as FGF-2 and 
VEGF and degradative enzymes that enable tumour invasiveness such as MMP-9 2  p53 has recently 
been shown to transcriptionally repress eIF4E by binding to c-myc and inhibiting its interaction with the 
51 eIF4E promoter. 
12 
1.2.1 c-,nyc and p53. 
In contrast to eIF4E, the p53 tumour suppressor plays a pivotal role in preventing 
tumour occurrence and development. Although p53 may exert its tumour suppressing 
action through multiple mechanisms, primarily it functions as a transcription factor 
activating or inactivating the transcription of its target genes 52 . Genes activated by p53 
include those that mediate cell cycle arrest, DNA repair and apoptosis, whereas many 
pro-proliferative and anti-apoptotic genes are suppressed by p53. 
The eIF4E promoter contains two canonical CACGTG motifs known to be the c-myc-
binding site 
53,54.  One problematic feature of c-myc is its relatively weak activity in 
reporter gene assays 55. Importantly, myc could transactivate the eIF4E promoter in 
standard reporter assays but, more importantly, dominant negative forms of c-rnyc 
down-regulated eIF4E promoter activity 53 . These formal connections between myc's 
transactivating activity and a gene involved in protein synthesis revealed an important 
connection between c-myc and growth control. A connection between 
myc and 
translation initiation makes particular sense because translation initiation elements have 
particular effects on translation of cell cycle regulators 56 ' 57 , and how cell growth might 
regulate cell division. 
Zhu et a 15  showed that p53 negatively regulates eIF4E which is positively regulated by 
c-myc. p53 interacts directly with c-myc and this interaction significantly inhibits the 
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binding of c-myc to the eIF4E promoter and c-myc induced eIF4E promoter activity. 
eIF4E controls the translation of various malignancy-associated mRNAs which are 
involved in pathological process, the co-regulation of eIF4E by p53 and c-myc may 
represent one of the mechanisms for p53 and c-myc mediated cancer formation and 
progression. Zhu et a15  also showed that the inhibitory effect of p53 on eIF4E promoter 
activity was abrogated by the p53 inhibitory oncogene MDM2 58 . 
The translation of the c-myc mRNA is normally repressed in B cells unless stimulated 
by mitogens or growth factors 59 . Deletion mutations in the c-myc 5'-UTR, which are 
present in several Burkitt lymphomas (resulting from translocation of the c-myc gene), 
result in enhanced translation of the c-rnyc mRNA 6064 . C-myc is implicated in several 
biological processes such as cell growth, proliferation and apoptosis 65 ' 66 . C-myc is 
expressed ubiquitously during embryogenesis and in post-developmental tissues with a 
high proliferative capacity. C-myc also inhibits terminal differentiation of most cell 
types and sensitises cells to growth factor withdrawal induced apoptosis 67 ' 68 . Activated 
oncogenic c-myc plays a critical role in the progression of Burkitt's Lymphona, its 
expression is elevated or deregulated in a wide range of other human cancers and is 
associated with aggressive tumours with poor prognosis 6566 . 
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1.2.2 Ornithine decarboxylase - ODC. 
ODC mRNA contains a GC-rich 5'UTR (see figure 6), rendering it poorly translated 69 ' 70 . 
Over-expression of eIF4E in cells leads to a 30-fold increase in ODC protein levels, as 
well, depletion of eIF4E using anti-sense RNA suppressed ODC mRNA translation in 
the eIF4E over-expressing Cells7 L72• Polyarnines are ubiquitous cellular components that 
are involved in normal and neoplastic growth. Polyarnine biosynthesis is tightly 
regulated in mammalian cells by the activities of two key decarboxylases, ornithine- and 
S-adenosylmethionine decarboxylase. Polyamines are essential for growth, 
differentiation, survival and mediate cellular transformation 
73,74. Over-expression of 
ODC transforms NIH 3T3 cells 
75,76. Transgenic expression of polyarnine biosynthetic 
enzymes, such as ODC and S-adenosylmethionine decarboxylase in mice, causes skin 
cancer 77 . Also, both intracellular polyamine concentrations and ODC activity are 
increased in colorectal cancer tissue and in premalignant polyps 78 . The polyamine 
pathway is also implicated in carcinogenesis and tumour progression of breast cancer 79 . 
Thus, the polyamine synthetic pathway is considered to be an anti-cancer target 80 ' 81 . 
Since eIF4E directly regulates ODC mRNA translation, targeting both eIF4E and ODC 
may serve as an important target for anti-cancer therapy. 
1.2.3 Cyclin Dl. 
eIF4E expression leads to an increase in cyclin Dl protein 82 '83 . eIF4E also enhances the 
transport of the cyclin Dl mRNA from the nucleus 8387 . The progression of mammalian 
cells through GI phase of the cell cycle is governed by the D-type cyclins (Dl, D2, D3). 
These proteins are induced at the beginning of the GI phase and associate with 
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serine/threonine cyclin dependent kinases to form activated holoenzymes. Cyclin Dl 
expression is increased in several human cancers (colorectal and mammary 
adenocarcinomas and pancreatic tumours) 8891 , as well as in several cancer cell lines 92 . 
Both cyclin Dl and polyamines are required for entry into S phase and their increased 
expression has been linked to transformation 93 . 
1.2.4 VEGF and FGF. 
eIF4E over-expression results in a dramatic increase in the secretion of vascular 
endothelial growth factor (VEGF) without affecting mRNA levels 94 . VEGF mRNA in 
eIF4E transfected cells is associated with heavy polysomes indicating that increased 
VEGF expression is achieved through its translational upregulation 94 . Similarly, 
fibroblast growth factor-2 (FGF-2) rnRNA is also loaded onto heavy polysomes in cells 
expressing eIF4E, leading to increased secretion of FGF-2 50 . The formation of new 
blood vessels from pre-existing ones is a well-controlled process 95 ' 96 . Currently, several 
VEGF inhibitors which inhibit VEGF and VEGF receptor production or VEGF-VEGFR 
interactions are undergoing clinical testing in several malignancies 97 . 
Increased eIF4E expression in cells regulates the translation of several other proteins 
involved in autocrine growth stimulation (PDGF, IGF2), cell survival (BCL-2, BCL-xL), 
invasion (MMP-9) and communication with the extracellular environment (NMDA) 29 ' 93 . 
Thus, the eIF4E mediated translational modulation of these malignancy associated 
niRNAs plays a pivotal role in both tumour formation and metastasis. 
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Figure 6: 5' UTR structures of competitive and non-competitive rnRNAs 31 . The 5'-un trans] ated regions 
from a strong mRNA (fl-actin) and two weak rnRNAs (Vascular endothelial growth factor, VEGF, and 
ornithine decarboxylase, ODC) are shown. These were generated using the Zucker rn-fold program 37 . Note 
that the non-competitive rnRNAs have highly structured, lengthy 5' UTRs, which encumber efficient 
scanning and recognition of the translation start codon. These structures must be resolved by the helicase 
activity of the e1F-4F complex to enable translation. 
1.3 Cap-independent translation. 
Translation of FGF-2, VEGF and c-myc mRNAs that are found to be enhanced in eIF4E 
over-expressing cells can also be driven by an internal ribosome entry site, or 1RES 9 ' 9899 . 
Their translation may occur even in the presence of limiting eIF4E (i.e. cap independent) 
under certain conditions. For example, translation of c-myc mRNA can occur at the M-
phase of the cell cycle where cap-dependent translation is inhibited 100 . Another study 
has shown that the mechanism of c-myc translation is more consistent with shunting 
63  a 
form of initiation that requires cap-proximal entry of ribosomes and eIF4E. It is 
currently unclear what contribution IRES-dependent translation has or may have on the 
increased expression of these potent growth regulatory molecules in cancer cells. 
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1.4 Elevated expression of eIF4E is common in human carcinomas. 
High levels of eIF4E expression are found in several cancers; breast cancers, head and 
neck cancers, bladder cancers, prostatic adenocarcinomas, lung cancers, cervival cancers 
and lymphomas. 
Breast cancer. Elevated eIF4E expression was initially researched in breast cancer. 
The basal level of eIF4E in normal breast tissue is low, making the abnormally elevated 
eIF4E expression in carcinomas very evident. eIF4E is elevated three- to 30 fold above 
normal breast and benign lesions and is a ubiquitous feature of breast carcinoma's' 01 ' 102 . 
eIF4E levels are also a strong, independent prognostic indicator of recurrence and death 
from breast cancer 103,104 
Head and Neck cancers: Head and neck squamous cell carcinomas (HNSCC) have a 
high local occurrence rate due in part to incomplete tumour resection. The high lethality 
of this type of cancer is not due to metastasis, but due to local occurrence in most cases. 
Complete resection of the tumour is critically important for survival. Incomplete 
excision will almost invariably lead to rapid reoccurrence and death from tumour burden. 
cIF4E expression is low in benign lesions, such as polyps and leukoplakia, but is clearly 
elevated in HNSCC. The presence of as little as 5% of eIF4E positive cells present at 
the surgical margins was sufficient to predict local reoccurrence within two thirds of the 
patients with the reoccurrence occurring in two years 48"
0 
. 
Lung cancer. eIF4E expression in bronchial adenocarcinomas (but not squamous cell 
carcinomas) is three to eight-fold higher than in the normal lung
106. In an independent 
study of adenocarcinornas of the peripheral lung, eIF4E was found to be elelvated by up 
to seven fold relative to normal lung tissue and was specifically associated with 
histological grade and invasiveness of the tumour 107 . These studies indicate enhanced 
eIF4E expression in the development and progression of lung cancers. 
1.5 Role of eIF4E in metastatic progression. 
The metastatic phenotype is extremely complex requiring the metastasising tumour cells 
to hurdle numerous divergent challenges. To establish a successful metastatic colony, a 
tumour cell must induce angiogenesis, which enables continuous tumour growth and 
provides access to the vasculature. The tumour cell must also dislodge from the primary 
tumour site, break down and penetrate surrounding normal tissue, enter the blood or the 
lymphatic system, survive with in that circulation and exit at a site distal to the primary 
tumour site. Challenged by a different growth factor milieu in the tissue of the 
metastatic site, a metastasising tumour cell must be able to attract a new blood supply 
and to generate the necessary growth and survival factors to support and establish a 
successful metastatic colony. This shift towards growth factor autonomy is essential for 
the successful establishment of metastases. Indeed, although many tumour cells are able 
to break from the primary tumour, enter the circulation and colonise at a distal site, only 




Enhanced eIF4E function can stimulate autocrine growth factor signalling. eIF4E 
expression stimulated expression of activin, a member of the tumour growth factor 13 
family, which in turn stimulated mesodermal development in Xenopus oocytes' 09 . Over-
expression of eIF4E in NIH3T3 cells induced transformation, in part, by establishing an 
autocrine growth stimulatory loop that triggered signalling through the ras-MAP kinase 
pathway' 10 . In CREF cells over-expression of eTF4E triggered signalling through the 
ERK pathway 37 . These reports indicate that enhanced eIF4E function can play a role in 
the acquisition of growth factor autonomy - a critical phenotype necessary for the 
successful establishment of melastases 29 . Enhanced eIFE function has also been linked 
to metastasis in both experimental tumour systems and in human disease. 
Reduction of eIF4E by antisense RNA has been shown to suppress the ability of ras-
transformed CREF cells to metastasise to the lungs in an experimental metastasis assay. 
The few metastases that did form regained normal levels of eIF4E expression, indicating 
that the successful establishment of metastases selected for cells with greater levels of 
eIF4E expression 46. CREF cells transformed by the ectopic over-expression of eIF4E 
were capable of forming both spontaneous and experimental metastases 37 . The 
metastatic colonies formed routinely showed even higher eTF4E expression levels than 
that of the parental, transfected cells 37 . Tumour progression to metastases involves 
selection for increased eIF4E expression. 
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Inhibiting eTF4E function by blocking the signalling cascades that release eIF4E from 
4E-BPs also profoundly suppresses metastasis. The macrolide antibiotic rapamycin, 
which suppresses mTOR activity and thereby prevents the the release of 4E-BPs from 
eIF4E (figure 1), suppresses the capacity of murine colon tumour cells to grow as 
experimental liver metastases' . Rapaniycin treatment also prevents pulmonary 
metastasis of human renal cell carcinoma cells' 
2 
Transcriptional profiling of metastatic human solid tumours revealed a molecular 
signature for metastasis. Expression of nine genes were routinely decreased across a 
diverse range of solid tumour metastases, whereas eight genes were found to be 
consistently upregulated, eIF4E was identified as one of this set of genes. Enhanced 
expression of eIF4E serves as part of a molecular signature for human solid tumour 
metastases' '. These reports support the role that eIF4E may play a role in metastatic 
progression and further supports eIF4E as a target for anti-cancer therapy. 
1.6 Exploiting eIF4E as therapeutic target. 
Metastatic progression is driven by the concerted actions of many diverse protein-
protein interactions that govern cell cycle progression and growth factor autonomy 
(ODC, c-myc, cyclin Dl), angiogenesis (VEGF, FGF-2), survival BCL-2 and invasion 
(MMP-9, CD44v6). Though expression of these key genes is specifically regulated by 
distinct stimuli, translation of every one of these proteins is suppressed under cellular 
conditions wherein the activity of the eIF4F translation initiation complex is low. The 
activity of this complex is regulated by the availability of eTF4E. Both human and 
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experimental tumours commonly show a marked increase in the ratio of eIF4E:4E-BP; a 
consequence of eIF4E overexpression, diminished 4E-BP expression and/or enhanced 
intracellular signalling through the P13 kinase and ras-ERK pathways. Such enhanced 
eIF4E availability facilitates formation of the eIF4F complex and selectively upregulates 
the translation of malignancy related mRNAs. Inhibiting the function of eIF4E should 
diminish the assembly and function of the eIF4F complex and selectively diminish the 
translation of these malignancy related mRNAs 12 ' 29 
Currently several approaches are being used to exploit eIF4E as a therapeutic target 
including antisense RNA' 14,  standard small molecule therapy' 
' 1.112 and, excitingly gene 
therapy29 . Antisense RNA-mediated reduction of eIF4E in both epithelial and fibroblast 
models reduced translation of key malignancy related molecules (ODC, VEGF and 
FGF-2) in concert with diminished tumour growth, invasion and metastasis. Whether 
anti-sense RNA strategies prove useful for therapy remains to be fully explored. 
However a number of anti-sense oligonucleotides have now entered clinical trials for 
cancer 12,29 
Rapamycin and its derivatives inhibit the kinase mTOR and thus prevent 
phosphorylation of 4E-BP and the subsequent release of 4E-BP from eIF4E. 
Consequently, rapamycin treatment prohibits eIF4E from engaging and activating the 
eIF4F complex. Treatment of murine colon carcinoma cells or human renal cell 
carcinoma cells with raparnycin suppresses metastasis' 
I LI 12 Rapamycin treatment may 
be particularly effective in tumours lacking PTEN function, such as glioblastomas and 
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prostate cancers' 15,16, Early phase clinical trials with the rapamycin derivative, CCI-
779, have indicated that this approach may be a promising therapy, even as a single 
agent, for cancer treatment"  7,118 
The increased function of eIF4E in tumour cells has provided a potential avenue for a 
gene therapy approach. Metastatic murine breast cancer cells were injected into the tail 
vein of mice to facilitate the formation of pulmonary metastases. Mice were 
subsequently injected with plasmids expressing thymidine kinase (TK) to facilitate the 
cytotoxic conversion of ganciclovir. Mice injected with plasmids encoding TK linked to 
the translationally repressive 5'-UTR showed a 90% reduction in pulmonary metastases. 
Importantly, these mice showed no evidence for systemic toxicity as the translationally 
suppressed TK was exclusively expressed only in the tumour tissues, where eIF4E 
activity was highest. In contrast, the mice injected with the uncontrolled TK plasmid 
showed significant toxicity attributable to the expression of the TK protein in all tissues 
and, subsequently, the systemic cytotoxic conversion of ganciclovir' 
1.7 Structure based drug design rationale. 
There are three main ways of interfering with eIF4E action utilising a structure based 
drug design rationale (see figure 7): (1) to develop cap-analogs with high affinity and 
specificity for eIF4E, (2) to develop peptide mimics to interfere with the eTF4G and 
eIF4E interaction and (3) to develop kinase inhibitors to interfere with specific points 
within the signal transduction pathway responsible for regulation of eIF4E and 4E-BP 
activity. Cap analogues are a promising lead, with the major advantage of structures 
23 
being available 1211-12'  and the mechanism of binding being reasonably understood' 824 
making this an ideal candidate for virtual screening (discussed in chapter 3 and 5). 
Signal transduction pathways are not a prime candidate as the best defined kinase in this 
class has already been identified as the target of rapamycin. Rapamycin is a known 
anti-proliferative, having been developed as an immunosuppressant. It has also been 
tested and developed for uses in oncology' 11.1 12• There are several other kinases in the 
pathway that are potential targets, but developing understanding of them suggests they 
would be difficult to use to target eIF4E activation. The number of proteins that interact 
with eIF4E make it a promising target for the utility of peptides as drug development 
templates (chapter 3). 
To develop peptid 
mi meti Cs. 
To develop cap 
analogues 
To develop kinase inhibitors to interfere with 
the signal transduction pathway regulating 
eIF4E and 4E-BP. 
Figure 7: cIF4E can he targeted with 3 distinct structure based drug design strategies: ( I ) to develop 
cap-analogs with high affinity and specificity for eIF4G, (2) to develop PePlicle mimics to interfere with 
the eIF4G and eIF4E interaction and (3) to develop kinase inhibitors to interfere with specific points 
within the signal transduction pathway responsible for regulation of eIF4E and 4E-BP activity. 
24 
It is the aim of this work to develop cap-mimetics for the mRNA cap structure. To 
achieve this high resolution crystals of eIF4E are needed for soaking and crystallisation 
experiments and a primary screen to identify potential hits must be developed. To 
facilitate this a source of purified protein is also required. As well as these main goals 
the interactions of the cap-analogue must also be studied to identify the main 
determinants required for binding as these are of great importance to structure based 
drug design efforts. 
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Chapter 2: Expression, purification and crystallisation of eIF4E. 
2.0 Introduction and aims. 
A number of different purification protocols exist for eTF4E. Affinity 
chromatography using m7GTP agarose 4B affinity beads has been successfully used 
to extract eIF4E from lysed whole cell extract. Other methods used to purify eIF4E 
have involved the use of MBP tagged eIF4E 2  or classical chromatography techniques 
such as ion exchange 3 . The main objectives for the purification protocol were: 
To provide large quantities of protein (on the scale of milligrams) for use in 
biophysical characterisation e.g. crystallography, mass spectrometry and 
tryptophan fluorescence experiments. 
To provide highly purified eIF4E that has not been contaminated by 
exposure to any ligands. 
The production of a wild-type protein free from recombinant tags that may 
interfere with its structure and function. 
The techniques fulfilling the above objectives are classical chromatography 
techniques (such as ion exchange and hydrophobic interaction chromatography) and 
affinity chromatography exploiting the rn7GTP affinity interaction, providing a KC1 
salt gradient is used for elution of bound protein. Neither of these techniques is 
dependent upon recombinant protein tags and both avoid using m7GTP in the elution 
phase. The use of rn7GTP could potentially interfere in any type of ligand screening 
assay or co-crystallisation of a target ligand with eIF4E. Previous studies on eIF4E 
have mainly utilised protein production in E.coli. Advantages of using E.coli as an 
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expression host include high expression of protein and lack of post-translational 
protein modifications 4 . Expression of eIF4E in E.coli also has the advantage that it 
does not come into contact with any cap-analogues or capped mRNA as the m7Gppp 
5'-5' modification is not found in bacteria . 
2.1 Expression and refolding of full length human eIF4E. 
2.1.1 Fundamental aspects of protein expression. 
The full-length human eIF4E construct in the pET1 id vector was kindly provided by 
Cyclacel Ltd., Dundee. The pET system has been developed by Novagen Ltd., for 
the cloning and expression of proteins in E.coli. Target genes are cloned in pET 
plasmids under control of strong bacteriophage T7 transcription and optional 
translation signals. Providing a source of T7 RNA polymerase in the host cell 
induces expression. T7 RNA polyrnerase is highly selective and in certain cases, in a 
few hours after induction, the desired product can comprise 50% of total cell 
protein. It is possible to attenuate expression levels by decreasing the concentration 
of the inducer. Decreasing the expression level may enhance the soluble yield of 
some target proteins. The system also allows target genes to remain transcriptionally 
silent in the uninduced state. Target genes are initially cloned into hosts that do not 
contain the T7 RNA polymerase gene, thus eliminating plasmid instability due to the 
production of proteins potentially toxic to the host cell. Once established in a non-
expression host target protein expression is usually initiated by transferring the 
plasmid into an expression host containing a chromosomal copy of the T7 RNA 
polymerase gene under lacUV5 control. Expression is induced by the addition of 
IPTG to the bacterial culture 6 
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Even in the absence of IPTG, there is some expression of T7 RNA polymerase from 
the lacUV5 promoter in DE3 lysogens and therefore basal expression of the target 
protein. Recombinant protein expressed in E.coli may or may not be toxic to the 
bacteria by interfering in the normal functions of the cell. The degree of toxicity will 
vary from protein to protein. If target genes are sufficiently toxic to E.coli, this basal 
level of expression can prevent vigorous growth and establishment of plasmids in 
ADE3 lysogens. Protein expression can be tightly controlled in the pET system by 
either using the T7/T71ac promoter, use of pLysS or pLysE hosts or by adding 
glucose to the medium depending on the characteristics of the target protein. The 
pETI id plasmid, which was used to express cIF4E, contains the T7/T71ac promoter 6 . 
T7Iac allows control of basal expression of the target gene. These plasmids contain a 
lac operator sequence just downstream of the T7 promoter. They also carry the 
natural promoter and coding sequence for the lac repressor (lad), orientated so that 
the T71ac and lacl promoter diverge. When this type of vector is used in DE3 
lysogens, the lac repressor acts both at the lacUV5 promoter in the host chromosome 
to repress transcription of the T7 RNA polymerase gene by the host polymerase and 
at the T71ac promoter in the vector to block transcription of the target gene by any T7 
RNA polyrnerase that is produced 6 . 
2.1.2 Expression of full length human eIF4E. 
The full-length human pETI 1 d eIF4E construct was transformed into competent 
Rossetta pLysS, Novagen, E.coli cells and plated out on ampicillin (lOOug/ml) 
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plates. The Rosetta TM  strains enhance expression of eukaryotic proteins that contain 
codons rarely used in E.coli. Most amino acids are encoded by more than one codon, 
and each organism carries its own bias in the usage of the 61 available amino acid 
codes. In each cell the tRNA population reflects the codon bias of the RNA 
population. When the mRNA of heterologous target genes is over expressed in 
E.coli, differences in codon usage can impede translation due to demand for one or 
more tRNAs that may be rare or lacking in that population. Insufficient tRNA pools 
can lead to translational stalling, premature translation termination, translation frame-
shifting and amino acid misincorporation. Rosetta' TM  strains supply tRNAs for the 
codons AUA, AGG, AGA, CUA, CCC and GGA on a compatible chioramphenicol 
resistant plasmid. All of the 13 strains (BL21, Rossetta TM , B834, Origami' TM , 
Tuner TM , BLR) are deficient in the Ion protease and lack the ompT outer membrane 
protease that can degrade proteins during purification 6 . 
Rossetta pLysS variants were used as another method of tightly controlling basal 
expression of the target protein. pLysS host strains contain a compatible 
chlorarnphenicol-resistant plasmid that provides a small amount of T7 lysozyme, a 
natural inhibitor of T7 RNA polymerase. T7 lysozyme is a bifunctional protein: it 
cuts a specific bond in the peptidoglycan layer of E.coli cell wall, and it binds to T7 
RNA polymerase, inhibiting transcription. Relatively high levels of T7 lysozyrne 
can be tolerated by E.coli as the inner membrane prevents it reaching the 
peptidoglycan containing cell wall. pLysS has little effect on growth rate but does 
aid in lysing the bacterial cells. When the bacterial cells are initially broken up via 
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sonication, detergent treatment and other various methods T7 lysozyme is released 
and facilitates in lysing the cells 6 . 
Single colonies from successful transformation of pLysS Rosseta cells were used to 
inoculate lOmi LB (100Lg/m1 ampicillin) cultures and incubated over night at 37°C. 
The overnight cultures were used to seed 800m1 of LB (1 OOp.g/ml ampicillin) each in 
2L shaker flasks. The bacterial cultures were grown to optical densities between 0.6 
and 0.8 before induction. 1mM IPTG was used to induce protein expression, 
cultures were incubated at a temperature of 37°C with shaking at 200 rpm. The 
cultures for full length human eIF4E were incubated for 3 hours before being 
centrifuged for 15 mins at 5,000rpm, the supernatant was discarded and the pellet re-
suspended in 50mM pH 8.8 Tris and 10% w/v sucrose buffer and stored at -80 °C. 
eIF4E is expressed predominately in inclusion bodies with approximately 10% in the 
soluble fraction (see figure 1). Several attempts were made to solubilise the protein 
by altering the expression conditions but these were ultimately unsuccessful. 
Expression conditions were changed by lowering the concentration of IPTG used for 
induction, lowering the induction temperature and inducing in the presence of 10% 
sucrose or 5% ethanol. Sucrose and ethanol cause the bacterial cells to grow in an 
osmotically stressful environment. This leads to expression of bacterial chaperones 













Ohr 	lhr 	21ir 3hr 	Ohr 	lhr 	2hr 	3hr 	PM 
32 .5 kDa 
25kDa 
16.5kDa 
Figure 1: Denaturing SDS-PAGE GEL showing IPTG induced expression of 
full-length human eIF4E. in ROSETTA pLysS cells, over a period of 3 hours at 
37C. eIF4E is almost exclusively expressed in inclusion bodies. Lane PM 
contains pre-stained NEB marker proteins. 
2.1.3 Purification and refolding of eIF4E from inclusion bodies. 
Two possible approaches were available for purification of eIF4E after its 
expression, either it could he purified from the soluble fraction or the insoluble 
fraction. The main disadvantage of purifying from the soluble fraction was that very 
large volumes of E.coli culture would be required to produce the amount of protein 
needed for the planned experimental work. The option of purifying eIF4E from 
inclusion bodies was taken as it has several distinct advantages; it produces 
approximately —30mg of eIF4E protein from 11 of culture, the protein is protected 
from the action of scrine proteases due to the insoluble nature of inclusion bodies and 
also eIF4E is —80% pure after being isolated from the inclusion bodies by a washing 
protocol 9 . 
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After eIF4E had been isolated from its inclusion bodies and solubulised in 6M 
guanidine chloride, 50mM HEPES-KOH pH 7.6, 5mM DTT buffer it was refolded 
using a rapid dilution technique, whereby the protein was only exposed for a short 
period of time to intermediate denaturant conditions. DTT was added to reduce any 
misformed disulphide bonds 10 . Refolding was carried out by slow addition of the 
unfolded protein (-1 mg/ml) to a larger volume of refolding buffer (contains no 
denaturant) under vigorous stifling, leaving the protein at a final concentration of 0.1 
mg/ml. By carrying protein refolding out under conditions of dilute protein 
concentration the chances of protein aggregation occurring should be 
Apart from using the rapid dilution technique for protein folding there were other 
alternative methodologies that could have been used for refolding. These range from 
over-night dialysis into the refolding buffer or carrying out protein refolding on 
columns. There are three basic approaches: immobilisation of the denatured protein 
on a matrix and subsequent denaturant dilution to promote protein refolding; 
denaturant dilution using size exclusion chromatography (SEC); and immobilisation 
of folding catalysts onto chromatographic supports so that the column behaves like a 
catalytic folding reactor' 0 . 
Immobilisation of denatured protein on a matrix can be achieved through non- 
specific interactions or through specific affinity interactions e.g. his-tag. The aim is 
to isolate individual proteins spatially, thus inhibiting aggregation. 	Refolding 
conditions require careful optimisation because of non-specific protein-matrix 
interactions 10 
Refolding by SEC aims to inhibit aggregation by restricting the diffusion of various 
protein forms in the refolding mixture. High dilution factors are achieved during 
SEC refolding and consequently the final sample concentration is significantly 
reduced. SEC has a key advantage over simple dilution refolding - material leaving 
the column has been fractionated on the basis of size. It is therefore possible to 
obtain free refolded protein free from any contaminants present in the initial 
solubilsation solution, and also free of aggregates and any unfolded protein 10 . 
Catalytic column refolding exploits the action of naturally occurring enzymes 10 . 
Fersht and co-workers'' developed an oxidative refolding column that has three 
components immobilised on agarose: GroEL mini-chaperone, which can prevent 
aggregation; DsbA, which catalyses the oxidation and shuffling of disulphide bonds 
and peptidyl isomerase 11 . 
2.1.4 Assessing refolding of eIF4E. 
Analytical methods exist to analyse successful re-folding depending on the nature of 
the protein. Enzyme renaturation can be probed using a suitable activity assay. 
Therapeutic proteins can be assayed using immunoassays when a suitable antibody 
exists, or by using suitable bioassays. Proteins that possess internal aromatic amino 
acids can be probed using intrinsic tryptophan fluorescence. Protein aggregation can 
be determined by measuring turbidity at 450nm. Limited proteolysis can be used to 
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assess the compactness of refolded protein and can he used to compare refolding 
carried out in different environments. Circular dichroism (CD) can also be used to 
detect the presence of secondary structure. Correct folding of eIF4E was assessed by 
examining the protein solution for the presence of visible precipitate and by 
analysing whether it bound m7GTP 4B agarose beads or not using SDS-PAGE gel 
(see figure 2)10. 
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Figure 2: 12% SDS-GEL showing isolation of eIF4E with 0.8mls of m7GTP 4B agarose beads. Lane 
I is the sample of refolded eIF4E used, lane 2 is the elution traction from the washing step. lane 3 is 
the elution fraction horn the first wash with buffer A (see 7.2.3) containing 0.1mM rn7GTP and lane 4 
the elution fraction from the second wash with rn7GTP containing buffer. Lane PM contains pre-
stained NEB marker proteins. 
In Figure 2 lanes 3 and 4 show a high proportion of eIF4E is capable of binding the 
m7GTP 4B agarose beads showing that the refolding protocol has produced a high 
yield of eTF4E. Lane 2 shows a small amount of eIF4E has not bound but this is 
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Figure 3: CD spectra of eIF4E with (green) and without the ligand m7(,TP (blue) at 4°C. For 
experimental details see chapter 7.2.6. 
The CD spectra, as shown above in figure 3, are highly similar to spectra seen in the 
literature' 23 . The spectra were analysed using a suite of programs on Dichroweb' 4 . 
The output from these programs forms a consensus that the spectrum of eIF4E is 
dominated by beta sheet (-42%) with some evidence of alpha helical secondary 
(-4%) structure, proportions that agree roughly with the crystal structures of eIF4E 
seen in the PDB 17 , where the protein is shown to contain 8 beta sheets and 3 alpha 
helices. Also a conformation change is seen in the spectra upon binding of m7GTP, 
further indication that eIF4E is correctly folded and capable of binding the cap 
analogue. 
2.2 Purification of Human Full Length eIF4E 
2.2.1 Affinity purification using m7GTP 4B agarose beads. 
Refolded protein was directly applied to a Tricorn FIR 10/50 column packed with 
4mls of m7GTP 4B agarose beads. Both items were supplied by Amersham 
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biosciences. 	The column was pre-equilibrated in buffer A containing 20mM 
HEPES-KOH pH 7.6, 0.IM KCL and 1mM DTT. After application of the protein 
the column was washed with buffer A and the protein eluted with a block gradient of 
buffer B. Buffer B consisted of 20mM HEPES-KOH pH 7.6, 2M KC1 and 1mM 
DTT. The block gradient was maintained until the UV trace returned to base line. 
Instead of using an elution buffer with a high ionic strength, protein can also be 
eluted with 0.1mM m7GTP or as reported elsewhere 0.6mM GTP 18 . After elution 
the column was equilibrated again with buffer A (see figure 4). 
The purification produced eIF4E of >95% purity that was suitable for both 
crystallisation trials and biophysical experiments. However, even with the use of no 
ligand in the elution buffer there was contamination from m7GTP due to leaching 
from the column. This was noticed as the amount of protein that was eluted off in 
subsequent purifications was reduced until the column displayed no affinity for 
eIF4E. This residual contamination of the protein sample made eIF4E purified in 
this manner unsuitable for ligand binding/screening experiments. 
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Figure 4: eIF4E was directly loaded onto a rn7GTP agarose column, alter refolding. The column 
was then washed using buffer A and the protein was eluted of as a sharp peak with a KCI block 
gradient. (A and B) shows a 15 17(.; SDS-PAGE analysis of the indicated fractions. (C) indicates which 
fractions from the flow-through were taken for analysis and (D) shows which elution fractions were 
taken for SDS-PAGE analysis. Flow-through (C) and elution (D) sections are shown on the UV 
chromatogram. Fractions 8. 9. 10 and 11 were taken for further experiments. 
72 
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2.2.2 Anion exchange purification of eIF4E using monoQiS beads. 
Refolded eIF4E was concentrated and desalted using PD 10 columns prior to loading 
on to a HR 10/10 monoQ column. Desalting was required to remove guanidine 
chloride that otherwise would prevent the protein binding to the column. The 
column was equilibrated in buffer A containing 20mM HEPES-KOH pH 7.6 and 
1mM DTT. After application of the protein the column was washed with buffer A 
and then a KCI gradient was applied to the column. eIF4E eluted from the column at 
a salt concentration of 03M. After elution the column was equilibrated again with 
buffer A. eIF4E purified via this method was >95% pure despite containing some 
contaminants not seen in the affinity purification (see figure 5). The main advantage 
of this purification scheme is that the eIF4E has not come into any contact with 
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Figure 5: eIF4E protein was desalted using a PD 10 column and loaded onto a rnonoQ column. 
The monoQ column was then washed using buffer A and the protein was eluted of as a sharp peak 
with a KCI gradient. (A) ShOWS a 15 1/c SDS-PAGE analysis of the indicated fractions. (B) 
indicates which fractions from the flow-through were taken for analysis and (C) shows which 
elution fractions were taken for SDS-PAGE analysis. Flow-through (B) and elution (C) sections 
are shown on the UV chromatogram. Fractions 14 to IS pooled for further experiments. 
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2.3 Crystallisation trials of human full length eIF4E. 
2.3.1 Principles of protein crystallisation. 
Obtaining suitable single crystals is the least understood step in the X-ray structural 
analysis of a protein. Protein crystallisation is mainly a trial and error procedure in 
which the protein is slowly precipitated from solution. The presence of impurities, 
crystallisation nuclei and other unknown factors play a role in this process. As a rule 
of thumb, the purer the protein the better the chances of crystallisation 19 . 
The protein is usually dissolved in a suitable water based buffer system (e.g. HEPES, 
TRIS). Normally, the precipitant solution is usually added, but only to such a 
concentration that a precipitate does not develop. The solution is slowly brought to 
super-saturation. In this step small aggregates are formed, which are the nuclei for 
crystal growth. Spontaneous formation of nuclei is best achieved at a higher level of 
saturation. Once nuclei have formed, actual crystal growth can occur. The 
attachment of new molecules to the surface of a growing crystal occurs at steps on 
the surface. This is because the binding energy is larger at such positions than if the 
molecule attaches to a flat surface. These steps are either created by defects in the 
crystalline order or occur at nuclei formed randomly on the surface. To achieve 
crystal growth, super-saturation must be reduced to a lower level; maintaining a high 
level of super-saturation would result in the formation of too many small nuclei and 
therefore too many crystals (figure 6). Also crystals should grow slowly to reach a 
maximum degree of order in their structure19. 
Precipitation of the protein can be achieved in several ways. One method involves 
increasing the effective concentration of the protein, usually by adding a salt (salting 
out) or polyethyleneglycol (PEG). Either serves to immobilise water, thereby 
increasing the effective protein concentration. Some proteins are poorly soluble in 
water but do dissolve if a small amount of salt is added. By removing the salt the 
protein precipitates. One can regard salting in as the result of competition between 
charged groups on the surface of the protein molecule and the ions in solution. In the 
absence of solvent ions the protein precipitates by columbic attraction between 
opposite charges on different protein molecules. If ions are added they screen the 
charged groups on the protein and increase solubility. A second method of protein 
precipitation is to diminish or increase the attractive forces between protein 
molecules. These forces are: electrostatic, hydrophobic and hydrogen bonding. 
Additives and conditions that can be used and changed for this purpose are alcohols, 
salts, PEGs, pH and temperature 19 . 
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Figure 6: A typical solubility curve for a protein, as a function of the salt concentration or another 
parameter. Ideal crystal growth occurs at lower levels of super-saturation than is required for the 
formation of nuclei. 
Several experimental methods exist for carefully controlling protein precipitation. 
These range from batch crystallisation, dialysis, sitting drop, liquid-liquid diffusion 
and hanging drop vapour diffusion. 
In this work only the hanging drop method was used so only a brief description of 
this method will be included. In this method drops are prepared on a siliconised 
microscope glass cover by mixing X p.1 of purified protein, usually 2.5 p.1, with the 
same volume of precipitant solution. The cover slip is placed upside down over a 
well that contains the required precipitant solution (- I ml). The well is sealed by 
applying oil or grease to the circumference of the well before the cover slip is put 
into place 19 . 
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Drop volume decreases, 
increasing concentration 
of both protein and 
precipitant 
Thus resulting in crystal 
formation 
Figure 7: The process of vapour equilibration in a single well. Through loss of water vapour to the 
larger volume reservoir, the droplet comes into equilibration with the precipitant concentration in the 
reservoir, thereby inducing crystallisation. 
This method works by adding precipitant to the aqueous protein solution just below 
the point required to precipitate the protein (see figure 7). The water is allowed to 
evaporate slowly, which gently raises the concentration of both the protein and the 
precipitant until precipitation occurs. At this point the protein hopefully forms 
crystals instead of brown amorphous precipitate. Crystal growth depends on many 
solution properties. including protein concentration, ionic strength etc. Finding the 
exact conditions to produce good crystals of a specific protein usually requires many 
careful trials' 9 . 
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2.3.2 Crystallisation trials of human full-length eIF4E with m7GTP. 
Crystallisation trials were initially carried out with apo protein, however no 
promising hits were found. Screens using various PEGs (4000, 6000 and 8000) and 
ammonium sulphate at varying pH produced no promising hits. A brown amorphous 
precipitate was the most frequently seen result. This observation, supported by the 
conformational change seen in the CD spectra of eIF4E upon addition of m7GTP, led 
us to the conclusion that ligand is required for stabilisation and could be an important 
criteria for successful crystallisation. In the literature successful crystallisation of 
e[F4E has only been carried out with a cap-analogue present (see figure 8)1 31516. 
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Figure 8: n17GDP (A) and rn7GpppA (B) are cap-analogues that have been used in the crystallisation 
of niurine cIF4E and human eIF4E respectively. 
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Preliminary crystallisation trials of eIF4E in complex with rn7GTP were carried out 
with a PEG 6000/pH screen, an ammonium sulphate/pH screen and another screen 
based around crystallisation conditions described in Tomoo el al' 5 (100mM HEPES-
KOH, pH 7.5. 0.2M Ammonium Sulphate, 27% PEG 6000) using the hanging drop 
vapour diffusion method. Duplicate plates were setup at both 4°C and 18'C. Small 
needle like crystals were formed in all the screens except in the ammonium 
sulphate/pH screen where microcrystalline showers were observed. Results were 
similar at both temperatures. The screen based on previous crystallising conditions 
at 4°C produced a cluster of long thin needle crystals, similar to those shown in 





Figure 9: Cluster of needle-like crystals grown under conditions of 100mM HEPES-KOH pH 7.0, 
20% PEG600() and 0. I M ammonium sulphate. 
The crystals that diffracted grew at 100mM HEPES, pH 7.0, 22% PEG 6000 and 
0.2M ammonium sulphate at 4°C; unfortunately these conditions were not 
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reproducible. The PEG6000/pH screens were repeated in regions of pH (6.5-8.5) 
where crystals were seen at O.1M, 0.2M and 03M ammonium sulphate 
concentrations. These screens produced numerous needle-like crystals. However all 
were too small to diffract. Crystal screens with a lower amount of protein in the 
drops were tried in order to decrease the amount of crystal nucleation sites. This 
worked to a certain extent producing slightly longer crystals, but the problem of too 
many crystals and crystal clusters forming remained. Also due to the amount of 
crystal growth being seen it was felt that the protein supply in the drop was being 
exhausted thus potentially preventing larger crystals from forming. 
To control the large amount of nucleation being seen micro-seeding was carried 
out 20 . This technique involves eIF4E crystals being crushed and a set of serial 
dilutions being made from this stock. Cat whiskers were then used to seed pre-
equilibrated drops with these serial dilutions. Several conditions where crystal 
growth had occurred were taken and the amount of protein halved in the drop. The 
aim of this technique is to bring the protein concentration in the drop into the meta-
labile zone, where crystals are on the brink of forming. By seeding the drops 
nucleation sites are being inserted in order to 'kick start' crystal growth. The 
amount of crystals fornied is dependent on how many nucleation sites are introduced 
into the drop. A single cluster of long needle-like crystals were observed at 10% 
PEG4000 and 100mM TRIS-HCL, pH 8.0 (as shown in figure 10). 
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Figure 10: Crystals grown using the micro-seeding technique at 10% PEG4000 and 100mM TRIS-
HCI. pH). 
Unfortunately a single needle broken off from the cluster did not diffract. In order to 
freeze these crystals the drops containing them were re-equilibrated with fresh 
mother solutions containing 50% PEG6000 or PEG4000 depending on which was the 
major precipitant. In the case of the needle cluster derived from micro-seeding other 
single needle-like crystals grew during this process. None of these crystals 
diffracted. 
2.3.3 Crystallisation trials for human full-length eIF4E ternary complex with 
m7GTP and 4E-BPI motif peptide. 
In light of the poor success in crystallising full-length human eIF4E in complex with 
m7GTP alone, further trials were carried out with the 4E-BPI-motif peptide 
(RIIYDRKFLMECRN, provide by Cycalcel Ltd, Dundee). Preliminary trials were 
carried out with PEG/pH and ammonium sulphate/pH screens. These produced no 
crystals but did give grey crystalline precipitate across the pH range used (pH4-pH9). 
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Further trials were carried out using ammonium sulphate as an additive for the PEG 
screens and PEG 400 as an additive for the ammonium sulphate based screen at pH 
7.0. Both screens produced crystals with the most promising in terms of size from 
the PEG screen (see figure I1B). These were thin plate-like crystals whilst those 
seen in the ammonium sulphate screen were small crystalline clusters appearing to 






Figure 11: (A) Small crystalline clusters of eTF4E/m7GTP/4E-BPI peptide complex grown at 60% 
ammonium sulphate. 4% PEG400. pH7.5 100mM HEPES-KOH. (B) Thin-plate like crystals of the 
eIF4E/m7GTP/4E-BPI peptide complex crystallised at 25% PEG 6000. 5% ammonium sulphate. pH 
7A0 100mM HEPES-KOH. 
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The crystals grown in the PEG screen, with ammonium sulphate as an additive, were 
analysed at the 1D29 station at the ESRF. Grenoble where they diffracted to 
approximately 2A (see figure 12). The crystal structure solution is discussed in 
chapter 3. 
Figure 12: Diffraction pattern of the thin-plate like crystals of the eIF4E/in7GTP/4E-BPI peptide 
complex (crystallised at 25% PEG 6000, 5% ammonium sulphate. pH7.0 100mM HEPES-KOH) as 
observed in figure 11W 
Crystallisation trials were also carried out with just full-length eIF4E and 4E-BPI- 
motif peptide. Crystals were observed at 60% ammonium sulphate with either 5% 
PEG400 or PEG600 at pH7.5 (100mM HEPES-KOH) (see figure 13). However it 
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was quickly noted that these crystals only grew after protein purification had been 
carried out using the m7GTP affinity column. It was concluded that m7GTP 
leeching from the column was responsible for the appearance of these crystals. The 
crystals grown were flash frozen in liquid nitrogen using immersion oil as a 
cryoprotectant. Diffraction was observed to 3A, however after a rotation of 90° in 
the phi axis the spots become very diffuse and streaky. 
Figure 13: Crystals were observed at 60 6/0 ammonium sulphate with either 5 17o PEG400 or PEG600 
at pH7.5 (100mM HEPES-KOH). Diffraction was observed to 3A: however after a rotation of 900  in 
the phi axis the spots become very diffuse and streaky. Crystals were only seen after an affinity 
column preparation: highly suggestive of ni7GTP leaching from the column and allowing formation 
of m7GTP/peptide complexed crystals. 
2.4 Conclusions 
eIF4E is principally expressed in inclusion bodies which allows it to be purified in a 
simple two step procedure: inclusion body wash followed by anion-exchange 
chromatography. This allows us to purify to a in large quantities (30 mg/l) of apo 
eIF4E to a high degree of homogeneity. cIF4E was readily crystallised in the ternary 
complex with m7GTP and the 4EBP1 peptide and produced crystals that diffracted to 
2k Trials of eIF4E with no m7GTP were unsuccessful. With the ability to purify 
and crystallise elF4E rational drug design methodology is now open to us for the 
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search for anti-cancer drug leads. Virtual screens utilising in silico technologies such 
as DOCK" and LIDAEUS 22  can be used to investigate the cap-binding site and 
generate potential drug leads. Virtual hits can then be screened against eIF4E. 
Techniques for screening these hits will be discussed in chapter 5. Ligands that 
have then been shown to interact with eIF4E can be used in co-crystallisation trials 
or soaking trials with ternary crystals of eIF4E. 
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Chapter 3: Crystallographic and biophysical analysis of full length human 
eIF4E complexed with m7GTP and the 4E-BPI motif peptide. 
3.0 Introduction and aims. 
The aims of this chapter are to provide crystallographic insight into the distinctive 
features of the cap-binding site and the peptide interactions of the 4E-BPI peptide 
with e1F4E. The interactions of the 4E-BPI peptide were further examined using 
surface plasmon resonance with the 4E-BPI peptide immobilised on a streptavidin 
chip. 
3.1 eIF4E's protein interactions. 
For the efficient translation of mRNA, systematic interactions are required between 
the niRNA and the eukaryotic initiation factor proteins. These constitute eIF4B, 
eIF4A, eTF4B, eIF4H and eIF4G. eIF4A, eIF4E and eIIF4G form a stable ternary 
complex in mammals termed eIF4F 1 . Cap-dependent translation begins with the 
eIF4F complex recognising the 7-nicthyl-G5'N cap of mRNA, via eIF4E, and 
recruiting the ribosome and the mRNA 1 . eIF4A is a DEAD family RNA helicase, 
which is hypothesised to unwind secondary structure in the mRNA 5' untranslated 
region to facilitate ribosome binding to the rnRNA and its subsequent scanning to 
reach the initiation codon 2 . eIF4A and eIF4E interact with the large modular 
scaffolding protein eIF4G. eIF4G also interacts with the multi-subunit initiation 
factor eIF3 that binds directly to the ribosome, as well as the poly-A-binding protein 
(PABP)'. The PABP-eIF4G interaction brings about the circularisation of the 
mRNA, 
62 
Cap-dependent translation is inhibited by 4E-BPI, 2 and 3, without affecting cap 
recognition by eTF4E 4 . Biochemical studies have shown that eIF4Gs and 4E-BPs 
occupy overlapping sites on the surface of eIF4E 5 . Further work demonstrated that 
both sets of proteins converged on the same eIF4E binding mechanism, which 
employs a Tyr-X-X-X-X-Leu-(I) eLF4E recognition motif (X is variable and is Leu, 
Met or Phe) 6 . The e1F4GII and 4E-BPI recognition motifs have also been 
crystallised in a ternary complex with truncated mouse eIF4E and the cap-analogue 
m7GDP 7 . In both complexes the peptides were seen to adopt an L-shaped, extended 
chainlalpha-helical confbrmation that docks into an invariant portion of the convex 
surface of eIF4E (see figure 9). The 4E-BPI peptide acts as a molecular mimic of 
eIF4GII and carries out inhibition by competing for the same binding site on the 
convex dorsurn of eIF4E and blocking assembly of the translation machinery. 
Biophysical techniques have also demonstrated that these peptides are unordered in 
solution before becoming ordered upon binding 
7,8. Phosphorylation of 4E-BPI leads 
to its dissociation from eIF4E, leaving e[F4E free to bind eIF4G and form the eIF4F 
complex. 
Recently an NMR structure has been solved of the yeast eIF4E protein in complex 
with m7GTP and the eIF4GI binding domain 9 . Here they have described the N-
terminal domain of eTF4E becoming ordered with the eIF4GI fragment forming a 
'bracelet' around it and the remainder of the N-terminal forming a molecular 'fist' 
(see figure 1). From yeast to mammals, e1F4G mediates increased association of 
eIF4E with capped mRNA whereas the motif peptides alone are unable to cause such 
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an effect 9 . Gross et a1 9  have proposed that the N-terminus acts as a remote sensor' 
for the binding slot. From SPR and ITC data for binding of eIF4GI to a series of N-
terminally deleted eIF4E constructs they observed that a two state binding model 
described the results for MO and A20 eW4E and that a one state binding model 
described results for the A30 and A35 data 9 . From this they have proposed that the 
consensus peptide may participate in encounter complex formation as it hinds to 
eIF4E which is followed by the formation of the interlocking interface. The 
interlocking interface promotes strong binding and slow dissociation kinetics 9 . 
ng 
Figure 1: The N-terminal of eIF4E (yellow) becomes ordered when it interacts with the eIF4GI 
fragment (purple). forming a 'bracelet around it with remainder of the N-terminal forming a 
molecular'fist' () . 
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3.2 Crystal structure and modelling of eIF4E ternary complex. 
3.2.1 Data collection. 
Thin-plate like crystals of the eIF4E/m7GTP/4E-BPI peptide complex, crystallised 
at 25% PEG 6000, 5% ammonium sulphate, p1-I 7,0 100mM HEPES-KOH, were 
cryo-frozen using freezing solution containing 20% Glycerol, 5% ammonium 
sulphate, 25% PEG 6000 and pH 7.0 100mM HEPES-KOH. The eIF4E/m7GTP/4E-
BPI peptide crystal was mounted in a random orientation and 120 degrees of data 
were taken with an oscillation aiigle of 1° using the Phi rotation method at lOOK at 
the ESRF 1D29 beamline at Grenoble. France. Keeping the crystal at lOOK increases 
the lifetime of the crystal in the X-ray beams. The X-ray beam generates heat and 
reactive free radicals. By freezing the crystal the diffusion of free radicals is limited 
and crystal deterioration is thus limited at sites were free radicals have been 
generated. Symptoms of x-ray damage are loss of resolution in the diffraction image 
and deterioration of scaling statistics when processing the data 10 . The goal of data 
collection is to determine the indices and record the intensities of as many reflections 
as possible. Diffraction data was indexed in MOSFLM'' and sealed in SCALA" 
revealing the unit cell to be P2 1 2 1 2 1  (see table 1 for unit cell dimensions and sealing 
statistics). 
3.2.2 Structure solution. 
The Mathew's coefficient calculated using the CCP4 suite of programs 	2.4 
giving a solvent content 47.7% for the eIF4E/m7GTP/4E-BPI peptide crystal. This 
result indicated the presence of two ternary complexes in the asymmetric unit of the 
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unit cell. The structure of the ternary complex containing full-length human 
eIF4E/4E-BP1/m7GTP was solved by molecular replacement using MOLREP1 . 
The search model was the 2.2 angstrom structure of A27 murine e]IF4E complexed 
with the 4E-BPI peptide, with m7GDP and any structured waters removed. Data up 
to 3.5 angstrom was used for the MOLREP 1 ' solution. MOLREP" isolated the 
positions of two ternary complexes in the asymmetric unit. These initial co-ordinates 
were used to begin refinement. 
3.2.3 Model building and refinement. 
Prior to refinement, 2F,,-F, and F,-F, maps were calculated using FFT in CCP4 using 
data in the resolution of 30-2.3 angstrom''. The model was examined and was found 
in electron density for the entire length, except for the N-terminal and a section of the 
C-terminal loop. The starting model was subjected to 10 cycles of rigid body 
refinement and followed by 10 cycles of restrained refinement in REFMAC 5.01 112. 
This gave an R-factor of 28.3 and an R-free of 32.8. At this point waters were added 
using ARP/WARP 1 1,13  . After this the m7GTP ligand was used (REFMAC' 
1,12  library 
files generated using PRODRG' 4 ) in the refinement and placed into clearly visible 
electron density. This was then followed by continuous cycles of manual refinement 
of the model using COOT' and 10 cycles of restrained refinement using REFMAC 
50 1112 
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Unit Cell Dimensions a37.9, b=99.6, c=135.3 
= J3 = 	= 90 0 
Space Group P2 1 2 1 2 1 
Temp(K) lOOK 
Number of collected reflections to 23Angstroin 112855 (12976) 
Number of unique reflections to 2.3Angstrom 22656 (3030) 
• sym 0.157 (0.574) 
• factor 19.5 
• free 24.9 
RMS bonds 0.010 
RMS angle 1.352 
Average B value 26.3 
% completeness 96% (89.5%) 







92.2% residues in most favoured regions 
6.1% residues in additional regions 
1.2 residues in generously allowed regions 
0.6% residues in disallowed regions 
Table 1: The table shows the unit cell dimensions and space group for the plate-like crystals of full 
length human eIF4E co-crystallised with m7GTI' and the 4E-BPI motif peptide. Also shown are the 
data collection statistics and the parameters of the final model. 
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3.3 Crystallographic analysis of the eIF4E ternary complex. 
3.3.1 eIF4E general structure and fold. 
The structures of truncated murine eIF4E bound to m7GDP/m7GpppG" 7 and full 
length human cIF4E complexed with m7GTP/m7GpppA' 8 have been solved by X-ray 
crystallography. The yeast homolog has also been elucidated by NMR studies 19 . 
These proteins have high sequence similarity (see figure 3) and resemble a cupped 
hand, consisting of a curved, eight-stranded anti-parallel beta sheet, with three long 
alpha helices packed behind them (Fig 2). The three long alpha helices lie along the 
beta sheet on the opposite side of the cap-binding site running almost parallel in 
direction to the strands (figure 2). The cleft that forms the cap-binding site is formed 
by the concave side of the beta sheet, the short alpha helix (A) above it and a loop (B) 






Figure 2: The crystal structure shown above is full length human eIF4E complexed with the 4E-BP I 
motif peptide and m7GTP. eIF4E possesses an /J3 fold typical of the RNP fold of RNA binding 
proteins. The 4E-BPI motif peptide is located on the dorsal side of the protein with the cap binding 
side lying on the opposite side of the protein. A) and B) indicate the short helix and loop that together 
with the 13 sheet form the binding site for m7GTP. 
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5 	 15 	 25 	 35 
Human 	MATVEPETTP TPNPPTTEEE KTESNQEVAN PEHYIKHPLQ 
Mouse VAN PEHYIKHPLQ 

































125 	 135 	 145 	 155 
Human 	KQQRRSDLDR FWLETLLCLI GESFDDYSDD VCGA 
Mouse KQQRRSDLDR FWLETLLCLI GESFDDYSDD VCGA 
Yeast 	--GKGADIDE LWLRTLLAVI GETIDEDDSQ ING\JVLSI K 
165 	 175 	 185 	 195 
Human 	IGIIAI TT ECENREAVTH IGRVYKERLJG LPPKIVIGYQ 
Mouse GIAI TT ECENRDAVTH IGR\TZKERLG LPPKIVIGYQ 
Yeast 	 GFAL T- KSEDKEPLLR IGGKFKQVLK LTDDGHLEFF 
.... 	I .... 	I .... 	I .... 
205 215 
Human 	SHADTATKSG STTKNRFVV 
Mouse SHADTATKSG STTKNRFVV 
Yeast 	PHSSANGRHP QPSITL--- 
Figure 3: Sequence alignment of human, mouse and yeast eIF4E sequences. Tryptophans that stack 
with m7G are highlighted in M, the glutamate that forms hydrogen bonds with the m7G ring is in 
bold, the residues that form the phosphate binding pocket are highlighted in • and the third tryptophan 
that the m7G ring packs against is shown in M. The part of the mouse sequence not highli Thted in 
• shows the construct used for the crystallisation of the mouse structure. The section in also 
contains the majority of amino acid differences between the mouse and human sequences. 
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3.3.2. Cap-binding site. 
Our structure is highly similar to the mouse, yeast and previously solved human 
structures 7 " 6 " 5 ' 19 . The ni7G moiety of the cap structure is sandwiched between two 
tryptophans (W56 and W102) forming Tc-cation interactions 20 ' 21 (figure 4). The 
tryptophan residues are located in a narrow slot on the molecule's concave surface 
(see figure 2). The methyl group of the m70 moiety makes a van der Waals contact 
with a third conserved tryptophaii (W166). The structure of the cap-binding pocket 
is conserved between human, mouse and yeast cIF4E. Two NH groups on the m7G 
moiety form H-bonds with the carboxyl group of E103 stabilising the ligand/protein 
interactions (figure 4). Our structure displays disorder in the C-terminal loop (Ala 
203 to Thr 211) that in other strLlctllrcs containing the dinucleotide analogue 
m7GpppA is seen to be structured (figure 
5)18,  This stabilisation is brought about by 
hydrogen bonding between the adenosine ring with Thr 205 and Thr 211 via a water 
molecule and is stabilised by some Van der Waals contacts with Ser 207 and 
neighbouring residues (figure 5). 
The a-phosphate has a direct electrostatic interaction with R157 and interacts with 
several conserved water positions (figure 6). The second phosphate group forms 
three direct contacts to K159, K162 and R157 (figure 6). The gamma phosphate 
forms a direct ionic contact but also interacts with other structured waters that 
mediate its interactions with the cap-binding site (figure 6). For further discussion of 





m-dentate HA and HD 
angement on m7G 
g Negatively chai 
triphosphate ta 
Positive delocalised charge on m7G 
ring 
Figure 4: (A) The m7G moiety intercalates itself between the W102 and W56 side chains, the N7 methyl 
group forms a van der Waals contact with W166 and three hydrogen bonds are formed between the m7G 
ring and the E103 side chain and the backbone amide of W102. The triphosphate tail is recognised by 
RI 12, R 157, K 159 and K 162 and via several water-mediated contacts (see figure 4). (B) Distinguishing 
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C-terminal loops becomes 
ordered in the (1IPB) eLF4E 
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Figure 5: A) the m7G moiety intercalates between the tryptophans (yellow) as normal and the 
triphosphate tails resides on the positive binding pocket as described previously (figure 4). The area 
highlighted by the rectangle (B) in A is shown in C. Here it can be seen that the adenine moiety 
stabilises the C-terminal loop which is not seen in other eIF4E structures. The ribose rings forms a 
water mediated hydrogen bond to '17211 (yellow dashes) whilst the adenine rings forms a variety of 








	 } m7GTP 
A 
C 	 % - 0 
K162 
Figure 6: A) shows a water network between the triphosphate tail and eIF4E residues. B) is a 
water network that forms behind the cap binding site involving W102, the 0' of the ribose ring. 
T205 and H200. Potential hydrogen bonds shown with yellow dashes and direct contacts shown 
with magenta dashes. Both these networks constitute part of a larger network at the protein/ligand 
interface. C) Direct contacts fornied between the triphosphate tail and the residues R157. K159 and 
K162. K159 in other crystal structures is seen projecting into the solvent. Contacts shown with 
magenta dashes. 
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3.3.3 Other cap-binders in biology. 
CBC is a cap-binding complex present in the nucleus and consists of two subunits 
CBP20 (the cap-binding protein) in association with an ancillary protein CBP80. 
The complex is thought to aid in the transport of pre-mRNAs through the different 
maturation processes 22.  Some viruses e.g. retroviruses, utilise the host cellular 
capping mechanism 23 . Most viruses have evolved their own virus specific capping 
system 23 . They can be divided into two groups. 
The first group includes viruses such as poxviruses, coronaviruses, flaviviruses and 
reoviruses that replicate in the cytoplasm of the cell. Vaccinia virus (a double-
stranded DNA pox virus) is a well studied example of such viruses. Thus VP39, the 
vacciiiia viral protein 39, recognises its own capped niRNAs. After binding the cap 
structure, the enzyme acts as a 2'-0-methyltransferase transferring a methyl group to 
the 2' atom of the moiety of the first residue of the cap structure 23 . Baculoviruses, 
like flaviviruses, also appear to have evolved cap-dependent 2'-0-
niethyliransferases, but the mechanism of cap-binding by the flavivirus 2'-0-
methyl trans ferase domain may differ from that of VP3 
923• 
The second group includes negative-strand RNA viruses replicating either in the 
nucleus, like orthomyxoviruses ( e.g. influenza virus) or in the cytoplasm, like bunya 
viruses 23 . These viruses have not evolved capping enzymes. Instead they have 
evolved a mechanism to 'hijack' the cap structure from host cell mRNAs. The viral 
polymerase binds to cellular capped rnRNA in infected cells. An endonuclease 
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activity associated with the polymcrasc then cleaves the capped oligonucloetides, 
which subsequently act as primers to initiate viral transcription 23 . 
Several isofonns of cap-binding proteins have also been found in Leishinania and 
C'.elegans24 . in C.elegans it has been discovered that cap-binders selectively lead to 
an increase in translation of a certain subset of mRNAs 25 . 
3.3.4 Comparison of rn7GTP binding in VP39 and CBC. 
Cap-binders that have successfully been structurally detemiined are VP39, CBC and 
eIF4E. The overall structure of the three cap-binding proteins eIF4E' 6 ' 18 " 9 , CBC26 
and VP3927  diFFer widely due to their evolutionary unrelated origin. However their 
cap-binding sites are essentially very similar, In addition to the two aromatic 
residues sandwiching the n37G moiety, they possess a basic area to accommodate the 
triphosphate moiety of the cap structure and acidic residues that recognises the HA 
and HD on the m7G ring. 
All three proteins accommodate the m7G ring sandwiched between two aromatic 
residues (W102/W56 in eIF4E, Y20/Y43 in CBC and Y22/17180 in VP39) (figure 7). 
The presence of the aromatic sandwich was suggested from earlier crystallographic, 
spectroscopic and theoretical studies on small molecule models, like tryptophan 
containing peptides and/or indo Ic derivatives 28 
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Figure 7: The figure displays the 
cap-binding site of VP397, CBC21 
and eIF4E and the common 
features used in recognition of the 
cap-analogue. The most distinctive 
feature is the intercalation of the 
cap-analogue between two 
aromatic residues (shown in red). 
shows the cap-binding site in 
the CBP2() subunit of CBC. The 
dinuchoetide 	(m7GpppG) 
intercalates itself between Y2() and 
Y43. Dl 16. the carbonyl ofWl 15 
and DII 4 form hydrogen bonds 
with the m7G ring. 	The 
triphosphate section is recognised 
by R127, R135 and Q133. Y138 
stacks against the guanine ring. 
shows the cap-binding site of 
VP39. Again the m7G ring stacks 
between two aromatic residues: 
Y22 and F180. The N2 on the 
m7G ring is again recognised by 
acidic side-chains: D182 and E233. 
The carbonyl on Y204 forms a 
contact with the methyl group. 
The 	triphosphate 	section 	is 
recognised by the amide of E207 
and the 0 of the S205 side-chain. 
The m7G moiety intercalates 
itself between the W102 and W56 
side chains, the N7 methyl group 
forms a van der Waals contact with 
W166 and three hydrogen bonds 
are formed between the m7G ring 
and the E103 side chain and the 
backbone amide of W102. The 













a RL% W166 
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The almost perfect alignment of the three aromatic rings, a nearly optimal inter-
planar distance (between 3.2 and 3.6 angstrom), substantial areas of overlap in the 
stacked rings (see figure 8) and the de]oc.alisation of positive charge arising from the 
N7-methylation of the guanine ring all contribute to strong interactions between the 
rc-electrons of the stacked aromatic rings 33. The strength of these specific 
interactions explains the low affinity of cap-binding proteins for non-methylated 
analogues (>100 fold difference in affinity aff i -ilty compared with N7 methylated ones) 
17 
Hydrogen bond formation occurs between NI and/or N2 of rn7G and the carboxylate 
groups of Glu or Asp in the cavity. This cavity contains at least one critical acidic 
amino acid - E103 in elF4E, Dl 16 in CB 
C26  and E233 in VP39 27 (figures 7). 
Mutations of these residues to Ala decrease affinity as well as specificity 26 ' 27 '34 . 
There arc differing results in the literature of the VP39 phenotype resulting from the 
mutation of E233 to Q 35 . Additional contacts are made between 06, Ni and N2 of 
rn7G (figure 7) and other amino acids. W102 is involved in these additional contacts 
in the case of eIF41E (figure 7), although this residue is also involved in the stacking 
with m7G. Dl 14, RI 12 and Wi 15 are involved in these contacts in the case of 
CBC 2 ' ( figure 7). D182 and water molecules make contacts with m7G in the case of 
VP392 7 (figure 7). 
The triphosphate moiety is bound in the cavity by residues forming salt bridges with 
the oxygen atoms of the phosphate groups. R157, 1(162, K159, RI 12 and water 
molecules form a binding cavity in the case of eIF4E (figure 6 and 7). In CB 
C26, 
R135, R127, Y20, Q133 and V134 are involved (figure 7), while in VP39 27 , R177, 
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E207 and S205 form the cavity (figure 7). The N7 methyl group of the m7G moiety 
is stabilised by vaii der Waals or weak polar interactions with WI 66 in the case of 
eIF4E and Y204 in the case of VP39 27 . In CBC 2 ' there is no interaction with the N7-
methyl group. Interactions \vith base I of the cap structure also contribute to 
binding, although non-specifically, to accommodate any base at that position. Base 
1 (guanine, in CBC' and adenine in the eIF4E structure) is stacked with Y138 in 
CBC 2  (figure 7) or is stabilised by hydrogen bonds and electrostatic interactions 















Figure 8: The figure shows intercalation of the ni7G moiety between the aromatic residues of VP39. 
CBC and eIF4E. The structure of m7GMP, top right-hand corner, shows the position of the 
delocalised charge. If the charge is localised around the N7 atom 
36 (m7G moiety shown in blue) it can 
he seen in all three cap binding proteins eIF4E. VP39 and CBP2() that it is off centre in respect to both 
aromatic residues involved in the cation-pi interaction. A situation similar to the optimal stacking of 
heterocyclic ring systems via it-it interactions. Also the aromatic side-chains principally overlap with 
the six-membered ring section of the m7G moiety. 
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3.3.5 4E-BPI peptide: the molecular mimic 
Source PDB Details Target RMS backbone (37-200) 
Chain A Full length human Chain B 0.72 
eIF4E/m7GTP/4E-BP I 
motif peptide  
1EJI N-terminal truncated Chain B 0.80 
murine eIF4E/m7GDP 
1 IPB Full human Chain B 0.74 
eIF4E/m7GTP 
1IPC Full human Chain B 0.72 
eIF4E/m7GpppA 
IRF8 Solution structure of the Chain B 0.73 
yeast translation Initiation 
factor eIF4E In complex 
with rn7GDP and eIF4GI 
residues 393 To 490  
IEJH: chain A N-terminal truncated Chain B 0.91 
muririe eIF4E/eIF4GII 
peptide/m7GDP  
IEJH: chain B N-terminal truncated Chain B 0.63 
murine eIF4E/eIF4GII 
peptide/rn7GDP  
1EJH: chain C N- terminal truncated Chain B 0.67 
murine eIF4E/eIF4GII 
peptide/m7GDP  
1EJH: chain D N-terminal truncated Chain B 0.54 
murine eIF4E/eIF4GII 
peptide/rn7GDP  
Table 2: RMS values for backbone superimposition of available eIF4E structures in the PDB for 
residues 37-200 showing a high overall similarity for the structures. All structures were aligned on to 
chain B of our refined eIF4E structure, The N-terminal truncated murine 4E-BP 1 peptide structure was 
not included. 
The biological function of eIF4E is carried out when bound to eIF4G which then 
associates to the ribosomal apparatus and leads to mRNA translation. This process 
is inhibited by 4E-BP1 competing with eIF4G for binding to the dorsal side of 
eIF4E. The crystal structures of mouse eIF4E complexed with eIFGII (1EJH) 7 and 
4E-BP1 motif peptides (1EJ4) 7 demonstrate that His 37, Val 69 and Trp 73 play an 
important role in binding eIFGIT and 4E-BP1 '. The 4E-BP1 peptide containing the 
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I EJ4 mimic the structure of the eIF4GII peptide by forming the same alpha helix 
with an extended strand conformation (figure. 9). The RMS differences (table 2) 
between the cap binding sites of peptide bound and peptide free structures are small 
and clearly show that peptide binding has no effect on the final configuration of the 
binding site. The shift seen in the position of K159 in our structures compared to 
others is not observed in the other peptide structures in the PDB 7 and is most likely 








4E-BPI motif peptide 
Figure 9: Picture demonstrating the adoption of the L-shaped conformer by the 4E-BPI peptide that 
is used to imitate the eIF4GII peptide. Also indicated are areas of negative charge that presumably 
repel phosphorylated region of the 4E-BPI protein (Bold circles). Dashed circle indicates position of 
hydrophobic residue in respect to the hinge area of the L' conformer. S65 3 ' is a residue (not present 
in the peptide used for crystallisation) that is phosphorylated on 4E-BPI and is electrostatically 
repulsed by the eIF4E residues E70 and D7 I. and has a role in abrogating 4E-BP binding to eIF4E and 
relieving inhibition of cap-dependent translation. 
54 	 60 
Consensus SEQ 	 Y-X-X-X-X-L- 
4E-BP1 	 R-I-I-Y-D-R-K-F-L-i-E-C--R-N 
M 4E-BP1 R-I-I-Y-D-R-K-F-L-Iii-E-C-R-N-S-P -V 
M eIFGII 	 K_K-Q-Y-D-R-E-F-L-L-D-F-Q-F-M-P - A 
624 	 630 
Figure 10: Alignment of 4E-BPI and elF4Gll peptides (used in crystallisation of cIF4E) and the 
binding consensus motif. Residues highlighted in red are strictly conserved while those in blue must 
he hydrophobic. M indicates eTF4GII and 4E-BPI peptides used in other complex structures in the 
PDB 7 . 
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3.3.6 Structural analysis of 4E-BP1 peptide binding to eIF4E. 
In contrast to the previous published structure (1 EJ4) 7 that contains only one ternary 
complex in the asymmetric unit, the X-ray structure of the human full length/4E-
BP1/m7GTP contains two complexes within the asymmetric unit. Electron density 
is also clearly seen for all the peptide residues in both units. 
H37 	Ii 	W73 
4Fç 1j: 
W73 







Figure 11: (A) Hydrogen bond interactions conserved in the crystal structures between eIF4E and the 
4E-BPI motif peptide are shown in yellow 7 . These are Y54 to G139 and P38 respectively. L59 to 
W73 and 152 to Q40. Peptide residues are coloured green whilst eIF4E residues are coloured blue. 
Note the 'T' shaped interaction between H37 and F58. The hydrogen bonds are predominately 
between the two strictly conserved residues of the peptide chain and eIF4E. (B) Diagram showing the 
hydrophobic cluster of residues at the protein/4E-BPI peptide interface with eIF4Es P38, V69, W73, 
F72 1138 and L135 seemingly forming a cage around the L59 of the peptide. Peptide residues are 
coloured in green and eIF4E residues are colured blue. L59 is shown with its Van der Waals radii as 
spheres. 
Four hydrogen bonds are observed between eIF4E and the 4E-BPI peptide that are 
found both in the full length human eIF4E complex and the N-terminal truncated 
murine complex (IEJ4) 7 . These hydrogen bonds are the OH group of Y54 to the 
carbonyl backbone of main chain P38 (2.45A. figure 1 IA), the amide nitrogen of 152 
to the main chain OE  of Q40 (2.92 A, figure 1 lA), L59 carbonyl with the NE1 of 
the main chain W73 (2.99A, figure 1 IA) and finally the amide of Y54 to the main 
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chain carbonyl of G139 (3.12 A. figure 1 1A). Y54 and L59 are strictly conserved in 
the binding motif of 4E-BPI and eIFGII for eIF4E (figure 10). 
When Tyr 624 is replaced with a Phe, in human eIF4GI, there is only a modest affect 
on binding . If the tyrosine is then mutated to Ala in yeast eIF4G then it induces a 
lethal phenotype . If Leu 629 and the hydrophobic residue at position 630 are also 
converted to Ala, in yeast eIF4G, then temperature sensitive phenotypes result 
39 
This evidence shows the importance of these residues, and the interactions they are 
involved in, in the binding of the consensus motif peptide to eIF4E (figure 10). 
Apart from the direct hydrogen bond interactions there are two common hydrogen-
bonded water interactions: the carbonyl oxygen of 152 bridged to the amide of 
eIF4E's Q40 and the carbonyl of eIF4E's 1138. IEJH contains 4 complexes in the 
asymmetric unit ', and the same arrangement of hydrogen bond interactions are also 
seen most frequently (see figure 12A). The only minor differences observed are that 
the amide of K622 instead of 152 interacts with the OE1 of Q40 in eIF4E and that the 
water bridged hydrogen bonds are also forming with 1(622 instead of the 152. 
The two conserved residues in the general peptide binding motif Y54 and L59 as 
well as being involved in hydrogen bond interactions are also excluded from the 
solvent substantially more than other peptide residues. L59 is surrounded by a cage 
of amino acid side chains essentially hydrophobic in character (figure 1113). The 
eIF4E residues involved are V69, G139, W73, 1138 and L135 and are almost 
exclusively buried away from solvent. The peptide residues M60 and Y54 are also 
part of this hydrophobic cluster and complete the cage. This packing of hydrophobic 
resides together at the protein/peptide interface explains why the amino acid at 
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position 60 in the peptide must be hydrophobic (figure 1 I B). The hydrophobic 
cluster is also observed in the eIF4GII peptide/eIF4E interface and indicates its 











Figure 12: (A) Hydrogen bond interactions conserved in the crystal structure between eIF4E and the 
eIF4GII motif peptide  that are analogous to those in 4E-BP I are shown in yellow. These are Y54 to 
G139 and P38 respectively, L629 to W73 and K622 to Q40. Peptide residues are coloured green 
whilst eIF4E residues are coloured blue. Note how the H37 and F628 and F632 residues form a 
trimeric ring arrangement. The hydrogen bonds are predominately between the two strictly conserved 
residues of the peptide chain and eIF4E. (B) Diagram showing the hydrophobic cluster of residues at 
the protein/eIF4GII peptide interface with elF4Es P38. V69, W73. 1138 and L135 seemingly forming 
a cage around the 1,629 of the peptide. Peptide residues are coloured in green and eIF4E residues are 
colured blue. L629 is shown with its Van der Waals radii as spheres. 
If W73 in eIF4E is mutated to an Ala the interaction with 4E-BPI or eIF4GI is 
greatly reduced 40  Other residues located on eIF4E do not have such a marked 
effect and this highlights the importance of W73 in the hydrophobic cluster. H37 
appears to form a 'T shaped interaction with eIF4E's F58 (figure 1 1A.) However 
in 1EJH 7 the residues F628 and F632 are seen together to be involved in forming 
hydrophobic interactions against H37 (figure 12A). 
Ml 
The three arginines found in the peptide are all involved in binding eIF4E. R51 
interacts eleciro-statically with D143, D144 and D147, whilst R56 forms a salt 
bridge to E132. R63 seems to lay flat across the W73 and then projects away from 
eIF4E. However this data does not include the position of phospho-acceptor sites in 
4E-BPI relative to eIF4E. NMR data from Gross et al ) have shown that eIF4GI 
(393-490) and the 4E-131 1 I binding site on yeast eIF4E partially overlap in two 
regions containing conserved electrostatic residues: Glu 72, 73 and Glu 140/Asp 
143/Glu 144 (see figure 9). These sites presumably repel phosphorylated 4E-BPI 
due to electrostatic repulsion. In I EJH' the peptide residue R626 interacts electro-
statically with E132, as seen for the 4E-BPI peptide. Q633 takes the place of R63 in 
the eIFG4II motif and carries out similar polar interactions against N77. Again 
another arginine residue is replaced with a conservative glutamine at position 633 in 
the eIF4G1I peptide and interacts with residues E140 and D143 as in the eIF4E/4E-
BP 1/m7GTP structures 7 . 
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3.3.7 4E-BPI Peptide is independent of N-terminal stabilisation. 
The N-terminus of eIF4E is absent from electron density in the human full 
lengthl4E-BP1/m7GTP crystal structure as well as all the other full length structures 
present in the PDB . The peptide it would seem plays no role in stabilising or 
ordering the flexible N-terminus of cIF4E and that the N-terminus is highly mobile. 
Experiments have shown that A35 and A30 constructs of yeast eIF4E binds yeast 
eIF4G with a much lower affinity than the A20 construct and imply that the flexible 
N-terminus is important in binding e1F4G °. Our structure clearly shows that peptide 
fonnation is independent of N-terminal stabilisation and could initiate binding 
between 4E-BPI and e1F4E. On the basis that yeast eIF4E has a high sequence 
similarity to human eIF4E and that the 4E-BP 1 and the eIF4GI motif peptides are 
identical to their yeast counterparts the lollowing conclusion can be drawn; that the 
structural evidence lends support to the hypothesis by Gross et al 9 that the binding 
of yeast eIF4GI to yeast eIF4E is initiated by a collision between eIF4E and the 
peptide motif where independent formation of the 'L' conformer occurs (see figure 
9). This model then proposes that the N-terminus then interacts with eIF4G in a 
second step to complete the association process. 
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3.4 Surface plasmon resonance studies on the 4E-BP1 peptide interaction with 
eIF4E. 
In this next section the kinetics of the 4E-BP I peptide interaction with eIF4E using a 
BIAcoie 2000 machine were studied. Surface plasmon resonance can be used to 
investigate the specificity of bimolecular interactions, the kinetics and affinity of an 
interaction and the concentration of spcci lie molecules present in the sample. The 
section will begin with a brief description of the fundamentals of the surface plasmon 
resonance technique before an analysis of how 4E-BP 1 interacts with eIF4E and what 
insights it may afford into inhibitor design. 
3.4.1 Surface plasmon resonance basics. 
Surface plasrnon resonance can be used to monitor the interaction between molecules 
in real time. The technique involves attaching one interacting partner to the surface of 
a sensor chip, and then passing sample containing other interaction partners(s) over the 
surface. Binding of molecules to the surface produces a response which is 
proportional to the bound mass 11-43 
Surface plasmon resonance is a phenomenon that occurs in thin conducting films at an 
interface between media of - different refractive index. The BlAcore 2000 system was 
used in the following experiments and the media used here are the glass of the sensor 
Chip, the sample solution and the conducting film, which is a thin layer of gold on the 
sensor chip surface 41-43 
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Under conditions of total internal reflection, light incident on the reflecting interface 
leaks an electric field intensity called an evanescent wave field across the interface 
into the medium of lower refractive index, without actually losing net energy. The 
amplitude of the evanescent field decreases exponentially with distance from the 
surface, and the effective penetration depth in terms of sensitivity to refractive index is 
about 20% of the wavelength of the incident light41 
-43 
At a certain combination of angle of incidence and energy (wavelength), the incident 
light excites plasmons (electron charge density waves) in the gold film. As a result, a 
characteristic absorption of energy via the evanescent wave field occurs and SPR is 
seen as a drop in the intensity of the reflected light 443 . 
Due to penetration of the solution by the evanescent waves, conditions for this 
resonance effect are very sensitive to the refractive index of the solution within the 
effective penetration depth of the evanescent field. Changes in the solute 
concentration at the surface of the sensor chip causes changes in the refractive index of 
the solution which can be measured as changes in the SPR conditions. The penetration 
depth of the evanescent wave determines the thickness of the solution layer where 
refractives index changes are monitored: only refractive index changes close to the 
surface affect the surface plismoti resonance signal 4143 . 
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3.4.2 4E-BPI peptide does not bind in a 1:1 Langmuir binding model. 
200 	 270 	 340 	 410 	- 	460 	 500 	 620 	
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Figure 13 (A) The graph shows the fitting of the two step binding model via a conformational change 
to the BlAcore sensograms ([A] + [B] <> [A][B]* <> [A][B]). (B) The figure shows the residuals of 
the binding model's fit to the sensograms. The overall chi2 of the fit was 0.495. 
BlAcore studies on the biotinylated version of the peptide used in the crystallisation of 
the ternary complex were carried out (biotinpAla-I3-Ala-RIIYDRKFLMECRN). 
eIF4E, at differing concentrations was injected over an SA chip (BlAcore, streptavidin 
chip) with the 4E-BP 1 peptide immobilised on it. When the experiment was conducted 
with no m7GTP present there was a discrepancy in the results caused by degradation 
of eIF4E. This was overcome by having m7GTP present in a 5:1 ratio to protein. The 
surface plasmon resonance results from this experiment were fitted to a two step 









describes the situation where the analyte [A] binds the ligand [B] and forms a complex 
[A][B] that then undergoes a conft,rmaliona] change to [A][B]*. However the model 
makes the assumption that [A][B]* cannot dissociate directly to [A] + [B]. The two 
step binding model gives an overall of Kd of 700nM. This compares to values of 
105nM for ni7GTP saturated cIF4E and 94nM for apo eIF4E derived by steady state 
fluorescence ''. The model fitted reasonably well with a chi2 value of 0.495 (fig 13B). 
The BlAcorc results demonstrate a curve that does not fit 1:1 binding but follows a 
two step binding mode more closely. Such a model is supported by the fact that the 
binding peptide motifs (4E-BP1 and eIF4GII) are unstructured in solution  
8  and 
undergo a conformational change when binding to cIF4E to form the 'L' conformer 
(figure 9). This may imply that the Y53 and L59 may bind first via specific hydrogen 
bond formation and surface area burial creating the turn between the extended strand 
and the alpha helix seen in the structure (figure 11 A), and then recruiting M60 to 
complete the hydrophobic cage (figure 11 B) which sets the stage for the other 
interactions to occur resulting iii ibinlation of the 'L' conformer (figure 9). 
The experimental BlAcore setup used also provides a means to assay small molecule 
inhibitors of the protein interaction between eTF4E and its partner proteins in a 
competitive manner. The cluster of hydrophobic residues that occur at the 
eIF4E/peptide interface could he used as a template for the design of small molecular 
drug-like compounds. 
This hypothesis could he further investigated and tested by using shorter peptides and 
looking for changes in binding affinity or mechanism of interaction. Crystallisation 
90 
studies could also be carried out side by side. Hopefully a minimal motif for binding 
could be sti-ucturally delineated and used as a refined hypothesis for structure-based 
drug design. An example of small molecules that target a protein-protein interaction 
are the nutlins which disrupt HDM2 binding to the tumour suppressor P53 44 . 45 
3.5 Conclusions. 
The cap is recognised by a common fold that is easily seen in the many structures 
available of eIF4E and the crystal structures of VP39 27 and CBC 2 . The m7G moiety 
forms 7t-cation interactions with two aromatic residues, the m7G ring forms several 
hydrogen bonds usually with all acidic residue and the triphosphate tail is recognised 
by a set of positively charged side chains. Despite these common structural 
characteristics for the recognition of' the cap-analogue none of these proteins share 
high sequence similarity or a common global Fold. The 4E-BPI peptide undergoes a 
disorder to order transition upon binding to c1F4E 46 . At the interface of the peptide 
and protein a hydrophobic Cluster of residues is formed that appears critical to 
binding. Biacore studies suggest that this interaction occurs via a two step 
mechanism, which would be expected as the peptide orders itself upon binding 
eIF4E. Upon binding 4E-BPI as in the case of the eIF4GII peptide forms an a-helix 
at the same site of interaction. 4E-BPI therefore inhibits eIF4GII binding by 
molecular mimicry. Both these sites as discussed in chapter 1 present themselves as 
targets for structure-based drug design. 
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Chapter 4: Probing the interactions of eIF4E cap analogue binding by mass 
spectrometry. 
4.0 Introduction. 
The aim of the following chapter is to characterise the cap-analogue interactions of 
the cap-binding site using mass spectrometry. The results of the experiments were 
compared and contrasted to solution based measurements in the literature to check 
the validity of gas-phase measurements and as a prelude to using mass spectrometry 
as a screening tecimique for eIF4E. 
4.1 Electrospray ionisation mass spectrometry for the study of non-covalent 
complexes. 
Weak non-covalent interactions play a fundamental role in the biological world. 
They regulate the interactions between substrate and enzymes, ligand and protein, 
protein and protein, and antibody and antigen. To successfully carry out mass 
spectrometry studies on non-covalent complexes the following criteria must be 
satisfied: 
• The ionisation method must be capable of generating intact gas-phase 
protein ions from solutions that contain biological buffers. 
• The internal energy transferred to the macromolecule during the ionisation 
process must be low enough to prevent dissociation of the complex. 
• The MS instrumentation must be of sufficient mass range to observe the 
ionised complex. 
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Two ionisation techniques have been developed that fit the above criteria, 
electrospray ionisation (ESI) and matrix assisted laser desorption/ionisation 
(MALDI). ESI-MS only will be discussed as this was the technique used to carry out 
the mass spectrometry work in this chapter. 
4.1.1 Electrospray ionisation (ESI). 
ESI is an example of an atmospheric ionisation source. These types of sources ionise 
the sample at atmospheric pressure and then transfer the ions in to the mass 
spectrometer. An Electrospray is produced by applying a strong electric field, under 
atmospheric pressure, to a liquid passing through a capillary tube with a weak flux 
(normally 1-10ul min') (see figure 1). The electric field is obtained by applying a 
potential difference of 3-6 kV between this capillary and the counter-electrode, 
separated by 0.3 to 0.2 cm, producing electric fields of the order of 106  V m 1 . This 
field induces a charge accumulation at the liquid surface located at the end of the 
capillary, which will break to form highly charged droplets. A gas injected coaxially 
at a low flow rate allows dispersion of the spray to be limited in space. These 
droplets then pass through either a curtain of heated gas, usually nitrogen, or through 















Figure 1: Diagram of ES! sorces. using skimmers for ion focalisation and a curtain of heated nitrogen 
gas for desolvation. 
If one examines with a microscope the nascent drop forming at the tip of the 
capillary while increasing the vohage, at low voltages the drop appears spherical and 
then elongates under the pressure of the accumulated charges at the tip in the 
stronger electric field; when the surface tension is broken, the shape of the drop 
changes to a 'Taylor cone' and the spray appears (see figure 2)1. 
Figure 2: Effect of ESI potential on the drop at the tip of the capillary with increasing voltage. 
(left) At low voltage, the drop is almost spherical. (Centre) At about I or 2 kV but below the onset 
potential the drop elongates under the pressure of the charge accumulating at the tip. (Right) At 
onset volta ge, the pressure is higher than the surface tension, the shape of the drop changes at once 
to a Taylor cone and small droplets are released. The droplets divide, producing spray. 
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The solvent contained in the droplets evaporates, which causes them to shrink to the 
point where the repelling coulombic forces come close to their cohesion forces, 
thereby causing them to break apart. Each rupture yields two charged droplets of 
similar size, but under the effect of the strong electrical field many smaller, highly 
charged droplets are produced too. When the electric field on the surface becomes 
large enough, desorption of ions from the surface occur. Charges in excess 
accumulate at the surface of the droplet. In the bulk, analytes as well as electrolytes 
(whose positive and negative charges are in equal number) are present. Desorption 
of charged molecules occurs from the surface, which means that sensitivity is higher 
for compounds whose concentration is higher at the surface. When mixtures of 
compounds are analysed, those present at the surface of the droplets can mask the 
presence of compounds that are more soluble in the bulk'. 
Electrospray is able to produce multiply charged ions from large molecules. The 
formation of ions is a result of the electrochemical process and accumulation of 
charge in the droplets. The Electrospray current is limited by the electrochemical 
process that occurs at the probe tip and is sensitive to concentration rather than to 
total amount of sample. This ionisation process is very soft and leaves the ion 
largely unfragmented; hence complexes involving non-covalent interactions can be 
studied. ESI experiments can be carried out in aqueous solution (near physiological 
pH) without the presence of organic solvent that tends to denature proteins
1,2
. 
Multiply charged ions for complexes such as protein-protein quaternary complexes 
exhibit relatively low charge at high m/z. The distribution of charge state is typically 
low e.g., 3-5 charge states. For several tetrameric proteins, Light-Wahl et al. 3 noted 
that the average charge per subunit has the order: monomer> dimer> tetramer 3 . The 
amount of charging that a biomolecule exhibits in an ESI mass spectrum has been 
correlated to a global solution structure. It has been observed that disulphide 
containing proteins show less average charging than their disulphide reduced 
counterparts, presumably because either fewer charge sites are exposed or the 
Coulombic restraints restrict charging for a more compact structure 4 . The same 
rationale may apply to subunit protein complexes. The narrow charge distribution of 
a low charge state represents retention of the higher order structure of the native 
protein complex. If a protein is denatured a greater number of charge states with 
lower m/z are observed. 
MS does not provide direct structural information but can provide important 
stoichiometric information, including systems where there may be heterogeneity in 
the stoichiometry of the complex. Specificity is a critical advantage of ESI-MS. 
Proteins affect each other and come together and recognise ligands via specific 
interactions, based on key structural and/or energetic features and non-specific 
aggregation. MS can monitor ligand binding by detecting the non-covalently bound 
ligand complexes. Smith and co-workers used this property to screen a 289-
component library (based on benzene sulphonamides) against zinc loaded carbonic 
anhydrase 7 . The mass and relative abundance of a released ligand by a subsequent 
tandem MS experiment can provide information regarding its identity and relative 
binding constant8. 
4.1.2 Electrochemistry and electric fields as origins of multiply charged ions. 
Charges of ions generated by ESI do not reflect the charge states of compounds in 
the sample but are the result of both charge accumulation in the droplets and charge 
modification by the electrochemical process at the probe tip (see figure 3). This is 
demonstrated clearly by Fenselau and coworkers 9 . They showed that negative ions 
of myoglobin can be observed at pH 3.0, whereas a calculation based on known pK 
values predicts that only one molecule per about 3500 would have one negative 
charge in the original solution. The results show the role of charge accumulation in 
droplets under the influence of the electric field on the formation of multiply charged 
ions. The "pumping out" of the negative charges can be performed only if, at the 
same time, the same number of positive charges is neutralised electrochemically at 
the probe tip. The negative ion spectrum of myoglobin at pH 3.0 has a better signal-
to-noise ratio than the same spectrum at pH 10. This results from the fact that 
protons have a high electrochemical mobility, and is an indication of the importance 
of the reduction process, when negative ions are analysed at the probe tip'. 
Capillary Tip 
+_ ++ - - + 	o 	+ 	+ 	
I Reduction 
+ I 
Oxidation 	0 	0 +. + 
Positively charged I 
Positive ions 
drops 
Electrons 	 +1 	 I 
- 	 Electrons 
High-voltage power supply 
Figure 3: Schematic presentation of the electrochemical process in ESI (for positive ions). 
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As shown in figure 3, when positive ions are extracted for analysis electrons have to 
be provided in the circuit from the capillary. This will occur through oxidation of the 
species in the solution at the capillary tip, mainly ions having sufficient mobility. In 
other words, the same number of negative charges must be "pumped out" as positive 
charges are extracted to the analyser. ESI is an electrochemical process with its 
dependence on ion concentration and mobility as well as polarisation effects at the 
probe tip. For the detection of positive ions, electrons have to be provided by the 
solution and thus oxidation occurs. For negative ions, electrons have to be consumed 
and thus reduction occurs. A major consequence is that the total number of ions per 
unit time that can be extracted to the spectrometer is actually limited by the electric 
current produced by the oxidation or reduction process at the probe. This explains 
why ESI is concentration dependent, except at very low flow rates 1 . 
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4.1.3 Can a gas-phase measurement reveal solution phase binding 
characteristics? 
Gas phase studies need to be consistent with solution phase experiments in order for 
work done with ESI-MS to have some utility for the biochemist. Complex 
stoichiometry is easily provided and in most published reports the observed 
stoichiometry is consistent with the expected result 2 . Occasionally more ligand is 
observed to bind to the protein receptor perhaps due to non-specific gas phase 
aggregation 2 . Reducing the solution concentration of the analytes can decrease the 
prevalence of non-specific gas phase aggregation' ° . However numerous reports 
suggest that ESI-MS has some utility for studying non-covalent complexes 2 . 
The nature of the non-covalent interaction will have an effect on the mass 
spectrometry experiment. There are at least four types of non-covalent forces 
involved in protein folding and interactions: ionic interactions, hydrogen bonds, the 
hydrophobic effect and van der Waals forces. Going from solution to a solventless 
gas phase environment has many ramifications. Electrostatic interactions may be 
strengthened in vacuum. The binding of highly basic spermine to an acidic 
spermine-binding peptide containing 4 glutamic residues was studied in the gas-
phase 2 . Despite a weak binding constant (lO g  M) in solution, the sperrnine-SBP 
complex could be readily detected by ESI-MS. This complex is unusually stable in 
the gas-phase as demonstrated by collisionally activated dissociation (CAD) studies. 
The avidity of the gas-phase complex may or may not be similar to that found in 
solution. For the spermine-peptide complex, a solvent free environment may 
enhance Coulombic stabilisation of opposite charges. 
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Most gas-phase complexes are relatively fragile. ESI interface (atmosphere/vacuum) 
conditions need to he as gentle as possible to maintain the intact complex. Enough 
energy needs to be expended to reduce solvation of the complex for sensitive 
detection (see figure 4)11.12 
Figure 4: The process of solvent evaporation as the non-covalently hound complex is transferred 
from solution to the gas-phase. Gentle desolvation conditions are generally required to maintain the 
intact gas-phase complex. For several protein systems, the ESI-MS data may he consistent with the 
solution phase binding constants. Although some features of the solution structure may be preserved 
in the gas-phase ions, the stability of the gas-phase complex may not be reflected by the solution 
phase binding constant. 
Depending on the interface, instrument and the complex there is a very fine line 
between sufficient desolvation of the gas-phase complex and dissociation of the 
complex. However there are examples at both ends of the scale. Protein complexes 
with oligonucleotides usually involve extensive electrostatic forces. Studies of 
1fl protein-DNA complexes and protein-RNA complexes"""' 3,14 .are examples where 
dissociation of the gas-phase complex is very difficult: i.e. the multiply charged ions 
of the complex are stable at high interface energies. At the other extreme Robinson's 
work with acyl CoA analogues illustrates an example where the ESI-MS data do not 
agree with the solution phase data Acyl CoA analogues with different solution 
dissociation constants were not differentiated by the ES I-MS experiments. A 
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combination of hydrophobic, electrostatic and non-polar stacking interactions 
maintains the protein-ligand binding in this example. Changes in the length of the 
hydrocarbon acyl chain, although greatly affecting solution binding, did not appear to 
greatly affect the stability of the gas-phase complex. As noted by Robinson 15 
"Where hydrophobic interactions have been shown to play a major role in the 
solution state of other systems, for example, the leucine zipper peptides and the 
receptor-ligand interactions, the fraction of the complexed species in the gas phase is 
low (typically - 10-20%) since such interactions are in large part attributed to the 
role of the solvent." Caution is needed in interpreting ESI-MS results but perhaps 
ESI-MS can be used to assess the type of bonding interaction that keeps complexes 
together. 
It has yet to be conclusively proven that a gas-phase dissociation energy (or 
thermodynamics) can be used to predict or even to reflect the solution-phase binding 
strength e.g. studies on FKBP and rapamycin analogues in the gas-phase do not 
reflect solution based measurements 16. ESI-MS studies on protein subunit 
complexes show gas-phase complexes that are not stable species in solution. 
However, recent binding studies have suggested that the stabilities of the gas-phase 
and solution-phase complexes are similar for selected systems e.g. studies on haem 
binding to variant forms of apomyoglobin and apocytochrome b 5 17 . 
4.1.4 Experimental consideration for ESI-MS experiments. 
The solution conditions that are needed to maintain an intact complex are not optimal 
conditions for "normal" ESI operation. For maximum sensitivity, a solution pH of 2- 
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4 for positive ionisation and pH 8-10 for negative ion ESI are typical for polypeptide 
analysis. The addition of an organic modifier, such as methanol or acetonitrile, also 
enhances sensitivity and ion signal stability. These conditions are generally not 
tolerated when trying to maintain a non-covalent complex. Many protein 
complexes are denatured in solution at a pH value outside the pH range of 6-8 and 
the addition of a high concentration of an organic co-solvent can likewise disrupt the 
stability of the complex 2 " 1 . 
Quadrupole ESI mass analysers were the first systems used to detect non-covalent 
complexes; essentially all the major types of mass spectrometers, such as TOF ion 
traps etc have successfully been used. Analysers with high mass-to-charge range 
(greater than rn/z 4000) have advantages for studying the full range of biochemical 
complexes because of the tendency of many non-covalent complexes to exhibit 
relatively low charge states. Every type of atmospheric pressure ionisation (API) 
interface has been utilised to observe such complexes (differentially pumped nozzle-
skimmer interface, heated glass or metal capillary inlet with or without concurrent 
gas2" 5. 
Variables that affect droplet /ion desolvation and ion activation can affect the success 
of the experiment 2". Solvent molecules need to be stripped from the ion prior to 
detection. Desolvation is achieved through a variety of methods, including the use of 
a counter-flow of nitrogen gas, heat (either a warm counter current gas, a heated 
capillary inlet or a warm interface chamber) and optionally a CAD downstream of 
the initial interface 2,11 .Some gas-phase complexes are extremely fragile and the 
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amount of activation (voltage difference between the capillary-skimmer or nozzle-
skimmer lens elements) must be reduced to maintain the intact complex 
2,1  The gas-
phase complex between acyl CoA binding protein and Acyl CoA derivatives was 
found to be sensitive to the ESI source temperature; increasing the temperature from 
20-80°C reduced the proportion of complexed species to zero 15 . Best results were 
obtained by cooling the ESI nebuliser gas and analyte solution 15 . 
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4.2 Results and discussion: Studying eIF4E cap analogue interactions using 
mass spectrometry. 
4.2.1 Observation of the non-covalent complex. 
The mass spectra of full-length human eIF4E were obtained under a variety of ESI 
conditions as shown in figure 5 and figure 6. The spectra from these different 
conditions are clearly distinct, indicating the protein retains a history of its solution 
environment in the gas phase. The spectrum obtained from the denaturing ESI-MS 
conditions, 50% methanol in water and 10mM ammonium acetate pH 3.0 and a 
source temperature of 60 °C is shown in Figure 5A. These standard ESI-MS 
conditions usually denature the protein but allow accurate mass determination and 
confirm the molecular weight of the protein as - 24960 which differs from that 
anticipated from the amino acid sequence (25097.2). The difference between the 
calculated and observed mass is approximately 137. The mass difference probably 
corresponds to loss of the N-terminal methionine (131). The spectrum obtained 
from samples in 10mM ammonium acetate pH 50, figure IB, exhibits a marked 
change in the charge state distribution from that observed in Figure 5A, with a shift 
of the charge state maximum from +25 to +11. This reduction in charge has been 
found to be a feature of spectra obtained from solutions in which proteins remain in a 
native-like conformation during introduction to the ESI source. 
The spectrum obtained, under identical conditions to those of Figure 5B, but after 
addition of 3.7iM of m7GTP, is shown in Figure SC. An additional series of peaks 
is observed, labelled with filled in circles, whose mass corresponds to the sum of 
rn7GTP plus full-length eIF4E. The mass of the ligand derived from the spectra in 
107 
figure 5 is 539 and is within experimental error to the true value of 537.2. When this 
protein ligand complex was observed under denaturing ESI-MS conditions, ions 
corresponding to the mass of the complex were not seen. 
eIF4E upon titration with m7GTP (figure 5B and 5C) exhibits no significant change 
in its charge species distribution, as might be expected with the addition of two 
negative charges. This lack of change in the eIF4E spectrum, upon binding 
negatively charge ligands, is seen for the monophosphate derivatives (see chapter 5, 
section 5.7.3), as well as rn7GDP, GTP, GDP and GMP (not shown). Work by 
Samalikova et a1 18  shows that by increasing the lysine content of RNase SA no major 
shift is seen in its spectrum. However they did show a shift of +1 in the spectrum of 
the peptide angiotensin upon substitution of an aspartate residue with an 
asparagine 18 . Other work by Wilson et al studying RNase A binding to 2'CMP and 
CTP also observed a similar lack of effect on the charge species distribution 19. A 
plausible explanation for this is that the negative charge of the phosphate groups is 
being compensated for, in some manner, by the protein when bound, which may or 
may not result in altering the positive charge distribution on the protein. An 
alternative explanation is that the ligands are binding in their neutral form. However 
the pKa  of phosphate is very low and this would seem highly unlikely. Further 
evidence for this (results not shown) is that increasing the cone voltage does not 
generate a greater proportion of the apo peak in the complexed species indicating a 
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Figure 5: Positive ESI mass spectra of eIF4E under a variety of experimental conditions. The mass 
spectra on the left have been deconvoluted using a transform method in Mass Lynx to give the 
molecular masses on the right. The charge states and molecular masses marked with a filled in circle 
represent the eIF4E m7GTP gas-phase complex. The other peaks arise from free protein in solution. 
Experimental conditions: A) the running solvent and protein sample solution contained 50% methanol. 
50% water and 10mM ammonium acetate pH 3.0 and the source temperature was set at 60 °C, B) the 
running solvent and protein sample solution contained 10 1Yv methanol and 10mM ammonium acetate pH 
5.0 and C) contained 10% methanol and 10mM ammoniuni acetate pH 5.0 and 3.76tM m7GTP. ESI 
source conditions were optimised for overall signal intensity. An additional series of peaks is observed 
in C. labelled with filled in circles, whose mass corresponds to the sum of m7GTP plus full-length 
eIF4E. 
Figure 6 shows the spectra obtained from flying eIF4E at pHs 3.0, 4.0 and 5.0 with 
and without ligand. With out the addition of rn7GTP gradual denaturation of the 
structure is observed by the accumulation of more charge. However in the presence 
of a saturating concentration of m7GTP the structure of eIF4E appears to be 
stabilised with a less noticeable shift in the charge distribution to lower mlz values. 
As the apo protein in figures 6A, 6C and 6E is gradually denatured the development 
of distinct charge distributions can be observed, as indicated in figure 6E. Partial 
unfolding or emergence of non-native conformations of proteins in solutions can be 
induced by a variety of agents, including variations in solvent composition (e.g., 
addition of chaotropes, such as detergents, alcohols and urea). pH adjustment within 
certain cellular compartments is a universal mechanism that often triggers 
complicated protein interaction cascades by inducing specific conformational 
changes 20.  The development of these different charge distributions is indicative of 
the presence of multiple conformational isomers of apo (see figure 6E) eIF4E 
coexisting in solution under equilibrium, and is consistent with observations by 
Wang 21  and Konerrnann 22 on myoglobin. 
Spectra of apo-eIF4B and m7GTP bound to eIF4E exhibit tendencies that are 
consistent with Fenn's model of electrospray ionisation 23 . Tightly folded protein 
molecules are expected to have significantly smaller projected areas (as compared to 
less structured protein molecules), resulting in accommodation of a fewer number of 
charges on the protein surface at the ion evaporation stage. Most globular proteins 
are known to have multiple folding intermediates states (not just folded and unfolded 
states), some of which may have only minor structural differences. Subtle 
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differences are unlikely to lead to significant change in the overall shape of the 
protein. (e.g., projected areas, and, therefore, in the average number of charges 
accommodated upon protein ion desorption). Due to this the charge state 
distributions corresponding to various protein conformational isomers may be 
unresolved or poorly resolved (i.e. two or more different conformers may give rise to 
ions carrying the same charge). Close examination of the protein ion charge state 
distributions in figure 6 reveals in many cases the presence of multiple (>2) 
maximums on continuous distributions (e.g. 23+, 18+ and 10+ for apo eIF4E at pH 
3.0; see figure 6E). This indicates the presence of at least three different protein 
conformations with significant Boltzman weight. This straight forward approach, 
however, can not determine the actual number of protein conformational isomers nor 
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Figure 6: Panels A. C and E show the mass spectra for apo eIF4E at pHs 5.0, pH 4.0 and pH 3.0 
(10mM ammonium acetate and 10% methanol). The adjacent panels B, D and F show mass spectra 
at identical conditions (pH 5.0. pH 4.0 and pH 3.0 10mM ammonium acetate and 10% methanol 
respectively) with eIF4E saturated with rn7GTP at a concentration of 3.721.tM. The 11+ and 10+ 
peaks are also labelled. For apo eTF4E there is a distinct change in the charge distribution as pH is 
decreased, with higher charged state species seen. At pH 4 and 3 new distributions of charged 
species can be seen which are analogous to different conformations of eIF4E. These are indicated in 
panel E. Bracket 3 corresponds to the correctly folded conformation seen alone at pH 5. whilst 2 and 
3 indicate more unfolded conformations that are capable of becoming more highly charged. In panels 
B, D and E the presence of m7GTP stabilises the eIF4E in respect to pH and favours the more folded 
form. At lower pH a larger proportion of apo eIF4E (indicated by the asterisk) is seen suggesting that 
affinity for rn7GTP does decrease. Also more peaks corresponding to higher charge states are seen as 
well. 
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Another pH experiment was carried out with eIF4E complexed with 3.531iM GTP at 
pHs 3.0, 4.0, 5.0, 6.0 and 7.0 (see figure 8) and an identical set of experiments with 
non-saturating levels of m7GTP (see figure 7). It was only with the presence of 
ligands (in this case rn7GTP and GTP) that any signal in the mass spectra was seen at 
pHs 7.0 and 6.0. Apo eIF4E did not "fly" under these conditions. Under non-
saturating conditions of m7GTP, the charge distribution associated with the native 
fold of e1F4 is not as strongly retained at lower pHs (figure 8) in comparison to 
saturating conditions of m7GTP (figure 6). Even under conditions of non-saturating 
levels of m7GTP the different charge distributions corresponding to different 
conformational isomers of eIF4E do not develop as strongly. Under denaturing 
conditions (figure 7F) the m7GTP eIF4E binding interaction is abolished. The 
spectra under denaturing conditions exhibit the two higher charge state distributions 
and thus indicate that the conformations of eIF4E responsible for these distributions 
have no affinity for m7GTP. Graph 7E shows the peak intensity for the apo and 
m7GTP complex peak (as indicated in figure 5) against pH. The 11+ peak and 10+ 
charge species were used for these calculations. It is immediately obvious that the 
affinity of eIF4E for rn7GTP increases between the pH of 5.0 to 7.0. At these pHs 
(see figure 7) eIF4E exhibits the charge distribution centred around the 10+ and 11 + 
peaks and represents the e1F4E conformation that is in the correct fold to bind eIF4E. 
The spectra for eIF4E against GTP at varying pHs show a similar type of behaviour 
to those with non-saturating levels of m7GTP (see figure 8). The most interesting 
difference is the presence of a third peak with the 11 + and 10+ charge species. This 
third peak corresponds to the association of two GTP molecules to eIF4E. However 
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under denaturing conditions (figure 8F) both peaks corresponding to the binding of 
one and two ligands are no longer present, suggesting that the interactions being 
observed are linked to the folded conformation of eIF4E. Again binding of GTP 
with eIF4E increases between pH 5.0 and 7.0 (see figure 8E). The binding of the 2L 
peak also shows an increase but with a slight decrease at pH 7.0. 
The eIF4E/rn7GTP complex is easily observed in the gas-phase (figures 5, 6 and 7) 
with distinct peaks forming for apo elF4E and the complex, for each charge species. 
At a saturating concentration of m7GTP (see figure 7) the apo peak decreases 
reciprocally. GTP behaves quite differently in the gas-phase, when compared to 
m7GTP, where a peak corresponding to the binding of two ligands occurs for each 
charge species (see figure 8), as well as the apo and the complex peak seen with 
m7GTP. This third peak could either correspond to another binding site or be some 
form of non-specific aggregation taking place. Under denaturing conditions, for both 
the rn7GTP/eJF4E and GTP/eIF4E complexes, all peaks corresponding to complex 
formation disappear. These observations imply that the formation of the eIF4E 
complexes are a function of the native fold. For both ligands the proportions of 
complex formation (see figures 7 and 8) increase as pH increases, indicating that at 
more physiological pHs eIF4E is either more correctly folded or a larger population 
of the protein is correctly folded and hence shows stronger affinities. The pH effect 
seen is more likely to be protein associated that any altered property of the ligands. 
The next section will further investigate the nature of the third peak seen with the 
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Figure 7: Mass spectra of eIF4E with I .86tM m7GTP at several different pHs (A is pH 7.0. B is 
pH 6.0. C is pH 5.0, D is pH 4.0. G is pH 3.0. F is pH 3.0 with 50% methanol). Graph E 
demonstrates the behaviour of the apo and IL peak (apo with one molecule of m7GTP associated) 
against pH. The numbers used for the peak signal over total signal intensity are the 11+ and 10+ 
charged species averaged out. In the spectra A. B, C. D and C the peak (IL) can he distinctly seen. 
However in the denatured spectra (F). the IL peak is not seen and thus its association is linked with 
eIF4E retaining its fold at less denaturing conditions. The IL peak increases significantly between 
pHs 5 and 7. which suggests that m7GTP's interaction with eIF4E is strongest at physiological pHs 
were eIF4E is known to function. The spectra show the characteristic reduction of charge species 
distribution as pH is increased. Spectra A. B and C (pHs 7.0, 6.0 and 5.0 respectively) show 
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Figure 8: Mass spectra of eIF4E with 3.53l-LM GTP at several different pHs (A is pH 7.0. B is pH 
6.0, C is pH 5,0. D is pH 4.0, G is pH 3.0, F is pH 3.0 with 50% methanol), Graph E demonstrates 
the behaviour of the apo peak, the IL peak (apo with one molecule of GTP associated) and the 2L 
peak (apo with two molecules of GTP associated) against pH. The numbers used for the peak 
signal over total peak intensity are the 11 + and 10+ charged species averaged out. In the spectra 
A. B. C, D and G the two peaks (IL and 2L) associated with GTP binding of eIF4E can be 
distinctly seen. However in the denatured spectra (F) these are not seen and that their association 
is thus linked with eIF4E retaining its fold at less denaturing conditions. The IL and 2L peaks 
increase as the pH increases which suggests that their interaction with eIF4E are strongest at 
physiological pHs were eIF4E is known to function. The spectra show the characteristic 
reduction of charge species distribution as pH is increased. Spectra A, B and C (pHs 7.0. 6.0 and 










4.2.2 Mass spectrometry studies reveal that N7 methylated compounds interact 
specifically with eIF4E compared to a non-specific pattern of interaction seen in 
non-methylated compounds. 
Titrations of molecules closely resembling the cap structure against eIF4E reveals the 
minimum criteria for ligands to interact with the cap binding site. The conditions 
chosen to conduct these experiments were 10% methanol and pH 5.0. The reason for 
the choice of these conditions were high signal intensity, the charge distribution of 
the native conformation was observed, interaction with m7GTP was preserved and 
that apo-eJF4E also "flies" at these conditions. When eIF4E is titrated against GTP 
the behaviour of the interaction in the gas-phase contrasts starkly with that of 
m7GTP. The apo peak of the 10+ and 11+ species is quickly saturated in the 
presence of m7GTP and there is a concurrent development of the ligand bound peak 
for both charge species (figure 10). In the case of GTP there is a quick development 
of peaks corresponding to the binding of one and two ligands whilst over the course 
of the titration the apo peak is never saturated (see figure 10). As the concentration 
of GTP is further increased there is a gradual development of peaks that are 
equivalent to the binding of three or more ligands. The ni7GTP titration peaks 
corresponding to the binding of two ligands or more only occur after saturation of the 
apo peaks. m7GTP shows a much more specific interaction with the cap-binding 
site. Thus only when the cap binding site is saturated by rn7GTP does the non-
specific binding to other parts of the protein occur as shown by the development of 
the 2L peak (see figure 9). With GTP the cap binding site shows no strong 
preference for it and thus this non-specific interaction occurs before saturation of the 
apo peak (see figure 9 and 10). 
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Figure 9: Diagram showing potential complexes in the m7GTP and (ITP titrations in figures 1013 
and IOC respectively. In the GTP panel complexes are shown that could form in the gas-phase that 
correspond to IL and 2L Note how the ligand when it does not bind in the cap-binding site May bind 
any where else on the surface. In the ni7GTP section two potential samples of complexes (A and B) 
are shown from two points on the titration curve (figure 10). Section A corresponds to the part of the 
curve where only apo and the IL peak are present, and section B corresponds to the part of the curve 
where the 2L peak (associated with non-specific binding) occurs. Note in section B saturation of the 
apo species and how the second ligand has the potential to interact anywhere on the protein surface. 
The correlation between the proportion of the complex present in ESI spectra and the 
relative concentrations of protein and ligand in solution often suggests the possibility 
of non-specific protein—ligand interactions. However, non-specific interactions in the 
gas phase are also likely to alter the observed stoichiometry of the complex ion in a 
concentration-dependent manner as is seen for GTP. Interestingly it is occurring at a 
concentration where in the m7GTP titration complexes containing multiple ligands 
are not occurring. Also the GTP IL and 2L peaks disappear under denaturing 
conditions (see figure 817) which suggests that eIF4E has in contrast to its interaction 
with m7GTP a general non-specific interaction with GTP. Surface plasmon 
II 
resonance experiments with capped and non-capped mRNA have demonstrated a 
tight interaction between eIF4E with the capped variants and a non-specific 
interaction with the non-capped variants 24 . These observations support the 
hypothesis that eIF4E's non-specific behaviour with GTP may be an intrinsic 
mechanism that comes into play when binding the rest of the mRNA chain after cap-
binding has occurred. From these titrations with m7GTP and GTP the presence of 
the delocalised charge on the m7G ring, induced by the methylation of the N7, is the 
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Figure 10: Titrations of m7GTP (panel B) and GTP (panel C) against eIF4E showing development of 
peaks corresponding to the binding of one (IL) and two (2L) ligand molecules. Panel A shows mass 
spectra (of the I I+ charge species) for the points indicated on the titrations in panel B and panel C. It 
is clearly seen in the m7GTP titration (panel B) that almost total saturation of the apo peak occurs 
before the occurrence of the peak corresponding to the binding of two ligands. In the GTP titration 
(panel C) the peaks corresponding to the binding of one and two ligands appear almost simultaneously 
and develop as a function of concentration. These titrations demonstrate that eIF4E specifically 
interacts with rn7GTP and it is only at near saturation that non-specific aggregation as indicated by the 
third peak occurs. In the case of GTP, eIF4E only has a weak affinity and as a result non-specific 
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Figure 11: Titrations of GTP. GDP and GMP against eIF4E (A, Band D respectively) examining 
the effect of the non-specific binding described in figure 9. However as the length of the 
phosphate tail is decreased the strength of binding is decreased, but the non-specific interaction is 
still being observed. The concentrations at which 50% saturation of the apo peak occurs 
demonstrate this point (Table B). At these points of 50% saturation on the graphs. the proportion 
of the signal due to IL and 2L complex species are similar (roughly 30 91c IL and 10 11o. 2L). The 
pattern of non-specific binding is related to the size of the negative charge in this set of ligands. 
Peak signal! Total peak signal was calculated from both I 1+ and 10+ charged species. 
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Titrations were then carried out with GDP and GMP to explore the effect of the 
length of the phosphate tail on the non specific interaction observed with GTP (figure 
The type of interaction, as seen for GTP remains the same, with the gradual 
development of multiple ligand peaks with the apo peak never becoming saturated. 
The values at which the peak corresponding to the apo species is at 50% for these 
titrations (50% sat) clearly decrease as a function of the phosphate tail length (figure 
bC). For GTP, GDP and GMP, when the apo peak is 50% saturated, the proportion 
of the signal corresponding to the binding of one and two ligands is approximately 
the same, -30% and 10% (see figure 11 Q. This indicates that the concentration, at 
which development of the peaks with multiple ligands occurs, is correlated to the 
length of the phosphate chain. The non-specific interaction being observed for 
guanine with no methylation at the N(7) in the gas phase masks any weak binding 
that maybe occurring at the cap-binding site. Hence (figure 11) the development of 
peaks corresponding to multiple ligands before saturation of the apo peak, as 
opposed to the m7GTP/ eIF4E interaction (figure 10) where the binding of multiple 
ligands is only seen after the apo peak is almost saturated. Titration series carried 
out for m7G, guanosine and ribavirin, using the same concentration range for 
m7GTP and GTP, revealed no apparent binding in the gas phase. This lack of a 
visible interaction with m7G, ribavirin and guanosine confirms that for either the 
specific or non-specific pattern of interaction to occur the phosphate moiety is 
required. 
The same sets of experiments were carried out with ATP, ADP and AMP (see figure 
These compounds again displayed the same type non-specific interaction noted 
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for GTP, GDP and GMP. 	However ATP behaves quite differently with the 
development of the 2L peak occurring before the 1L peak (see figure 12A). ADP 
and AMP behave like their counterparts with the guanine ring moiety. Again the 
values for ADP and AMP, at which the peak corresponding to the apo species is at 
50% for these titrations (50% sat), clearly decrease as a function of the phosphate tail 
length (figure 12D). At these points the signal contribution of the 1L and 2L peaks 
were 30% and 10% respectively, highly similar to what occurs for the guanine 
based ligands. The interaction with ATP may be caused by eIF4E having two sites 
with a weak affinity for ATP, which might explain the early development of the 2L 
peak over the 1L peak. Support for this model comes from the fact that in the 
m7GpppA eIF4E crystal the adenine moiety is clearly seen (see chapter 3). However 
with increasing concentrations of ATP the development of multiple ligand peaks are 
seen, which show that eIF4E's interaction with ATP is mainly non-specific in 
character (see figure 10 for an example of this with GTP). The way in which the 
adenine and guanine ligands behave in a similar manner points towards a dominant 
role for the phosphate chain over the hydrogen bond/donor relationship on the ring 
moiety. AMP and ADP do have 50% saturation points that occur at higher 
concentration than their guanine counterparts which may indicate the fact that 
different hydrogen bond partners are found on the adenine ring. ATP has a very 
similar 50% sat point to GTP, however this is probably a reflection of the early 2L 
peak development. 
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Figure 12: The titrations of ATP. ADP and AMP (A, C and B respectively) against eIF4E overall 
show a similar trend to the GTP. GDP and GMP titrations.. with the strength of binding related to 
the phosphate tail length. However there is one distinctive difference, in the case of ATP. where 
the 2L peaks starts to appear before the IL peak. The reasons for such an interaction are not 
obvious but could be due to either ATP aggregating together and binding to the protein or location 
of another site away from the cap-binding site that may have an affinity for it. The first option 
appears to be unlikely as this does not occur in titrations of ADP or AMP. 
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4.2.3 m7GTP and m7GDP interact identically with human full length eIF4E in 
the gas phase. 
An identical titration was carried out with m7GDP to the m7GTP one to investigate 
the effect of phosphate chain length, when a positive delocalised charge is present on 
the m7G ring (see figure 13). As with the m7GTP, in the m7GDP titration eIF4E is 
near saturation before development of the 2L peak. However where a clear effect 
was seen for decreasing the phosphate tail length in the guanine and adenine based 
ligands, there is no such difference between m7GDP and m7GTP. 
An explanation for this behaviour in the gas-phase can be seen in the crystal structure 
of full-length human eIF4E with rn7GTP (see figure 13C). The 13  phosphate of the 
triphosphate tail has four close contacts with the residues in the phosphate-binding 
pocket (indicated by the yellow dashes) whilst the y phosphate has only one contact. 
The y phosphate mainly interacts with eIF4E through water-mediated interactions 
(discussed in chapter 3 and 6), which are expected not to be present in the gas-phase. 
It is the absence of these structured waters seen in the crystal structure that may offer 
a reason for the similar behaviour of m7GTP and m7GDP with eIF4E as revealed by 
mass spectrometry studies. To further investigate this model a titration of m7GMP 
against eIF4E could verify it i.e. the 13 phosphate would no longer be forming any 
contacts and a much weaker interaction would be expected in the gas-phase for 
m7GMP. However m7GMP is not available commercially. The seemingly identical 
titration curves of m7GTP and rn7GDP were investigated by seeing how their 
interactions behaved in respect to increasing concentrations of ammonium acetate 
(figure 13D), whilst keeping the concentration of m7GTP to m7GDP identical. By 
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increasing the concentration of ammonium acetate, a volatile buffer, the ionic 
strength of the sample being flown is also increased. This should have the effect of 
attenuating the ionic part of the m7GTP/m7GDP interaction and differentiate them. 
The graph in figure 1OD confirms that the ionic interaction between eIF4E and two 
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Figure 13: Titrations of m7GTP (A) and m7GDP (B) against eIF4E. Both ligands demonstrate a 
highly specific interaction with eIF4E. However, both curves are highly similar with 50% 
saturation of the apo peak occurring at 1MM  and the onset of the non-specific aggregation peak 
(21L) at -.7MM and 9 MM respectively. This interaction was further investigated by monitoring the 
peak proportion (average of 11+ and 10+ peaks) at increasing concentrations of ammonium 
acetate (D). By increasing the ammonium acetate concentration the ionic strength of the sample 
to he run on the mass spectrometer is being effectively increased. This should attenuate the ionic 
strength of the ligands (m7GTP and m7GDP) interaction with eIF4E and allow it to he assessed. 
The ammonium acetate curves in graph (D) reveals no intrinsic difference in the ionic interaction 
between m7GTP and m7GDP. An explanation for this behaviour in the gas-phase can be seen 
in the crystal structure of full-length human eIF4E with m7GTP (C). The P phosphate of the 
triphosphate tail has four close contacts with the residues in the phosphate-binding pocket 
(indicated by the yellow dashes) whilst the yphosphate has only one contact (which is not seen in 
the other m7GTP structure in the PDB). The y phosphate mainly interacts with eIF4E through 
water-mediated interactions (discussed in chapter 3). which are expected not to he present in the 
gas-phase. It is the absence of these structured waters seen in the crystal structure in the gas 
phase that may offer a reason for the similar behaviour of m7GTP and rn7GDP with eIF4E as 
revealed by mass spectrometry studies. All samples were flown at 10% methanol. 3.2MM eIF4E 






4.2.4 Insights into the eIF4E cap-analogue binding mechanism from mass 
spectrometry. 
From the mass spectrometry studies e1F4E only shows a specific interaction when a 
phosphate group and a delocalised charge on the m7G moiety is present in the gas-
phase. When no delocalised charge is present on the m7G ring a more non specific 
pattern of interaction seen, with the presence of multiple ligand peaks at high 
concentrations of ligand. This is further supported by Kds, determined in the 
fluorescence studies by Niedzwiecka et a1 25 , which vary from 0.01 uM for specific 7-
substituted cap analogues to 1 0000uM for 7-unsubsituted cap analogues. The results 
of Niedzwiecka25  et al also reveal that although unmethylated guanosine phosphates 
are potentially capable of forming three Watson-Crick like hydrogen bonds that this 
does not occur. As shown by AG°(GMP) = -3.09(+/-0.90) kcal/mol) 25 when 
compared to the contribution of the single a-phosphate (AAG ° = -3.01 +/0 . 16)25 .  It 
is only when the guanine is N(7) substituted that the hydrogen bonds are formed. 
Hence the cation-'t stacking enhancement is a precondition for hydrogen bond 
formation, and a double role can be prescribed to the presence of the conserved 
residues 56 and 102 in the eIF4E binding site: stabilization of the 7-methyl guanine 
ring by stacking itself and enabling 7-methylguanine to form the hydrogen bonds to 
the site-chain of G1u103 and the amide backbone ofTrplO2 25 . 
The non-specific interaction observed in the gas-phase with GTP may indicate that 
eIF4E has a general promiscuity to negatively charged compounds, which may be a 
mechanism involved in interacting with the rest of the mRNA chain during 
translation via the phosphate backbone. VP39 has successfully been crystallised 
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with an RNA hexamer that interacts exclusively with the protein via the phosphate 







Figure 14: The m7G ring binds in a small pocket between the two tryptophans in VP39. The rest 
of the RNA is recognised in sequence independent manner via interactions with the phosphate 
backbone (shown in spheres). This mechanism could apply to eIF4E and may otter an explanation 
for the non-specific interaction observed for GTP in the gas-phase against eIF4E. 
Another element important for specific eIF4E-cap binding is the negative 
electrostatic charge of the phosphate chain, which depends upon the phosphate 
number. The increase of the K1 with single step-wise reduction of the phosphate 
chain in the series of 7-methylated mononucleotides, as demonstrated by 
Niedzwiecka et a1 25 . is followed by the same changes of Kd for the unmethylated 
compounds (-five and 25 fold for the removal of the y—phosphate and the 1 
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phosphate, respectively). Removal of the a-phosphate leads to a major increase of 
Kd which is 175-fold higher for m7G than that of m7GMP 25 . These results show 
much agreement with what was observed in the gas-phase. That is if the phosphate 
tail length is decreased in the case of the non-methylated ligands an attenuation in the 
non-specific interaction is seen (figure II). In the gas-phase no binding is seen with 
m7G which corresponds to the observation by Niedzwiecka et a1 2 that upon the 
removal of the a phosphate there is a significant drop in binding. However they 
observe a stronger interaction for m7GTP over m7GDP with eIF4E than appears to 
be the case in the gas-phase. The model proposed in the last section of structured 
waters having an important role in the interaction of the y-phosphate (figure 13) 
explains this discrepancy. Steady-state fluorescence measurements are solution 
based, where water molecules will be present to participate in any interactions, whilst 
gas-phase measurements are not. 
eIF4E requires a negative phosphate to be present on the cap-analogue for guanosinc 
to have any type of interaction and for m7G and Ribavirin to intercalate between 
W102 and W56. These experimental results indirectly show that in the gas phase it 
is more than likely that the phosphate tail anchors the m7G(p) molecule to eTF4E 
and that the m7G moiety then intercalates itself between the tryptopharis in the cap-
binding slot. Experiments by Blachut-Okrasinska et a1 27 observed a two-step 
binding mechanism for the cap-analogue eIF4E association by means of stopped 
flow spectroscopy. Thus it seems plausible that the phosphate tail serves as a 
molecular anchor enabling the m7G moiety to form further contacts within the 
binding site. 
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4.2.5 How does the mechanism of cap-binding in eIF4E compare to other cap-
binders? 
VP39 is another well-studied cap-binding protein that has been characterised via 
crystallographic techniques and fluorescence methods 28 '29 . VP39 can bind a variety 
of methylated nucleobases in the pocket of the binding site for the m7G moiety of the 
cap dinucleotide m7G(5')pppG and its nucleoside or nucleotide derivatives. 
Methylated compounds that were successfully soaked in to the VP39 crystals in 
contrast to their non-methylated counterparts were rn3Ade, m3Cyt, miAde and 
ml Cyl. These results again demonstrate how intercalation of compounds between 
the two aromatic resides requires a delocalised positive charge. 
In contrast to eIF4E where the cap-analogue seems to bind by a two-step mechanism 
the interaction with VP39 seems to be a single step (stop-flow studies carried out on 
mutant VP39 with Phel 80 replaced by a tryptophan). This is consistent with 
crystallographic data of VP39 that shows no structural rearrangement following 
binding of m7G and several other cap analogues to VP39 and other mutants 
studied 28 . The uppermost association rate constant (k 1 of-- 3 x 10 7 ni1 1) observed 
at pH 5.5 and 6.0 is about two orders magnitude lower than the diffusion limit, which 
appears fast for a binding process dependent on the precise and tight insertion of the 
in7Gua nucleobase between two aromatic side-chains (Trp 180 and Tyr22) 29 . The 
electron rich it clouds of both aromatic side chains, which possess a permanent 
electrostatic quadrupole, must therefore impart a strong attractive force on the 
electron deficient m7Gua moiety. It is this force that has a significant effect on cap-
binding by cap-specific proteins that rely on stacking interactions. 
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In the case of VP39 the presence of a positive delocalised charge on the ring, 
supported by mass spectrometry studies and other fluorescence studies in the 
literature on e[F4E, is critical to success in crystallographic soaking experiments 28 . 
However intercalation between the tryptophans in VP39, as shown by the 
crystallographic experiments, can occur with methylated bases without a phosphate 
group present 28 . This situation is in stark contrast to eIF4E, where any interaction in 
the gas-phase requires a phosphate to be present (fluorescence studies in the 
literature also report much weaker kds when all the phosphates are removed 25). It 
would seem that in VP39 that the aromatic cap binding residues are fairly rigid. In 
eIF4E, considering that no apo structure exists and that the m7GTP must be 
orientated by the phosphate tail to allow it to interact, that the tryptophans probably 
become rigid upon interacting with the m7G ring. 
4.3 Conclusion. 
Mass spectrometry studies on eIF4E and various cap- analogues reveal interesting 
and complementary data to solution based studies. Also mass spectrometry with 
knowledge from the crystal structure has allowed us to analyse the contributions of 
the y- and 3 phosphates in the gas-phase, and explain why m7GTP and 7GDP behave 
the same in the gas-phase. Mass spectrometry can also differentiate between GTP 
and m7GTP, allowing a specific interaction to be differentiated from a non-specific 
interaction. This offers the potential to use mass spectrometry as a potential 
screening tool to verify virtual screening hits against eIF4E. 
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Chapter 5: Identifying initial drug leads for eIF4E and development of an overall 
structure-based drug design strategy. 
5.0 Introduction. 
In this chapter the aims are to identify lead ligands for eIF4E by using virtual docking 
methods 1 , to synthesise compounds similar to the cap-analogue and to use other 
methodologies to search for compounds with an analogous N7 delocalised positive 
charge. The classic drug design cycle involves the ability to produce large amounts of 
protein that can be screened by various methods to find target ligands. In the case of 
eIF4E mass spectrometry is a technique that lends itself easily to ascertaining the 
activity of a potential ligand. There is also the potential of exploiting the intrinsic 
tryptophan fluorescence of eIF4E to screen for hits 1 . Successful hits can then be used in 
co-crystallisation trials. From binding data and successful structure elucidation a 
binding model can be developed that can be used in further rounds of drug design e.g. 
step-wise modifications of hits and refinement of virtual screening models. 
5.1 Screening for potential inhibitors using chemical libraries. 
The antithesis of rational methods for drug design is the reliance on chance discoveries 
of active ligands. High throughput screening is a chance-based method. The limitations 
of high throughput screening are the volume of the screen that can be achieved within 
commercial constraints and the theoretical coverage within the diversity of the 
compound set being screened 2.  If the number of compounds in existence were 108  and 
30 
the number of drug like compounds that could be made is 1 	then the probability of a 
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compound set of a size currently in existence showing useful statistical coverage in 
chemical space is minuscule 3 . 
Historically the number of compounds that could be synthesised by a chemist has been 
at most a few hundred. However, new technologies such as combinatorial chemistry and 
high throughput screening (HTS) offer a much broader range of possibilities and the 
capacity to synthesise many more compounds, even to contemplate numbers in the 
millions 4 . This new technology requires chemists to confront a large and diverse 
"chemical landscape" 3 . 
There are many chemical libraries that a trained chemist could reasonably hope to 
synthesise. Each library can, in principle, contain a large number of compounds. 
Combinatorial chemists have demonstrated in several systems that libraries containing 
1,000-100,000 compounds can be assembled. Figure 1 shows a 1,4 benzodiazepine 
scaffold along with components that this scaffold might also be modified with 5 . The 
components or "building blocks" in many cases are very simple and can be readily 
bought and/or synthesised. From such a set of compounds it is easy to imagine that a 
library could contain 10 9  or more possible compounds. It is reasonable to presume that a 
"a virtual chemistry space" exists that perhaps contains 10 100  possible molecules 2 ' 3 
Combinatorial chemistry and HTS have advanced rapidly 3 ' 4 . Many chemistries are still 
not amenable to rapid synthesis. Also screening a million compounds and following up 
hits is still a considerable effort. Both HTS and combinatorial chemistry labs are 
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confronted with the need to miniaturise and automate as ways to control costs, save 
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Figure 1: Generic 1 ,4-benzodiazepine showing locations of four variable R groups and the components 
from which the combinatorial library might be constructed 3 . 
137 
5.2 Virtual screening. 
To circumvent these problems a plethora of docking algorithms have been written that 
perform docking of large virtual libraries to structurally known sites and thus save on 
unnecessary compound screening 2 ' 3 ' 8 . Docking algorithms allow the user to search large 
virtual compound sets that have the right geometric and electronic features to fit the 
designated sites. This allows the user to commit fewer resources until after the in silico 
search has produced a refined set of compounds that can then be screened 
experimentally6 ' 8 . When the initial set of virtual hits is produced it is important to check 
the compounds for ease of chemical synthesis and modification and their stability. If 
they do not meet these criteria and produce positive results in the experimental screen 
they represent a dead end in the drug design cycle and use up valuable time and 
resources. 
With the ability to assay ligand binding in eIF4E using either steady state fluorescence 
or mass spectrometry based assays, virtual screening could now be used to produce 
viable hits from commercially available combinatorial libraries. In this study, 
LIDAEUS9  was used to carry out virtual screening. Docking protocols can be described 
as a combination of two components: a search strategy and a scoring function. The 
search algorithm should generate an optimum number of configurations that include the 




5.2.1 Search algorithms. 
A rigorous search algorithm in an ideal world would exhaustively elucidate all possible 
binding modes between the ligand and the receptor. All six degrees of translational and 
rotational freedom of the ligand would be explored along with the internal 
conformational degrees of freedom of both the ligand and the protein 
2, However this 
is impractical due to the size of the search space. As a result only a small amount of 
conformational space can be searched through, and so a balance must be reached 
between the computational expense and the amount of the search space sampled' ° . 
Carrying out such an exhaustive search involves the sampling of many high energy 
unfavorable states which can restrict the success of an optimisation algorithm. To 
sample such a large conformational space the computational expense is limited by 
applying constraints, restraints and approximations to reduce the dimensionability of the 
problem in an attempt to locate the global minimum as efficiently as possible". An 
early common approximation used in docking algorithms was to treat the ligand and the 
protein as rigid bodies and only explore the six degrees of translational and rotational 
freedom. The limitation of this rigid body docking method was that the ligand 
conformation must be close to the experimentally observed conformation when bound to 
the target. A more realistic approach in modelling molecular flexibility is to consider 
only the conformational space of the ligand, assuming a rigid receptor throughout the 
docking protoc012 ' 8 " 0 . 
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5.2.2 Scoring functions. 
Generating a diverse range of binding modes is ineffective without a model to rank each 
conformation that is both accurate and efficient. The scoring function should ideally be 
able to differentiate the experimental binding modes from all other modes sampled 
through the searching algorithm' 0 . A rigorous scoring function will usually be 
expensive and so often the complexity of the function is reduced, with a resulting loss of 
accuracy. Scoring methods range from molecular mechanics force fields such as 
AMBER'', CHARMM' 2 , etc, through to empirical free energy scoring functions or 
knowledge based functions 6 . 
Most current docking methods utilise the scoring function in one of two methods. One 
approach is to use the scoring function to rank a protein ligand conformation 6,  The 
system is then modified by the search algorithm, and the same scoring function is again 
applied to rank the new structure. The other method is to use a two stage scoring 
function' ° . Here a reduced function is used to direct the search strategy and a more 
rigorous scoring function is then used to rank the resulting structures. These directed 
methods make assumptions about the energy hypersurface, omitting computationally 
expensive terms such as electrostatics and considering only a few types of interactions 
such as hydrogen Algorithms such as these are therefore directed to areas of 
importance as determined by the reduced scoring function. Examples of directed 
methods are Gold 13 and Dock 13 . 
A limitation in many existing scoring functions is to either neglect solvatiori effects or 
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use solvent models in a snap-shot fashion' ° . A snap-shot method involves the 
generation of structures in vacua, that are then ranked with a scoring function that 
includes a solvent model. The search function is therefore directed to the 
conformational space which favours the in vacua conformations. The role of bound 
solvent molecules and ions is usually not considered' ° 
5.3 Chemical synthesis using the cap analogue as a template. 
An alternative route to the design of suitable drug leads has been the stepwise 
modification of the natural ligand. In the literature there is a large body of information 
on nucleotide chemistry and on the modification of the guanine ring 14 . Of particular 
interest is the large body of work on N7 derivatives and their inhibition effects on eIF4E. 
These molecules offer potential insights into cap-binding interactions and may offer 
alternative directions into successful drug design1 . 
5.3.1 N7 Guanine monophosphate derivatives. 
It has been shown in the literature that eIF4E binds more tightly to GMP derivatives that 
contain benzene moieties instead of smaller alkyl substitutions such as —CH3 at the N7 
position ' 6 . The first study that showed the preference of eIF4E for 7bzGMP over other 
N7 substituents such as ethyl, butyl, propyl, cyclopentyl etc, used an in vitro translation 
assay were inhibition of globin synthesis was monitored 16. In the same report these 
results were also supported by UV cross-linking studies of radiolabeled mRNA to cap-
binding proteins ' 6 . Further papers in the literature have reported, using the same in vitro 
translation assay, that modifying the benzyl ring at the para position with chloride 
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Figure 2: The above diagram based on results from the literature' 5 shows the affects of N7 substitution 
and methylation of the imino group on the activity of the cap-analogue to eIF4E. For m7GMP if the 
benzylation and methylation are carried out together the derivative shows the most potency towards eIF4E 
(K 1  = 13.9tM). X on the benzyl derivative represents the halogen fluorine or chlorine (K,s given for 
chlorine derivatives). Other N7 substitutions apart from the benzyl derivatives that increased potency are 
phenyl ethyl, ethyl, butyl, propyl and cyclopentyl 16 . The potency of m7GMP increases with phosphate 
addition' 5 
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increases potency of inhibition two-fold (see figure 2 and 
3)l5 	The same paper also 
showed that substituting at the para position with a methyl or nitro group made the cap 
analogue a poorer inhibitor' 5 . The para fluoride modification was not included in the 
monophosphate series analysis. Substituting 2-phenylethyl at the N7 position also 
improved efficacy over m7GMP. 
The exocyclic amino group N2 of the 7-methylguanine moiety is known to be important 
for binding, since cap-analogues containing 7-methyllinosine or 7-methylxanthosine fail 
to inhibit mRNA binding to ribosomes 17 . Other studies have shown that a single methyl 
subsistent is tolerated 17" 8 . Cai et al l   shows that the addition of a single methyl group at 
N2 increases the effectiveness of cap-analogues as translational inhibitors. This "rule" 
holds for 7-methyl substituted nucleoside monophosphates, 7-(2-phenyl ethyl) - 
substituted nucleoside monophosphate, 7-benzyl-substituted nucleoside triphosphate, 7-
(p-fluorobenzyl) nucleoside triphosphate, 7-(p-clorobenzyl) nucl eosi de triphosphate and 
others. The report by Cai et al' 5 also confirms that modification of the exocyclic amino 
group by two methyl groups is detrimental to inhibition of the translational assay. 
Combining the positive effect of 7-(p-chlorobenzyl) substituents with the positive effect 
of N2-methyl substituents produced a compound with improved pOteflCy' 5 . 
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Compound Reported K (J) Reference 
7-methyl GMP 382 
15 
7-benzylGMP 113 15 
7-(p-chlorobenzyl) GMP 51.2 ' 
2-methyl-7-(p-chlorobenzyl) GMP 13.9 
15 
7-methyl GTP 4.39 
15 
7-benzyl GTP 8.42 
15 
7-benzyl -(p-chlorobenzyl) GTP 7.04 15 
7-benzyl -(p-fiuorobenzyl) GTP 7.35 15 
Figure 3: Selected K i values (Cai et al' s) for N7 substituted m7G derivatives. Values were derived from 
a rabbit reticulate based lysate assay. The benzyl derivatives of GMP give a significant decrease in Ki 
against eIF4E over ni7GMP. However in the case of m7GTP such a decrease is not observed. 
Substitution of the benzyl group for the methyl at the N7 position was not beneficial in 
the triphosphate analogue (see figure 2 and 3)15  A marginal improvement was seen 
with p-halogen substitutions (chloride and fluoride) but these were also less effective 
than the 7-methyl analogue, In the diphosphate series, 	the 7-(p-clorobenzyl) 
substitution causes only marginal improvement. 	For the N2 —methyl nucleoside 
triphosphate series, the effect of substituting aryl for methyl at the N7 position produced 
a small improvement. However this is negligible compared to the monophosphate 
series 15 
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Essentially, 7-aryl substitutions have a strong positive influence on the weaker 
nucleoside monophosphate inhibitors (as long as the ring possess no methyl or nitro 
groups), but the effect of 7-aryl substituents on the stronger nucleoside diphosphates and 
triphosphates is marginal and varies from compound to compound 
15  (see figure 2). 
However, the 2-methyl-7-(p-chlorobenzy1) analogue was shown by Cai et alto be the 
best inhibitor in the nucleoside mono-, di- and triphosphate series' 5 (see figure 2). 
Later work by Ghosh et a!' 9 using a competition assay based on m7GTP resin beads 
report that increasing the bulk of the N7 substitution with either athyl, allyl or berizyl 
groups reduced inhibitor potency by 2- to 4- fold, in contrast to the results from Cai at 
al 15  for the monophosphate series.. The reason they suggest for this disagreement is that 
it may stem from differences in the conformation of eIF4E bound to 7-methyl GTP resin 
than when it is actively engaged in translation 19 . 
1 45 
5.4 Virtual screening with LIDAEUS. 
5.4.1 Fundamentals of LIDAEUS. 
LIDAEUS9  is a software tool written by P Taylor at the ISMB, University of Edinburgh. 
It works by using a solved ligand protein crystal structure to define the site on the 
protein to be used for virtual screening. When LIDAEUS 9 has been used to define the 
site to be searched it generates site points where the ligand is located. These can either 
be designated as hydrogen bond acceptor, hydrogen bond donor, hydrophobic and 
especially hydrophobic sites. These are used primarily for docking compounds. 
Compounds from the virtual library to be screened are docked into the sites in 
succession. LIDAEUS9  attempts to fit the ligand on to the site points and scores each 
pose. After a set number of attempts if the compound does not meet a threshold score it 
is rejected. In the next stage the ligand is more rigorously fitted into the active site and 
scored. LIDAEUS 9  retains a specified number of the best scoring compounds. 
5.4.2 LIDAEUS virtual screening results. 
The full-length human eIF4E in complex with m7GTP, crystallised by Tonioo et a1 2° 
(IIPC), was used for the LIDAEUS 9  screening run. The m7GTP ligand was used to 
target the cap-binding slot in order to generate the site points to be used in the 
LIDAEUS 9 docking protocol. LIDAEUS 9  was then used to screen the Maybridge 
combinatorial chemistry library. The initial virtual screen returned 250 ranked 
compounds. The top 30 compounds were then analysed to reveal what features seemed 
to be important in selection of compounds by LIDAEUS 9 . The hits were examined on 
the basis of what features they contained that mimicked those found in ni7GTP. These 
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ranged from satisfying the hydrogen bond donors and acceptors of the m7G ring, 
whether or not a group of some kind overlaid the triphosphate tail, whether or not there 
was any chemical group occupying space at the back of the binding site and what type of 
ring system was intercalating between the two aromatic residues. Figure 4 gives 
graphical examples of the types of ligands and features selected by LIDAEUS 9 , 
respectively. 
In the figure 4 the compounds fall into several families that satisfy some or all of the 
hydrogen bonding partners that recognised the m7G ring. These families are ring 
systems that intercalate between the aromatic residues, ring systems that intercalate and 
have a chemical group of some type occupying the position in space of the m7GTP 
triphosphate tail, compounds that have no ring system sandwiched between the two 
tryptophans but do have a group in the triphosphate tail position and compounds that 
have a chemical group that project into the back of the cap-binding pocket (see figure 
4E). The fourth family does have some overlap with the first family: compounds that 
intercalate and project into the back of the pocket (see figure 41)). The definition for 
ring systems used here is reasonably loose but encloses phenyl, napthyl and morpholene. 
Figures 4 and 5 show several of the chemical group structures that were orientated in the 
phosphate-binding site (i.e. overlapping the phosphates in m7GTP) and the ring systems 
intercalated between the two ring systems, respectively. The potential phosphate mimics 
identified by LIDAEUS (figure 5) could be used in the design of future ligands, if a drug 
lead is identified. In figure 6 the ring systems shown all have the potential of forming 
some of the hydrogen bonds formed by m7G and are capable of ut-it stacking 
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interactions with W56 and W102. However none possess a positive delocalised charge 
on the ring, like that seen on m7GTP, but some of the ring systems identified by 
LIDAEUS9  can be alkylated to induce such a charge on the ring system. The ligands 
that do possess a nitrogen containing ring systems may be protonated at physiological 
pHs that are found in the cell, which would also induce a positive delocalised charge on 
the ring system. However it is highly difficult and unreliable to predict whether or not 
these compounds could be protonated at physiological pHs. 
The classical approach for calculating dissociation constants (pK a) from molecular 
structure is given by the Hammet equation, which is based on a separation of the 
compound of interest into a suitable parent structure and substituents with associated 
increment values 21 . An alternative approach is given by knowledge based systems that 
make use of increment values for more generally defined features 21 . However these 
methods are limited by requiring a suitable catalogue of experimental data on related 
compounds21 . In other words, PKa S can only be reliably predicted for compounds very 
similar to those in the training set. This limitation also applies to semi-empirical 
treatments using quantum chemical continuum-solvation methods 22 . PKaS can also be 
calculated using ab initio methods, however these would be very computationally 
expensive and time consuming 22 . Especially if they were to be used on large databases 
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Figure 4: Virtual hits representative of some of the apparent families of li gands being selected by 
L1DAEUS. Panels A and E show ligands that possess no intercalating ring system, but still sandwich 
themselves between W 10 and W56, and project into the back of the binding. Panels B and D show 
ligands that have a ring system intercalated between the two tryptophans and that also have a chemical group 
projecting into the cavity of the cap-binding site. Panel C depicts a ligand that has a chemical group in the 
same position as the triphosphate tail of in7GTP and again that intercalates a ring system between the two 
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Figure 5: Above are shown the chemical groups that LIDAEUS overlaid with the triphosphate tail 
of m7GTP. In future ligand design efforts these groups could be useful potential phosphate mimics 
to investigate. Ligands that contain phosphate groups have poor ADME properties and are not 
membrane permeable, which makes them poor candidates for drug development. 
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Figure 6: Above are shown ring systems that LIDAEUS intercalated between the W56 and W102 
trptophans. The majority are planar ring systems except for E and J. All possess features that allow 
them to form potential hydrogen bonds to E103 and the backbone amide of W102. All the planar ring 
systems are capable of forming 71 stacking interactions with the two tryptophan residues. However 
none possess a delocalised positive charge on the ring system. Some of the nitrogen containing 
heterocyclic ring systems, such as B, I and K could be alkylated to induce a positive delocalised 
charge on the ring systems. 
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5.5 Ligand synthesis of cap-analogues. 
Maintenance of the N7 positive delocalised charge on the guanine ring and the presence 
of a phosphate group seem to be the two deciding factors on whether a ligand binds to 
eIF4E or not based on the mass spectrometry studies (see chapter 4). With this 
information a set of ligands were synthesised using different scaffolds with N7 
equivalent modifications in order to give them a positive delocalised charge. The 
scaffolds used for the N7 substitutions were guanine monophosphates, quinolene, 
isoquinolene and benzothiazole. The modifications themselves ranged from ethyl to 
benzyl groups. Figure 8 to 11 show the N7 analogue compounds that were successfully 
synthesised. 
The scaffolds were chosen for several reasons. Guanine monophosphate was chosen so 
that the original features of the cap structure were retained: the HA! HD pattern on the 
guanine ring and the presence of a phosphate group. The quinolene and quinene ring 
systems were chosen to explore whether inhibition could be achieved with no phosphate 
group and no HD/HA present. Also these ring systems gave us the opportunity to 
investigate whether the positioning of the N on the double ring systems and the 
subsequent reorientation of any N7 modification was important. Benzothiazole was 
chosen for the same reasons as well as the fact that it contained a sulphur atom that 
could be used as a marker in any resulting electron density map if the compound proved 
active. Also by carrying out these reactions the applicability of this reaction for 
modifying basic ring structures was being investigated. 
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The groups chosen to be substituted on to the heterocyclic ring systems and GMP were 
selected for one of two reasons: either there was literature precedent or modeling studies 
carried out using LUDI' °  indicating whether or not there was space to accommodate the 
modification in eIF4E's cap binding site. The benzyl modification was of particular 
interest as it has been shown to improve the inhibitory properties of m7GMP in relation 
to eIF4E 
The modifications were made to the respective ring systems by using an alkylation 
reaction ' 7 . The halide alkyl was incubated with the scaffold to be modified for a period 
of 48 hours under continuous mixing for a period of two days in DMSO or DCM. The 
halide alkyl modifies the ring system of the scaffold by an SN2  substitution reaction (see 
figure 7). 
CI: JN 	H3  
c*s l 
- O1CJNH. 
- 	 +.CH 3 
+ 
Figure 7: Example of an S2 substitution using quinolene and iodornethyl. The nucleophile, in this 
case the nitrogen containing ring system, attacks the alkyl halide (ICH 3 ) 180°  away from the halogen. 
The nucleophilic attack generates a transition state with simultaneous bond breaking and bond formation 
occurring. The transition state then breaks down to form the substituted N7 analogue compound and a 
free halide ion. 
After incubation the reaction was quenched with ice-cold acetone or distilled water and 
centrifuged. The top layer was decanted of and the bottom layer was washed via several 
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rounds of centrifugation with ethyl ether. The resulting crude extract was dissolved in 
90% H20 and 10% methanol and analysed using an electrospray mass spectrometer to 
ensure the compound being synthesised had been made. The compounds described, due 
to the presence of a positive charge, should fly at their exact molecular weight. In the 
case of the GMP derivatives they will fly in the form where the phosphate tail is fully 
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Figure 8: The figure shows the compounds based on the quinolene scaffold structure that were 
successfully synthesised, with the corresponding experimental mass spectra confirming their 
molecular mass and presence in the reaction mix. Due to the presence of a positive charge on the 
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Figure 9: The figure shows the compounds based on the isoquinolene scaffold structure that were 
successfully synthesised, with the corresponding experimental mass spectra confirming their 
molecular mass and presence in the reaction mix. Due to the presence of a positive charge on the 
nitrogen the isoquinolene based compounds flew at their calculated molecular weight. 
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Ethyl benzothiazole 
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Figure 10: The figure shows the compounds based on the benzothiazole scaffold structure that were 
successfully synthesised, with the corresponding experimental mass spectra confirming their 
molecular mass and presence in the reaction mix. Due to the presence of a positive charge on the 
nitrogen the benzothiazole based compounds flew at their calculated molecular weight. 
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Figure ii: The figure shows the compounds based on the GMP scaffold structure that were 
successfully synthesised, with the corresponding experimental mass spectra confirming their 
molecular mass and presence in the reaction mix. Due to the presence of a positive charge on the 
nitrogen the GMP based compounds flew at their calculated molecular weight for the form where 
the phosphate group is fully protonated as shown above. 
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5.6 Data-mining for potential ligands with an analogous charge to the N7 nitrogen 
on the m7G moiety using ISISBASE. 
As well as synthesizing this small family of potential inhibitors of eIF4E a variety of 
compounds were purchased that contained an N7 equivalent delocalised positive charge. 
Compounds similar to m7GTP can also be searched for using 213-similarity methods e.g. 
ISISBase (MDL information systems, Inc.). 2D methods are rapid and allow a small set 
of compounds to be selected quickly and efficiently based on certain features. Apart 
from the requirement for some type of quaternary cation, not necessarily located in a 
ring system, there were no other limits set on the search. Surprisingly few compounds 
were found in the search especially cationic nitrogen containing ring systems. In figure 
12 the compounds identified, apart from containing a delocalised positive charge, are on 
the whole bulky, contain no obvious phosphate mimics or numerous hydrogen bond 














Figure 12: The figure shows a selection of compounds identified through ISISBase. Search 
criteria consisted of searching for compounds from the ACD that had at least had a positively 
charged nitrogen on the ring system. These compounds on the whole are bulky, do not possess 
any groups that are known phosphate mimics and have few hydrogen bond donors or acceptors. 
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5.7 Experimental screening using mass spectrometry. 
Mass spectrometry was used as the primary screening technique on the basis that it has a 
greater potential of screening compounds more quickly and robustly than intrinsic 
tryptophan fluorescence. The disadvantages of intrinsic tryptophan fluorescence for 
screening of eIF4E are; many of the potential ligands absorb at the wavelength required 
for excitation, they can also fluoresce in the same wavelength regions as tryptophan 
itself, solubility issues can give rise to light scattering effects adding to the absorbance 
problem and also solvents used to dissolve these ligands can denature the protein and 
alter its fluorescence properties. 
5.7.1 Mass spectrometry screening. 
Mass spectrometry as shown in the previous chapter can be used to detect m7GTP and 
binding of other related nucleobases, and differentiate between what we have termed 
"specific" and "non-specific" binding interactions. Mass spectrometry lends itself 
easily to ligand screening for eIF4E in contrast to quenching of intrinsic tryptophan 
fluorescence. Unlike protein fluorescence mass spectrometry does not require as many 
control experiments e.g. ligand fluorescence, ligand absorbance. The only control 
experiments needed are to fly eIF4E with whatever solvent the ligand has been dissolved 
in e.g. methanol, DMSO. In the case of methanol if it is maintained at a constant 10% in 
the sample to be analyzed then all the control experiments have been carried out in 
chapter 4. These control experiments are still required for DMSO. For these 
experiments methanol was kept at 10% and the addition of DMSO with ligand to an 
absolute minimum (1%). The main effect from addition of DMSO was a shift in the 
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charge distribution seen at pH 5.0 from the 10+ charge species to the 8+ charge species 
(see figure 13). With addition of DMSO to the standard sample conditions (10% 
methanol and 10mM ammonium acetate pH 5.0) the GTP and m7GTP eIF4E complexes 
are still detectable (figure 13). However there is a noticeable drop in signal intensity 
presumably due to the viscous DMSO interfering with the process of ionisation in the 
electrospray source. Also the spectra with DMSO have more noise (see figure 5B and 
SC) that can make identification of bound ligand difficult. The cause of the noise is 
presumably due to aggregation with DMSO that has not desolvated completely during 
ionization. However by keeping DMSO levels to an absolute minimum, ligands that 
require it can be screened against eIF4E using mass spectrometry. 
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Figure 13: Panel A shows the behaviour of the 
apo e1F4E spectrum with and without 1% 
DMSO. The addition of DMSO causes a shift 
in the maxima of the charge species 
distribution from +10 to +8. Both spectra 
contain a second peak labeled "contaminant" 
and is most likely the result of abduct 
formation. Panel B shows the effect of DMSO 
on the spectrum of eIF4E when saturated with 
the m7GTP ligand (3.7211M). Again the shift 
in charge state distribution is seen but the 
complex is still detectible. Panel C shows the 
effect of DMSO on the spectrum of eIF4E 
when complexed with GTP(3.53!.LM). Here it 
is more difficult to identify the ligand bound 
peaks. This is partly due to the presence of a 
contaminant peak and also increasing noise in 
the spectrum. This noise (also seen with the 
rn7GTP complex) is probably caused by poor 
ionization of the sample due to the presence of 
DMSO, and also aggregation between eIF4E 
and DMSO as well. eIF4E in all samples was 
at a concentration of 3.21.tM. 
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A criterion was needed to differentiate between specific and non-specific binders in the 
mass spectrometry screening experiments. It was decided using the GTP, GDP and 
GMP titration experiments as a guide that 50% sat should not be equal to 30% 1 L and 
10% 2L peaks i.e. the 1L% should be higher and the 2L% lower for the interaction with 
eIF4E to be considered specific. If a ligand meets this requirement then the ligand can 
be recognized as a valid hit against eIF4E and used in co-crystallisation experiments. 
5.7.2 Mass spectrometry screening results. 
All ligands identified from the virtual screens were dissolved in DMSO as a 10mM 
stock. Compounds from the mini-library were dissolved in a 100% methanol at 
20mg/nil. The concentrations of these compounds was unknown as they were never 
purified to a 100% purity, so any concentrations mentioned in respect to this library are 
only apparent. Thus mass spectrometry in these cases can only be used to see if binding 
occurs and not to assess the strength of the interaction. All compounds identified using 
ISISBase were also dissolved in 100% methanol as a 10mM stock. 
The compounds from the virtual screening and ISISBase searches were found not to 
bind eIF4E under the screening conditions used, which were 10mM ammonium acetate 
pH5 .0 10% methanol (for mass spectrometer parameters see methods and materials). 
Compounds from the mini-library based on the quinolene, isoquinolene and 
benzothiazole ring systems also showed no interaction with eIF4E of any kind in the 
gas-phase. These results are not surprising considering the results seen in chapter 4 that 
indicate a positive delocalised charge and a negative phosphate tail are required for 
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binding to occur to eIF4E. The hits generated from virtual screening, as stated early, did 
not contain a positive delocalised charge on a ring system, the hits from the ISISBase 
searches were probably either too bulky and also contained no phosphate mimic group 
as did the compounds from the mini-library mentioned. However N7 substituted GMP 
analogues did exhibit binding in the gas phase with the following group: methyl, ethyl, 
henzyl and parafluoro-benzyl (see figure 14). These compounds unlike the others 
screened possessed a positive delocalised charge on a ring system (guanine in this case) 
and a single negatively charged phosphate group. 
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Figure 14: The figure shows the positive hits from the mass spectrometry screening. Panel A shows 
7-henzyl GMP (-4.4tM) saturating eIF4E. Panel B shows 7-(p-fluoiohenzyl) GMP (-4.2311M) 
binding to eIF4E and Panel C shows m7GMP (-529pM) interacting with eIF4E. Panel D shows 7-
ethyl GMP (-50pM) binding to eIF4E. These hits all saturate the apo peak to —50 0/c with out giving 
rise to the 2L peak, associated with the non-specific effect discussed in chapter 4. The exception to 
this is et7GMP that exhibits development of a 2L peak. All samples were run with 3.2pM of ell-41E. 
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The hits did not exhibit the presence of the apo + 2L peak associated with non-specific 
binding (see chapter 4), except et7GMP as indicated in figure 14D. The occurrence of 
this 2L peak could possibly indicate that out of the compounds which have shown an 
interaction with eIF4E that et7GMP one has the weakest interaction with the protein. 
5.8 Conclusion. 
Virtual screening methods selected a variety of compounds that initially appeared likely 
candidates to bind to eIF4E, possessing features ranging from ring intercalation between 
the W102 and W56 and phosphate mimicry. The majority possessed features that could 
mimic the hydrogen bonds that recognised the m7G ring. However none of these 
compounds showed binding in the mass spectrometry based screens. Also no activity 
was seen for compounds extracted from the ACD using ISISBase or from the 
compounds based on the quinolene, isoquinolene and benzothiazole rings. These results 
support the observations made in chapter 4 that a phosphate group and a delocalised 
charge are required for successful interaction with eIF4E. Features that the N7 
substituted GMP analogues possessed and which were screened successfully against 
eIF4E. 
It would appear that virtual screening results have not succeeded in producing viable hits 
against eIF4E; however there are several possible avenues to pursue to overcome this 
apparent dead end. The initial library used for screening could be pruned to contain 
compounds that possess a delocalized positive charge on a ring system or that possess 
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ring systems that could be chemically modified to induce such a charge. Nitrogen 
containing ring systems may be protonated at physiological pHs which would also give 
the ring a positive delocalised charge. The methods required to predict this are either 
not reliable enough if there is no prior experimental data or computationally expensive. 
It would be far easier just to screen and see if an interaction with eIF4E occurs. There 
are positives from the LIDAEUS screen; several possible groups appear in the screen 
that could be possible mimics for the phosphate groups in m7GTP and several ring 
systems that could be alkylated to give a positive charge have also been recognised. 
Another valid approach to attempt in order for LIDAEUS to produce hits with a bigger 
chance of interacting with eIF4E is incorporation into the scoring model of the cation-7t 
interaction. 
Mass spectrometry has been shown to be a tool that can be used to screen eIF4E for 
potential cap-analogue mimics. It managed to identify all the N7 subsitituted GMP 
analogues as potential leads which have reported K1s of 382tM to 13.9 pM. Also the 
alklylation reaction has been shown as a tool, that as well as modifying the GMP 
scaffold (as previously described), it can also be used to modify other ring systems such 
as quinolene, isoquinolene and benzothiazole. The hits for 7bzGMP, 7- pflbzGMP and 
m7GMP can now be forwarded to cocrystallisation trials with eIF4E. 
The main aim for any further drug design efforts is to modify potential scaffolds in order 
to possess a positive delocalised charge and move away from the need to have a 
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phosphate group. The most apparent being to try and find chemical groups that can 
mimic the phosphate. 
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Chapter 6: Crystallisation of eIF4E with N7 substituted cap analogues and 
insights into structure based drug design for eIF4E. 
6.0 Introduction. 
The N7 substituted cap-analogues, synthesised and screened in the last chapter, were 
used for co-crystallisation trials. The aims were to discover how the large bulky 
benzyl group was accommodated in the cap-binding site and how the monophosphate 
group also interacted with eIF4E. Successful crystallisation would also allow the 
reported tighter binding of the para halogen substituted benzyl derivatives over the 
non-substituted variants to be structurally rationalised. 
6.1 Prior proposed model for the binding of 7-bzGMP and 7-pclbzGMP to 
eIF4E. 
As discussed in chapter 5 it has been reported that the benzyl substitution of the N7 
position in GMP increases the strength of its interaction 3-fold (K i = 113jtM) with 
eIF4E as compared to m7GMP (K i = 382p.M), and that the p-chloro-benzyl 
substitution (Ki = 51.2) results in a two-fold increase in affinity compared to the 
benzyl only substitution'. It has also been reported that the higher affinity the benzyl 
substitutions have for eIF4E arises from a favourable entropy change 2 . Several 
explanations for the strong changes in binding entropy of the benzylated cap-
analogues been proposed. The most plausible being that the positive entropy change 
is caused by expulsion of a few water molecules from the depth of the cap-binding 
slot into the bulk solvent, proportional to the size of N(7)-substituent. In the case of 
the p-cloro-benzyl substitution it has been proposed that the large and electronegative 
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chloride atom at the N7-benzyl ring can attenuate the van der Waals interaction with 
Trp 166 and destroy the specific water network inside the eIF4E cap-binding centre 
due to steric and electrostatic effects 2 . 
6.1.2 Modelling the benzyl derivatives into the cap-binding site of eIF4E. 
The full-length human m7GTP eIF4E complexed to the 4E-BP1 motif peptide crystal 
structure was used to model in N7 benzylated eJF4E. Modelling was carried out 
manually using PYMOL 3 to orientate the benzyl group into the cap-binding site. 
E103 
:. 
Figure 1: Manual modelling of N7 benzylated OTP into the cap-binding slot of 
eIF4e. The benzyl group could not be orientated pointing into the cavity (B) or up 
behind the W102 (red) residue (A) without steric clashes against the surface of eIF4E. 
The position shown above appeared to he the most plausible orientation for the benzyl 
group. However this assumes there is no conformational change in the residues in the 
active site and that the individual phosphate positions also remain the same for the 
monophosphate, diphosphates and triphosphate derivatives. 
Modelling was carried out by adding a phenyl group to the N7 methyl on the GTP 
molecule, under the assumption that the phosphate positions remain the same in the 
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m7GMP, m7GDP and m7GTP and other N7 derivatives when interacting with 
eIF4E. Another inherent assumption is that the cap-binding site undergoes no 
conformational change. Modelling with PYMOL 3 showed that the pose (shown in 
figure 1) was the most convincing; all other poses had steric clashes with the protein 
surface of eIF4E. However the benzyl group is in close proximity to the negative 
phosphate tail and would be energetically unfavourable. The pose shown in figure 1, 
agrees with the main points of the proposed model by Niedzwiecka et a1 2 , showing 
contacts between the benzene ring and W166 and possible disruption of any 
structured waters in the cavity. To orientate the benzyl group into other positions in 
the cavity would entail disrupting the planar stacking arrangement of the tryptophan 
side-chains and m7G and weaken the hydrogen bonds to E103 and the backbone 
amide of W102. 
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6.2 Co-crystallisation of 7bzGMP, pflbzGMP and m7GMP with full-length 
human eIF4E and the 4E-BP1 motif peptide. 
Preliminary screens were carried out around the conditions required for 
m7GTP/eIF4E/4E-BP1 crystal growth. Protein solution for crystallisation was 
prepared by concentrating eIF4E to 8mg/mi and then adding an equivalent volume 
4E-BPI peptide solution (0.0032M) to produce a sample with eIF4E at 4mg/mi and 
the peptide at 0.0016M. The reaction product, from the alkylation reactions that 
produced m7GMP, 7bzGMP and pflbz-GMP (see figure 2 for chemical structures), 
were dissolved in 0.1 M KCL 100mM HEPES-KOH pH 7.6 at a concentration of 
50mg/mi. Ligand solution was added in a 1/6 dilution to the prepared eIF4E/4E-BPI 
solution. Vapour diffusion was carried out as described in the material and methods. 
Crystals were produced at --7% ammonium sulphate, 25% PEG6000 and 100mM 
HEPES-KOH at pHs 6.8 and 7.0 or 100mM MOPS pH 6.4 (see figure 2). The 
m7GMP/eIF4E/4E-BPI (figure 2C) screens produced crystals that looked more 
disordered and were more irregularly shaped than the 7bzGMP/eIF4E/4E-BP1 
(figure 2A) and 7-pflbzGMP/eIF4E/4E-BPI (figure 213) co-crystals. The 
7bzGMP/eIF4E/4E-BP 1 and 7-flbzGMP/eIF4E/4E-BP 1 co-crystals were very 
similar in morphology to the plate-like crystals of m7GTP/eIF4E/4E-BPI originally 
observed in chapter 2. Crystallisation trials with ribavirin, GTP and rn7G proved 
unsuccessful highlighting the need for a phosphate group and a delocalised charge on 
the guanine ring system. 
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Figure 2: Panel A shows co-crystals of the 7-bzGMP/eIF4E/4F-BPI motif peptide complex and 
Panel B shows co-crystals of the 7-pfLhzGMP/eIF4E/4E-BPI motif peptide complex. These co-
crystals exhibit the same crystal morphology as the m7GTP variants discussed in chapter 3. Panel 
C shows crystals from the crystal screening trials with m7GMP. These trials produced lower 
quality crystals that appeared to he more disordered and showed poor diffraction. 
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6.2.1 Structure solution of 7BzGMP/eIF4E/4E-BPI and 7FIBzGMP/eIF4E/4E-
BPI co-crystals. 
The thin-plate like crystals of the eIF4E and N7 substituted derivatives peptide 
complexes (figure 2) were cryo-frozen using freezing solution containing 20% 
glycerol, 5% ammonium sulphate, 25% PEG 6000 and 100mM of the buffer used in 
the well they were harvested from. The co-crystals were then mounted in a random 
orientation and 120 degrees of data were taken with an oscillation angle of 1 degree 
using the Phi rotation method at 100K at the 14.1 PX station at Daresbury. 
The structures of the ternary complex containing N7 substituted derivatives were 
solved by molecular replacement using MOLREP 4, the search model was the 2.3 
angstrom structure of full length human eIF4E complexed with the 4E-BPI péptide 
solved in chapter 3. m7GTP and any structured waters were removed from the 
search model. Data up to 3.5 angstrom was used for the MOLREP 4 solution. 
MOLREP4  isolated the positions of the two ternary complexes in the asymmetric 
unit. These initial co-ordinates were used to begin refinement (see table 1 for data 
collection statistics). 
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6.2.2 Refinement and validation of the 7bzGMP/eIF4E/4E-BPI and 7-
pflbzGMP/eIF4E/4E-BP1 complex structures. 
I 
Figure 3: Initial F,,-F, density map showing clear electron density for the 7hzGMP ligand (sigma 
2.). The density map was calculated from a crystal collected on the home source whose data was 
processed up to a resolution of 3.2 angstrom. 
Prior to refinement, 2F,-F and F,,-F, maps were calculated using FFT in CCP4i 4 . 
The models were both examined and were continuous in density for the entire length, 
except for the N-termini and the C-terminal loop. The starting models was subjected 
to 10 cycles of rigid body refinement and followed by JO cycles of restrained 
refinement in Refrnac At this point the F 0-F were recalculated for both 
structures revealing large peaks of density in the cap-binding site for both non-
crystallographic symmetry related complexes (see figure 3). These areas of density 
correspond in shape to guanine mono-phosphate showing clear density for the (X-
phosphate. The R-factors at this point were 4X for the 7bzGMP and 23.6 for the 7-
pflbzGMP ligand structure. The corresponding R-free values were 29.1 and 28.9. 
After this the N7 substituted guanine monophosphates derivatives were used 
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(refrnac 4 ' 5 library files generated using PRODRG 6) in the refinement and placed into 
clearly visible electron density. At this point waters were added using ARP_Warp 7 . 
This was then followed by continuous cycles of manual refinement of the models 
using Coots  and 10 cycles of restrained refinement using refmac Structure was 
validated using PROCHECK4  (see table 1 for final model statistics). 
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7-bzGMF co-crystal structure 7-p-flbzGMP co-crystal 
Unit Cell Dimensions A=38.2, b=100.2, c=135.2 A=38.4, b=100.7, c=135.3 
a=f3y=90 a3y90 
Resolution 2.3A 2.1A 
Space Group P2 1 2 1 2 1 P2 1 2 1 2 1 
Temp(K) 100 100 
Number of collected 77817 111399 
Number of unique reflections 21598 28510 
• sym 11.9(46.6) 12.5(52.7) 
• factor 19.9 19.9 
R free 25.6 24.9 
RMS bonds 0.008 0.016 
RI'1S angle 1.187 1.725 
Average B value 31.234 26.088 
% completeness 91%(87%) 91.1%(87.6%) 
Number of observed solvent 353 313 
molecules 
Peptide 2 2 
Ligand 2 2 
Rarnachandran data: 
Residues in most favoured 93.4% 92.5% 
regions 
Residues in most favoured 5.8% 6.4% 
regions 
Residues in generously 0.9% 0.6% 
allowed regions 
Residues in disallowed 0% 0.6% 
regions 
I/sigma 5.8(1.6) 5.0(1.4) 




6.3 Structural analysis of N7 substituted cap-analogue crystal structures. 
6.3.1 Flipping of the tryptophan 102 allows the N7 benzyl group to be 
accommodated in the cap-binding site. 
The m7G moiety of the cap structure is sandwiched between two tryptophans (W56 
and W102) forming it-cation interactions (see figure 4). The cap analogue makes 
three hydrogen bonds, involving a backbone amino group of W 102 and the side chain 
of the conserved E103 (see figure 4). The structural interactions of the cap-binding 
pocket with m7GDP/m7GTP are conserved between human, mouse and yeast eIF4E. 
Figure 4: Graphic summarising the interactions made by m7GTP with eIF4E. The cap-
analogue is intercalated between tryptophans W102 and W56. forms three hydrogen bonds with 
the side-chain of E103 and the aniide backbone of W102 and the triphosphate tail is recognised 
by R157, RI 12, K162 and K159. The ni7G ring interacts with the two tryptophans via a cation-n 
interaction. 
In the co-crystal structures containing 7-hzGMP and 7-1)flbzGMP a conformational 
change is induced in the cap binding site that allows the benzyl ring to pack 
efficiently into the cap-binding site. The W102 residue flips through 180 ° and 
allows the benzyl group to orientate itself into the cavity behind the two tryptophan 
residues (see figure 5). 
Figure 5: The co-crystal structure of' 7-bzGMP overlaid over the rn7GTP co-crystal structure 
revealing the flipping of the side—chain of WI 02 through 180". It is this flipping that allows the 
N7 henzyl group to orientate itself behind W102. The 7hzGMP ligand is shown in blue as well 
as the corresponding W102 side chain and the position it adopts in this crystal structure. The 
m7GTP ligand and the former position of the tryptophan are shown in red. Modelling studies 
failed to reveal this mode of binding due to steric clashes between the W102 side-chain, in the 
position as found in the m7GTP structure, and the benzyl group in that particular orientation. 
Modelling studies in section 6. 1 .2 could not orientate the henzyl group into the 
cavity, despite there being sufficient space, with out forming bad contacts in the cap- 
binding site or losing the planar arrangement between the side-chains of W102 and 
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W56 and the m7G moiety. The flipping of W102 does not disturb the tridentate 
hydrogen bonding arrangement to the m7G moiety, the planar packing arrangement 
of the ring systems in the cap binding site or the overlap between the tryptophans and 
the guanine ring (see figure 6). 


















Figure 6: Panel A shows the surface of eIF4E and how the henzyl group fits into the hack of the cap-
binding slot with a space tilling model. If the tryptophan was flipped, in the position seen in the 
ni7GTP co-crystal structure, a steric clash would occur. The flipping of the tryptophan allows the 
benzyl group to form a maximum number of contacts with elF4E, the rn7G ring to remain planar in 
respect to W102 and W56. ensure that the overlap between the ring systems is approximately the 
same and that the three hydrogen bonds recogonising the ring system are still formed. Panel B shows 
the maintenance of ring planarity and how the areas of ring overlap approximately remain the same 
between the ligands m7GTP. 7-BzGMP and 7-Bz-pFL-GMP. 
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The flipping of the W102 also ensures that as well as maintaining the amount of 
overlap with the m7G moiety it also overlaps with the same part of the molecule (see 
figure 6). The part of the m70 moiety that W102 overlaps in both configurations is 
the pyrimidine section rather than the imidazole section. Studies of model compound 
systems also indicate a stronger stacking interaction with the pyrimidine portion of 
the guaninium and adenine rings than with the imidazole portion"". For VP39 it has 
also been observed that F180, as well as having a larger area of overlap with m7G 
than Y22, also overlaps more substantially with the pyrimidine portion of the m7G 
ring system. This is consistent with their finding that the FI80A mutation led to a 
significantly greater reduction in VP39 methyl tran sfe rase activity than the Y22A 
mutation. 
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Figure 7: m7GTP (red) co-crystal structure overlaid with the NCS related ternary complex of the 
7-pflhzGMP(green) which showed partial density for the W102 side chain. This non-
crystallographic symmetry unit is showing that the W102 side chain is sampling multiple 
conformations (as shown by the lack of density) and that the p-fl-benzyl group is orientating itself in 
such a position as to stericalty hinder the freedom of the side-chain of W 102. This potential steric 
clash is shown by the close proximity of the red tryptophan to the N7 derivative. The red 
tryptophan corresponds to the m7GTP structure and the green tryptophan to the 7-Bz-pFLGMP 
structure. 
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In the other non-crystallographic related ternary complex located in the asymmetric 
unit, for both the 7-bzGMP and the 7-pflbzGMP co-crystal structures, there is partial 
electron density for the W102 and poor density (occupancy) for the N7 substitution 
on the m7G ring. However in the 7-pflbzGMP co-crystal structure the conformations 
of the N7 substituted cap-analogue differ (see figure 8). The phosphate tails are in 
identical positions but the orientation of the benzyl group has changed and the 
positions of the m7G ring and the ribose ring do not overlay precisely (see figure 8). 
The configuration of the N7 GMP derivative supports the two step binding 
mechanism with the phosphate binding first (their positions in figure 8 are identical) 
and then the rest of the ligand orientating itself between the two tryptophans (these 
do not overlay identically in figure 8). If this ternary complex from the 7-pflbzGMP 
structure is overlaid with either of the ternary complexes in the m7GTP structure (see 
figure 7) the benzyl ring and the W102 from the m7GTP structure clearly clash. This 
non-crystallographic symmetry unit is showing that the W102 side chain is sampling 
multiple conformations (as shown by the lack of density) and that the p-fl-benzyl 
group is orientating itself in such a position as to sterically hinder the freedom of the 
side-chain of WI 02. It is this steric clash, shown by the close proximity of the p-fl-
benzyl to the overlaid W102 in the m7GTP co-crystal structure, which is responsible 
for the side-chain of W102 stacking on the m7G ring in an alternate conformation. 
Evidence that the arrangement described in the other eIF4E molecule (chain A) is the 
final packing arrangement is supported by other published structures of eIF4E and 
other cap-binders, where for ligands ranging from m7GTP to dinucleotide derivatives 
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Figure 8: The figure shows the conformational differences between the 7-17tlbzGMP (green) 
bound ligand. in the NCS ternary complex showing partial density for the W102 side chain, 
compared to opposing ternary complex that shows good density. Other bound ligands overlay 
almost identically over the 7-1)flbzGMP ligand shown in turquoise. The 7-,ifibzGMP ligand 
(green) has not yet adopted the final planar arrangement noted for the other ligands and the benzene 
ring has not adopted its final orientation. The configuration of the 7-pflbzGMP derivative supports 
the two step binding mechanism with the phosphate binding first (the positions of the above are 
identical) and then the rest of the ligand orientating itself between the two tryptophans (these do 
not overlay identically). To move the ii17G moiety into the final hound position is a simple 
procedure. The block arrow shows the direction the m7G ring (green) needs to roll to adopt the 
final ligand (turquoise) position, and the chevron shows the direction the benzene rings needs to 
move to adopt the final bound position. 
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6.3.2 The large bulky benzyl group expels two structured waters from the active 
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Figure 9: Panel A shows the cavity which the benzyl group packs into in the 1117GTP co-crystal 
structure. Panel B shows the change in the water network, in the cavity behind the two 
tryptophans. where the benzyl causes two structured waters to be expelled and creates a new 
structured water position. This new position is in close proximity to the side-chains of T203 and 
H200 and the carbonyl backbone of Q 198. 
In the m7GTP structure the nitrogen atom of WI 02 is pointing in towards the cavity 
of the cap binding site and forms a direct hydrogen bond to the structured water (see 
figures 9 and 10). This structured water interacts with a further two: one of which is 
involved in interactions with the triphosphate tail of the ligand whilst the other 
interacts with T203 and H200 (see figures 9 and 10). Out of this set of three 
structured water molecules two are expelled by the benzylated GMP derivative and 
the other, at the back of the pocket, shifts its position (see figures 9 and 10). The 
structured water that shifts maintains the h-bonds to T203 and H200 (see figure 9 and 
10). These structured water positions are observed in both non-crystallographic 
symmetry related units. The two structured waters that are expelled by the bulky 
benzyl group confirm the hypothesis (Niedzwiecka et al) for why the energetics of 
the N7 benzyl substituted derivatives in relation to eIF4E are entropy driven. H200 
has been modelled into the position shown in figures 9 and 10 to maximise the 
number of hydrogen bonds formed with the c 2 nitrogen interacting with a structured 
water in the cap-binding slot and the & nitrogen interacting with another structured 
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Figure 10: In the m7GTP structure the nitrogen atom of W102 is pointing in towards the cavity of the 
cap binding site and forms a direct hydrogen bond to the structured water (Panel A). This structured 
water interacts with a further two: one of which is involved in interactions with the triphosphate tail of 
the ligand whilst the other interacts with T203 and H200) (Panel A). Out of this set of three structured 
water molecules two are expelled by the benzylated GMP derivative and the other, at the back of the 
pocket, shifts its position (see Panel B). The structured water that shifts maintains the h-bonds to T203 
and H200. The fluorine of the para-halide substituted benzene ring interacts with the structured water 
that shifts its position (Panel B). There is also an arginine residue in close proximity (Ri 12), which 
interacts electrostatically with the fluoride. This set of interaction explains the increased potency of 
halide substituted benzyl ring systems reported by Cai et al l 
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6.3.3 N7 —pfl-benzyl modification interacts with the altered water network. 
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Figure 11: The para fluoride atom on the benzyl ring forms a hydrogen bond interaction with the 
structured water at the back of the binding pocket The structured water is also in close proximity to 
the side-chains of T203 and H20() and the carbonyl backbone of Q198. It is the bulk of the benzyl 
substitution that causes the structured water to occur in this shifted position as discussed in the 
previous section. The fluoride atom is also situated near a positively charged arginine where an 
electrostatic interaction occurs. 
The same rearrangement of the cap-binding site occurs with the para-Iluoro 
substituted benzyl with the W102 carrying out the same movement. However the 
fluorine interacts with the structured water that shifts its position, in the small 
hydrogen bond network, to the back of the binding cavity. The structured water still 
interacts with T203 and H200. Apart from these interactions there is an arginine 
residue in close proximity (R112),  which interacts electrostatically with the fluoride. 
This set of interactions explains the increased potency of halide substituted benzyl 
ring systems reported by Cai et all 
In the other eIF4E molecule, in the asymmetric unit, density for the fluoride atom is 
not in the same orientation to form such tight interactions. However the structured 
water still forms the interactions described at the back of the cap-binding slot (see 
figure 10 and 11). The disruption of the two structured waters observed in the 
rn7GTP co-crystal structure by the presence of the large N7 substitution is the 
driving factor for the positioning of the shifted structured water. The hydrogen 
bonds formed by the para-fluoro halide are longer and weaker 3.5A in length. The 
fluoride is now also not in such close proximity to R112 - 5A instead of 3.09A. 
6.3.4 Monophosphate tails interactions. 
The N7 GMP derivatives are the first monophosphate molecules to be co-crystallised 
with eIF4E. The a-phosphate has a direct electrostatic interaction with Arg 157 and 
interacts with two conserved water positions (see figure 12A). One water position 
interacts with K162 and the other forms hydrogen bonds with RI 12 and another 
structured water (see figure 12A). This structured water eventually feeds into a water 
molecule that interacts with the indole ring of W166 and another that interacts with 
the carbonyl backbone group of V153. Upon the addition of a second phosphate 
group (as seen in the rn7GTP co-crystal structure) the water bridging to K162 is 
displaced and three direct contacts are made to K159, K162 and R157 (see figure 
1213). An interaction with a structured water occurs outside the cap-binding site on 
the lip of the pocket. The gamma phosphate, in the m7GTP structure, forms only one 
direct ionic contact with R157 and interacts with a structured water (see figure 1213). 
This structured water forms an h-bond with another water that mediates a hydrogen 
bridge between the ribose ring and the carbonyl backbone group of T203. These 
results show that the phosphate binding pocket is optimised to bind the beta 
phosphate which has the most direct contacts to eIF4E compared to the alpha and 
gamma phosphates that mainly interact through water mediated bridges. 
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Figure 12: Panel A shows interactions between the a-phosphate of the GMP derivatives and the 
phosphate binding pocket. A direct interaction is formed between the a-phosphate and R157. 
Water mediated hydrogen bridges occur with K162 and RI 12. Another interaction is formed to 
structured water that interacts with other waters in the binding pocket. Panel B shows the 
interactions between the triphosphate tail and the phosphate binding pocket. The F3-phosphate 
replaces the structured water and the interactions it made between the a-phosphate and K 162 and 
K 159 respectively. The 'y-phosphate forms a direct contact to KI 62 and two hydrogen bonds to two 
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6.5 Future drug design development for eIF4E. 
6.5.1 Design principles. 
The N7 -methyl group of the m 70 moiety points towards a large hydrophobic cavity 
that forms the floor of the eIF4E cap-binding slot and only forms a van der Waals 
contact with W166. The N7 henzyl substituted ligand structures reveal that the 
benzyl substituent is accommodated into the cap-binding site by flipping of the 
W102 tryptophan side-chain. Possible future pharmacophore subunits could he 
identified that optimally occupy the position of the benzyl in order to provide the 
bulk of the binding energy. The presence of the strongly negatively charged 
phosphate groups in potent cap analogues is the main reason for the lack of 
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Figure 14: The figure shows the functional moieties that in7G phosphate family can be broken down 
into and that need to be chemically explored in the design of an ideal drug candidate. Panel A shows the 
three functional groups of the generic cap-analogue and the role ribose plays as a linker and scaffold 
functionality. Panel B shows how these relate to the active site with the tryptopharis (W56. W 102 and 
W166) shaded red. E103 shaded yellow and the phosphate binding site shown in blue. The A label 
shows the area where the heni.yl group packs into which would he a site for exploration of other 
chemical groups. 
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Phosphate mimetic groups that are highly polar, but uncharged, should be 
investigated. These include polyhydroxylated systems, tn fluoromethylsulfonyl 
groups ' 1 , and squaryldiamides 12 . For ribose replacements emphasis should be on 
optimal spacing between the heterocyclic and the phosphate mimetic pharmacophore 
groups. Since the ribose group is not involved directly in interactions with eIF4E 
except via a single water mediated hydrogen bond, linker diversity can be explored 
to achieve optimal pharmaceutical properties and conformational constraint between 
the heterocycle- and phosphate-mimetic groups (see figure 14). The 3-phosphate 
would seem an optimal position for placement of a phosphate mimetic group because 
it forms more direct contacts to eIF4E that the other phosphate positions (see section 
6.3.4). The other phosphates groups of m7GTP interact mainly though water 
mediated contacts. Isosteric and isoelectronic replacements for the modified 
nucleobase should be sought, with heterocyclic azoles capable of delocalising a 
positive charge as in in  G being investigated. Potentially useful systems are purines, 
as well as thiazoles, imidazoles, pyrazoles, indazoles, triazoles, and their benzo- and 
pyrido-derivatives. At present the only known system other than m7G is based on 
benzimidazole' 3 . The amidotriazole system present in ribavirin also possesses a 
delocalized charge that has been reported to interact with eIF4E 14 . However recent 
reports contradict this 15 " 6 . 
Certain analogies with protein kinases, where mononucleotide (i.e. ATP)-antagonist 
inhibitor design has been highly successful 17 , can be discerned. In both cases the 
mononucleotide-binding site is not occupied fully by the natural ligand, the 
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triphosphate moiety contributes significantly to binding, and the nucleobase interacts 
with the protein through a tridentate H-bonding system. 
Potential starting point for chemistry 
arising from virtual screens 
Figure 15: Panel A shows the 7-benzyl OMP ligand structure, which has been shown as a potent 
binder of eIF4IE in the literature. 7-benzyl GMP can he redesigned using a step-wise strategy to 
synthesis a compound with more favourable ADMET properties. A compound that might arise from 
such an approach is illustrated in panel B. As well as using the step-wise strategy convincing hits from 
virtual screening can also be used as potential chemical starting points. Panel C shows an example of 
such a starting point. In these cases an obvious strategy would be to try an introduce some type of 
delocalised positive charge on the ring system to mimic the charge found on the rn7G ring system. The 
example in panel C has tail which could be a potential phosphate mimic (highlighted in blue). 
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In the case of kinases numerous ADMET-favourable pharmacophores unrelated to 
ATP have been identified and this has enabled the development of kinase-inhibitor 
drugs. Selectivity should be less of an issue with cap antagonists than with kinase 
inhibitors. Thus there is the potential of using these kinase antagonists by inducing 
some type of positive delocalised charge on them, and then assessing whether they 
are capable of then binding eIF4E. 
6.5.2 Medicinal chemistry based on m7GTP. 
In the first instance the above design principles can be applied in the context of 
7BzGMP (see figure 15), one of the most potent nucleoside monophosphate cap 
antagonists known to date which we have solved the ligand structure for 
Modifications of single pharmacophore groups (see figure 14) can be introduced ini-
tially in order to assess SARs at each position. This is convenient since established 
cap analogue chemistry can be applied (refer retrosyntheses in figure 16). Optimal 
individual solutions for the four pharmacophoric groups could then be combined 
using synthetic methods; a possible target structure is shown in figure 15 
(retrosyntheti c analysis to 5 ,6-dinitrobenziniidazo le not shown). 
De novo design. Additionally, inhibitor candidates with chemical complementarity to 
the cap-binding site could also be designed without explicit reference to the natural 
ligand. Initial feasibility work suggests that application of our LIDAUES high-
throughput docking program' 8 to the eIF4E—m7 GTP interaction can suggest plausible 
pharmacophore starting points (see figure 15 and chapter 5). This approach can be 
refined, especially in order to account for the m 7 Gua stacking interaction. Also the 
new eIF4E ligand structures with 7bzGMP and 7-pfLbzGMP have provided a 
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different conformation for virtual screening studies, which allows for the 
accommodation of large bulky hydrophobic groups. It is reasonable to expect that 
this approach could yield alternative pharmacophore hypotheses for medicinal 
chemistry. 
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Figure 16: Modifications of single pharmacophore groups can he introduced initially in order to 
assess SARs at each positions. This is convenient since established cap analogue chemistry can he 
applied. Above are shown potential series of compounds that could he designed around different 
functionalities to investigate there effects on binding, with commentary based on the model of 
interaction proposed in chapter 4 on whether these ligand types will bind or not. 
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6.5.3 X-ray crystallography. 
High-resolution X-ray crystal structures of recombinant human eIF4E constructs 
complexed with 4E-BP peptides and a reasonably potent cap-analogue, as has been 
shown, can be co-crystallised. Co-crystals have been grown for rn7GTP, 7bzGMP 
and 7-pflbzGMP. Both medicinal chemistry based on m 7 GTP and de novo design 
can be directed through the study of the structural consequences of modifications on 
eIF4E binding. Fragment-based crystallography screening' , which has been used 
successfully in kinase inhibitor discovery, is probably not applicable to eIF4E. With 
eIF4E the apo form has never successfully been crystallised and the crystals that 
have been grown have required the presence of a cap-analogue. It is this presence of 
the cap-analogue that would interfere with a fragment based crystallography screen. 
There is the potential to soak out the cap-analogue and then attempt to use the 
fragment based screen approach. However dialysing out cap-analogues such as 
m7GTP and m7GDP from eIF4E has not been successful. If eIF4E is in solution 
with 0.6mM rn7GTP and dialysed overnight and analysed via mass spectrometry 
afterwards the protein is still saturated. The tight attraction that eIF4E has for cap-
analogues and its need for them to be present when being crystallised are 
disadvantages against using the fragment based screening approach 
The fragment based screening approach could be used with VP39 20 to identify 
systems that could intercalate between the two tryptophans. The advantage of 
VP3920 over eIF4E is that it has been crystallised with the two aromatic residues 
required for cap-binding in the apo form. This makes it ideal for a fragment based 
screening approach. In the literature it has already been shown that methylated bases 
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can be soaked into V1P39 20 . A further option could be to mutate both aromatic 
residues to tryptophan. The strategy would be to soak VP39 20 crystals with pools of 
low-MW fragments potentially capable of intercalating between the aromatic 
residues of the cap-binding site.. 
6.5.4 Biological assays. 
Potential ligands can be screened via mass spectrometry (see chapter 4 and 5) and 
positive hits can be further investigated utilising intrinsic tryptophan fluorescence to 
characterise its behaviour in solution. Direct competitive binding assay based on 
streptavidin-immobilised biotin-derivatised m 7GMP and a fluorescence polarisation 
assay using y-phosphate-labelled rn 7GMP2 ' could also be developed. Functional 
activity of the test compounds can be assessed using in vitro and cellular 
transcription-translation assays based on a bicistronic dual luciferase assay system as 
described 22  in order to be able to distinguish between effects on cap- and IRES-
dependent translation initiation. The antiproliferative effects of test compounds could 
be examined using standard cell viability assays in a panel of transformed and 
normal human cell lines. Another technique that could be used to investigate the 
apparent flexibility of eIF4E is hydrogen-exchange monitored via mass 
spectrometry. This would provide direct evidence of whether eIF4E is indeed less 
constrained when ligand free and offer an explanation to why it does not crystallise 
in the apo form. 
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6.6 Conclusion. 
This body of work demonstrates that eIF4E can be easily purified in the large 
amounts required for successful structure based drug-design. High resolution 
diffracting co-crystals can be produced to investigate the interactions of any lead hits 
produced. Lead hits can be identified using mass-spectrometry as a primary screen 
and their behaviour in the gas-phase can then be further investigated. This work also 
describes the behaviour of eIF4E and the cap-analogues in the gas-phase for the first 
time. N7 derivatives which from previous work were known to be good binders of 
eIF4E were shown to interact in the gas-phase, and their interactions rationalised 
structurally using crystallography. This work also shows that for successful drug 
design to be applied to eIF4E, the interactions of the phosphates and the delocalised 
positive charge on the m7G ring need to be accounted for; as shown by mass 
spectrometry and the failure to crystallise compounds that do not contain both of 
these features. Another interesting characteristic to be revealed by crystallographic 
analysis is that the cap-binding site is conformationally flexible (shown by flipping 
of the W102 side-chain), a feature that has been implied by a number of studies. 
Using the knowledge gained from crystallisation of N7 substituted cap-analogues 
and applying it to virtual screening and medicinal screening efforts a more drug-like 
target compound should be producible. 
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Chapter 7: Materials and methods. 
7.1 Expression and protein induction methods. 
7.1.1 Expression of the full length eIF4E pETlid clone. 
Rossetta pLysS competent bacteria were transformed with the pET1 id expression 
plasmid containing the full length human eIF4E clone, both materials were provided by 
Cyclacel Ltd., Dundee. Bacterial transformation was carried out via a typical heat shock 
procedure (Molecular Cloning: A laboratory Manual (3 rd  edition) Sambrook and Russel, 
Cold Spring Harbour Laboratory Press, Cold Spring Harbour, New York, 2001) and 
plated out on l00ig/ml ampicillin LB Petri dishes and incubated at 37°C overnight. A 
single colony was picked from the plate and used to inoculate 10mls of LB media, 
containing I 00tg/ml ampicillin, and grown overnight in a shaker (200 rpm) at 37 °C. The 
inoculated lOmis was then used to seed 800m1 LB media, also containing lOOug/ml 
ampicillin, in a 2L conical flask and grown to an optical density between 0.4 and 0.6 
whilst on a shaker (200 rpm) at 37°C. Induction of Protein expression was started by 
addition of IPTG up to a concentration of 1mM. The culture was immediately incubated 
on a shaker for 3 hrs at 37°C (200 rpm). Afterwards the culture was placed in 250m1 
centrifuge bottles and spun at 5,000 rpm for I 5mins at 4 °C. The cell pellets were then re-
suspended in 50mM Tris pH8.0, 10% sucrose (re-suspension buffer), imI for every 
250mls of culture. Re-suspended cell pellets were placed in 1 .Snil eppendorfs and 
frozen at 70°C. 
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7.1.2 Analysis of soluble and insoluble protein fractions from expression studies. 
Centrifuge imi samples from set time points during expression of full length human 
eIF4E. Spin samples for 15 minutes at 2.5 krpm on a table top centrifugue. Discard the 
supematant and resuspend the pellet in 50iL 1-120. Sonicate the sample for 10 to 20 
seconds, and then centrifuge at 13krpm for 15 minutes. Separate the supernatant (soluble 
fraction) from the pellet and re-suspend the pellet in 40tL H20 (insoluble fraction). 
Analyse samples on SDS-PAGE gel (Molecular Cloning: A laboratory Manual (31 
edition), Sambrook and Russel, Cold Spring Harbour Laboratory Press, Cold Spring 
Harbour, New York, 2001). 
7.2 Protein purification methods. 
7.2.1 Purification of full-length eIF4E from inclusion bodies. 
Two 1 .5m1 eppendorfs containing re-suspended cell pellets were thawed under running 
cold water. 40.tl of Lysozyme at 10mg/mi and 60jil of 4M NaCl were added, and then 
incubated on ice for 45 minutes. Following incubation 5m1 of re-suspension buffer was 
added and the sample sonicated. This was carried out on ice in 6x20sec periods, with rest 
intervals of 20sec in between each sonication. The sonicated sample was then 
centrifuged for 10 min at 10,000 rpm at 4°C. Resulting pellet was re-suspended in 5ml 
Tris/Triton buffer (50mM Tris pH 8.0, 2mM EDTA, 100mM NaCL, 0.5% Triton X-100) 
and homogenized with a glass homogenizer. The sample was then centrifuged at 12,000 
rpm for 15min at 4°C. The pellet again was re-suspended in Tris/Triton buffer and the 
steps described repeated. The remaining pellet was then re-suspended in 7ml 
Guanidine/Buffer A (6M Guanidine Chloride, 50mM Hepes-KOH pH 7.6, 5mM DTT). 
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The protein concentration of the sample was measured via the Bradford assay and the 
concentration of the sample then adjusted to 1mg/mi by addition of Guanidine/Buffer A. 
7.2.2 Re-folding of eIF4E by rapid dilution. 
The sample from the "purification from inclusion bodies??  protocol was then stirred for 
2hrs at 4°C. Rapid re-folding via a 1/10 dilution was then carried out. The supernatant 
from the centrifuged sample was filtered via a 0.2gm filter and then slowly injected into 
pre-chilled refolding buffer (10 times the volume of the sample) under magnetic stirring. 
Refolding buffer consisted of 20mM Hepes-KOH pH 7.6, 100mM KCL and 1mM DTT. 
After addition of the protein sample to be refolded, magnetic stirring was carried on for a 
further ten minutes. The diluted refolded protein was then left at 4°C for 2hrs. The dilute 
refolded protein, at a concentration of-- 0.1mg/mi, was then concentrated to a volume of 
2.5rni, using Vivaspins with a 10,000KDa cut off, and run over a Amersham PD1O 
desalting column in order to remove residual Guanidine Chloride. The sample was 
desalted into refolding buffer. 
7.2.3 m7GTP 413 sepharose beads analysis. 
0.8mls of m7GTP beads were placed in a 12m1 column and equilibrated with 20ml of 
Buffer A (20mM Hepes-KOH pH 7.6, 100mM KCL, 1mM DTT). 1mg total of refolded 
eIF4E was added to the column. The column was rotated for 2hrs before the liquid was 
allowed to drip off. This was then followed with a lOrnI wash with Buffer A. After this 
step two elution washes were carried out with 3mls of Buffer A containing 0.1mM 
203 
rn7GTP, The column was then washed with lOmis of Buffer A and then stored with 
0.01% sodium azide. 
7.2.4 Purification of eIF4E via anion exchange on a high resolution MonoQ column. 
An Amersham MonoQ column was used on a FLPC AKTA (Amersham, Ltd.) machine 
in a refrigerated cabinet at 4°C. The column was equilibrated with 3 volumes of Buffer A 
(20mM Hepes-KOH pH 7.6, 1mM DTT) and the prepared eIF4E sample was loaded on. 
A washing step was then carried out that involved a 3 volumes wash of the column using 
Buffer A. The protein was then competed off with an increasing KCL gradient of up to 
1M over ten volumes. This was held for a further one volume wash and then dropped 
down to a salt concentration of OM to ensure all protein loaded was washed off. 0.5m1 
Fractions were collected while the gradient was run over the column. Peaks in the UV 
chromatogram were analysed by SDS-PAGE gel (Molecular Cloning: A laboratory 
Manual (3rd  edition), Sambrook and Russel, Cold Spring Harbour Laboratory Press, Cold 
Spring Harbour, New York, 2001). 
7.2.5 Affinity purification of eIF4E via m7GTP 413 sepharose column. 
5 mls of rn7GTP 4B sepharose beads were packed into a Tricorn FIR 10/50 column, both 
supplied from Amersham Ltd. The column was run on a FLPC AKTA machine in a 
refrigerated cabinet at 4 °C. The column was equilibrated with 5 volumes of Buffer A 
(20mM Hepes-KOH pH 7.6, 1 m DTT) and the prepared eIF4E sample was loaded on. 
A washing step was then carried out that involved a 5 volumes wash of the column using 
Buffer A. The protein was then competed off with a block gradient of 0.1mM m7GTP 
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over ten volumes (0.1mM m7GTP, 20mM Hepes-KOH pH 7.6, 1mM DTT). 0.5m1 
Fractions were collected while the gradient was run over the column. The column was 
then re-equilibrated with a five volume wash with buffer A. Peaks in the UV 
chromatogram were analysed by SDS-PAGE gel (Molecular Cloning: A laboratory 
Manual (3 edition), Sambrook and Russel, Cold Spring Harbour Laboratory Press, Cold 
Spring Harbour, New York, 2001).. 
7.2.6 CD spectroscopy. 
Sample solutions were adjusted to 0.3mg/mi by phosphate buffer (10mM sodium 
phosphate, pH 7.0, 1mM EDTA) through buffer exchange using an Amersham PD1O 
desalting column. CD spectra were measured using a JASCO-810 spectropol ari meter, 
reading in the region of 190nm-260nm, with a scan speed of lOnm/min, in a quartz cell of 
path length 0.02mm. Measurements were carried out at a constant temperature of 4°C. 
m7GTP did not exhibit any spectra in the region of 1 9Onm to 260nm. Samples that were 
complexed with the ligand contained 0. 1mM m7GTP. 
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7.3 Crystallisation methods. 
7.3.1 Protein preparation and hanging drop vapour diffusion method for 
crystallisation studies. 
For preliminary crystallisation screens involving: 
Apo eIF4E: eIF4E from monoQ preparations was concentrated, using a 6m1 vivaspin 
tube with a 10 000kDA cut-off membrane, to a final protein concentration of 10mg/mi. 
The sample before crystallisation trials was spun at l3krpm for 30 minutes on a tabletop 
centrifuge. 
eIF4E coinpiexed to rn7GTP: eIF4E from monoQ preparations was pooled and m7GTP 
added to a concentration of 0.6mM (stock solution 10mM in buffer A) It was then 
concentrated, using a 6m1 vivaspin tube with a 10 000kDA cut-off membrane, to a final 
protein concentration of 10mg/mi. The sample before crystallisation trials was spun at 
13krpm for 30 minutes on a tabletop centrifuge. 
eIF4E complexed to in 7GTP and 4E-BPI Motif Peptide: eIF4E from monoQ preparations 
was pooled and m7GTP added to a concentration of 0.6mM (stock solution 10mM in 
buffer A) It was then concentrated, using a 6ml vivaspin tube with a 10 000kDA cut-off 
membrane, to a final protein concentration of 8mg/mi. To the eIF4E sample solution an 
equivalent volume of4E-BP1 motif peptide solution was added. Lyophilised peptide was 
provided by Cyclacei, Ltd., Dundee and was dissolved in buffer A to make a stock 
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solution at a concentration of 0.0032M. The sample before crystallisation trials was then 
spun at l3krpm for 30 minutes on a tabletop centrifuge. 
apo eIF4E coniplexed to 4E-BPI Motif Peptide: eIF4E from monoQ preparations was 
pooled. It was then concentrated, using a 6m1 vivaspin tube with a 10 000kDA cut-off 
membrane, to a final protein concentration of 8mg/mi. Alternatively eIF4E eluted from 
the m7GTP 4B agarose beads using a KCL gradient was concentrated instead. To the 
eIF4E sample solution an equivalent volume of 4E-BP1 motif peptide solution was 
added. Lyophilised peptide was provided by Cyciacel Ltd., Dundee, and was dissolved 
in buffer A to make a stock solution at a concentration of 0.0032M. The sample before 
crystallisation trials was then spun at 13krpm for 30 minutes on a tabletop centrifuge. 
eIF4E coinpiexed to N7 derivatives and 4E-BPI Motif Peptide.' eIF4E from monoQ 
preparations was pooled. It was then concentrated, using a 6m1 vivaspin tube with a 10 
000kDA cut-off membrane, to a final protein concentration of 8mg/mi. To the eIF4E 
sample solution an equivalent volume of 4E-BP1 motif peptide solution was added. 
Lyophilised peptide was provided by Cyciacel Ltd., Dundee, and was dissolved in buffer 
A to make a stock solution at a concentration of 0.0032M. N7 derivatives were added in 
a 1/6 dilution from a stock of 50mg/mi dissolved in buffer A. The sample before 
crystallisation trials was then spun at 13krpm for 30 minutes on a tabletop centrifuge. 
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The hanging drop vapour diffusion method was used for all crystallisation studies. The 
drop size consisted of 1.5u1 of eIF4E mixed with 1.5u1 of liquid from the mother solution 
in the 24 well Linbro plates. Hanging drops were equilibrated with 1000ul of mother 
solution. Cover-slips were sealed to the wells using paraffin grease. 
7.3.2 Protein crystallisation screens. 
Preliminary screens carried out were structure base I and structure base II screens from 
Molecular Dimensions, Ltd. PEG screens against pH were also carried out corresponding 
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Tables 2 and 3: Grids used for initial anunoniuni sulphate based crystallisation screens. 
A similar screen to the PEG based screen against pH was also carried out using 
ammonium sulphate as shown above (tables 2 and 3). Any crystalline type precipitates 
observed from the initial screens were further optimised by generating a finer grid around 
the conditions used. In the case of the ammonium sulphate and PEG- based screens a 
range of additives were also explored. These exploratory screens were carried out by 
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keeping the pH constant and varying the major precipitant and the additive being used. 
Additives used are shown in the table 4 below: 
Major Precipitant Additive [Major 
Precipitant]  
[Additive] 
Ammonium Sulphate PEG 400-2000, MPD, 2,0-4.OM 6%-0.5% 
ethanol, methanol  
PEG 1000-20000 Ammonium Sulphate, 40-50% 0.2-0.6M 
Sodium Chloride, 
Sodium Formate 
Table 4: Additives used with major protein precipitating agents used in the preliminary protein 
crystallisation screens 
These screens were performed for each protein preparation described in section 7.3.1. 
All stock solutions of PEG 4000-8000, IM buffers and saturated ammonium sulphate 
were filtered using a 0.2tm filter. 
7.3.3 Micro-seeding technique. 
Drops containing crystals to be used were pippetted into lOul of harvesting solution. 
Harvesting solution has a 10% higher PEG concentration than the mother solution in the 
well. Crystals in the harvesting solution were then crushed with a pipette with its tip 
melted closed. Three serial dilutions were then made using harvesting solution of 1/10, 
1/100 and 1/1000. Pre-equilibrated hanging drops were then seeded using cat whiskers. 
The conditions used for micro-seeding were decided by choosing conditions were 
crystals had been observed in earlier screens and then halving the protein concentration in 
the drop to be seeded. 
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7.3.4 Cryo-freezing of protein crystals. 
The freezing solutions that were used, were based on the mother liquor of the well in 
which the crystal grew in, with the addition of 20% glycerol to prevent ice formation. 
Crystals were manipulated using a nylon loop to transfer the crystal from the hanging 
drop to a 5u1 drop of freezing solution (on a siliconised cover slip). Crystals were soaked 
in the drop of freezing solution for approximately 5s and then manually plunged into 
liquid nitrogen using the nylon loop. Crystals grown in high concentrations of 
ammonium sulphate were frozen using immersion oil. 
7.4 Data collection and crystal structure solution methods. 
7.4.1 Data collection. 
Thin-plate like c,ystals of the eIF4E1m 7GTP/4E-BPI peptide complex, crystallised at 
25% PEG 6000, 5% ammonium sulphate, pH 7.0 100mM Hepes-KoH, were cryo-frozen 
using freezing solution containing 20% Glycerol, 5% ammonium Sulphate, 25% PEG 
6000 and 100mM Hepes-KOH, pH 7.0. The eTF4E/m7GTP/peptide crystal was mounted 
randomly and 120 degrees of data were taken with an oscillation angle of 1 degree using 
the Phi rotation method at lOOK at the ESRF 1D29 beamline at Grenoble. 
Co-crystals of the N7 derivatives complexed with the eIF4E/4E-BPI peptide complex 
were crystallised at 25% PEG 6000, -7% ammonium sulphate either at pHs 7.0 or pH 6.8 
100mM Hepes-KOH or p1-I 6.4 100mM MOPS. The thin-plate like crystals of the eIF4E 
and N7 substituted derivative peptide complexes were cryo-frozen using freezing solution 
containing 20% Glycerol, 5% ammonium sulphate, 25% PEG 6000 and 100mM of the 
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buffer used in the well they were harvested from. The co-crystals were then mounted 
randomly and 120 degrees of data were taken with an oscillation angle of I degree using 
the Phi rotation method at lOOK at the 14.1 PX station at Daresbury. 
7.4.2 Molecular replacement and structure solution. 
in 7GTP/eIF4E/4EBPJ co-crystal structure: Molecular replacement solutions were 
carried out using MOLREP in CCP4 v5.0 1 . The Mathews coefficient was estimated 
using the CCP4 suite of programs, using a molecular weight of 27393kDa for the 
m7GTP/eIF4E/4EBPI peptide complex. This gave a unit cell with a solvent content of 
47.7% and a V,, of 2.4 corresponded to two ternary complexes in the asymmetric unit. 
The 2.2 angstrom structure of A27 murine eIF4E complexed with the 4E-BPI peptide 
was used as the search model in MOLREP 1 , all waters and the m7GDP ligand were 
removed from the model. Data up to 3.5 angstrom was used for the MOLREP 1 solution. 
MOLREP' isolated the positions of two ternary complexes in the asymmetric unit. These 
initial co-ordinates were used to begin refinement. 
N7 derivatives complexed with the eIF4E/4E-BPI peptide complex: The 2.3 angstrom 
structure of full length eIF4E with the 4E-BPI peptide (solved in chapter3) was used as 
the search model in MOLREP', all waters and the m7GTP ligand were removed from the 
model. Data up to 3.5 angstrom was used for the MOLREP' solution. MOLREP' 
isolated the positions of two ternary complexes in the asymmetric unit. These initial co-
ordinates were used to begin refinement. 
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7.4.2 Model building and refinement. 
Prior to refinement, 21 70 -17 and 170-17 maps were calculated using FFT in CCP4i 1 . The 
models for the co-crystal structures were examined to see whether density was 
continuous for the entire length of the polypeptide chains. The starting models were 
subjected to 10 cycles of rigid body refinement and followed by 10 cycles of restrained 
refinement in Refmac 5.012.  At this point waters were added using ARP Warp 3 . After 
this the different ligands for the co-crystals were used (refmac library files generated 
using PRODRG4 ) in the refinement and placed into clearly visible electron density. This 
was then followed by continuous cycles of manual refinement of the model COOT  and 
10 cycles of restrained refinement using Refmac 5.0I.2.  Positions of structured water 
were also verified and added using COOT 5 . Models were validated using PROCHECK'. 
7.4.3 Structural analysis. 
Final models were analysed using COOT 5, PYMOL6 and INSIGHTIT (Acceryls, Inc.). 
All structural superimpositions carried out were in [NSIGHTII (Acceryls, Inc.) 
overlaying the a-carbon backbone. Superimposition between the co-crystals structures of 
m7GTP and the N7 derivatives complexed with full-length eIF4E and the 4E-BPI 
peptide were overlaid in COOT 5 ,. 
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7.5 Surface plasmon resonance (SPR) studies. 
The SPR assay was performed on a BlAcore 2000 (BlAcore, UK). The Sensorchip SA 
(BlAcore) was used to immobilise the biotin labelled 4E-BP1 peptide and the full-length 
human eIF4E was injected over the chip in the presence of m7GTP (in a ratio of 5:1 
protein concentration). 600 RUs of biotinylated peptide were immobilised on the chip. 
Each cycle consisted of a 150tl injection of buffer C (10mM HEPES pH 7.5, 300mM 
KCL, 50j.tM EDTA and 0.005% surfactant p20 (BlAcore) followed by a 90p1 injection of 
eIF4E in buffer C. eIF4E was injected over the chip in a series of injections that covered 
a concentration range from 0.005 to 5 p.M. This was then followed by an injection of 
450p.l of buffer C to allow dissociation of eIF4E. The chip was regenerated after each 
cycle using 50mM glycine pH 3.0 buffer. All measurements were performed at a flow 
rate of 30p.1/min at 25°C. The resulting sensograms were evaluated using the 
BlAevaluation package. The response from the SA chips (control) without immobilised 
4E-BPI motif peptide was subtracted from the chips with the peptide immobilised. The 
control chips were coated with free biotin to prevent non-specific binding of eIF4E. The 
resulting data was analysed using a two step model. 
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7.6 Mass spectrometry Materials and methods. 
7.6.1 Protein preparation for mass spectrometry studies. 
eIF4E purified via a monoQ column was adjusted to a concentration of 2mg/mi and 
dialysed over night, using slide-a-lyzers from Pierce, Ltd, into 10mM ammonium acetate 
pH 6.5. The protein concentration was then measured at A 2 80  using an extinction 
coefficient of 53440. All the samples were run on the mass spectrometer at a protein 
concentration of 3.2M. 
7.6.2 Electrospray ionisation mass spectrometry. 
ESI mass spectra were acquired using a single quadropole mass spectrometer (Micromass, 
Wyntheshawe, UK) equipped with a Z-spray electrospray ionisation source. The mass 
spectrometer has a m/z range of up to 3500. Samples were injected directly into the 
source using a Harvard Model 22 syringe at a flow rate of 5L min - '. The conditions 
used to obtain mass spectra of eIF4E and the various ligand complexes were capillary 
voltage, 3.5kV; cone voltage, 45V;source block temperature, 60°C; desolvation 
temperature, 90°C; extraction voltage, 4V; RF lens, 0.3V: Spectra were acquired in 
positive ion mode over a m/z range of 500 to 3500 in continuous mode, with a scan time 
of 12s. The ESI spectra shown in this work and those used for measurements of the 
intensities of ion peaks were subjected to background subtraction and were smoothed. 
This data manipulation was carried out in Mass Lynx version v3.5 (Micromass, 
Wyntheshawe, UK). 
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7.6.3 Preparation of cap-anlogue/eIF4E complexes. 
Cap-analogues (m7GTP, m7GDP, GTP, GDP, GMP, ATP, ADP, AMP, ribavirin, m7G 
and guanosine) were ordered and supplied from Sigma-Aldrich, Ltd. The ligands were 
dissolved in 10mM ammonium acetate pH 5.0 at stock concentration of 30mM. Serial 
dilutions in 10mM ammonium acetate pH 5.0 were made to prepare cap-analogues for 
use in ligand titrations against eIF4E. Samples to be run on the mass spectrometer were 
prepared as follows: 
Reagent Amount LConcentrationJ 
eIF4E XtL 3.2pM 
Ligand X1iL XtM 
Methanol 104L 10% 
Buffer (ammonium acetate) XiL 10mM 
Distilled water X.tL (make up to a 
lOOpL) 
In experiments were ammonium acetate concentrations were varied a 1 M stock was used 
at p1-I 5.0 and the required amounts added to generate concentrations between 10mM and 
500mM. In experiments were pH was varied different ammonium buffers at different 
pHs were used. Glacial acetic acid was used to pH the ammonium acetate buffers. eIF4E 
was run under denaturing conditions on the mass spectrometry by increasing the 
concentration of methanol to 50% and using an ammonium acetate buffer at pH 3.0. 
216 
7.6.4 Mass spectrometry based screening. 
Compounds were screened at two different concentrations against eIF4E at 1:3 and 1:5 
ratios unless described otherwise. The concentration of eIF4E being analysed in these 
samples was kept at 3.2pM. Running parameters of the mass spectrometer were 
maintained as in section 7.6.2. Compounds that were soluble in methanol were added to 
the sample as described in section 7.6.3 but the methanol concentration was maintained 
at 10%. For compounds only soluble in DMSO, methanol was maintained at a constant 
10% in the samples to be analysed, whilst DMSO concentration were kept as low as 
possible without precipitation occurring. DMSO control curves were run on apo eIF4E, 
GTP complexed with eIF4E (3.53p.M) and m7GTP (3.721iM) complexed eIF4E at 1% 
DMSO. Spectra were acquired as mentioned in section 7.6.2. 
7.6.5 Mass spectrometry data analysis. 
The experimental data, from the cap-analogue titrations against eIF4E, were shown by 
plotting SPeak intensity/(apo peak intensity+ complex peak intensity) against the 
concentration of the ligand being used. Peak corresponds to the peak of the charge 
species being analysed, i.e. apo or apo + one ligand or apo + two ligand. The term 
complex peak includes all peaks corresponding to the binding of ligand molecules in the 
charge species being analysed. The height of the peak intensities of the 11+ and 10+ 
charge species were used for the plot described and averaged out. These charge species 
were used as they comprised> 85% of the total signal seen for eIF4E at pH 5.0 and peak 
shifts corresponding to ligand binding were easily resolved. Intensity values were only 
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taken after acquired mass spectra had been treated with a polynomial background 
subtraction and smoothed using default values in Mass Lynx v3.5. Plots were created 
using SigmaPlot 9.0 (Systat Software Inc.). The same procedure was applied to 
studying the effect of pH on ligand binding. SPeak intensity/(apo peak intensity+ 
complex peak intensity) was plotted against pH instead of concentration. All data 
points for titrations concerning m7GTP, m7GDP, GTP, GDP and GMP were done in 
triplicate and error bars shown. All other analyses were not duplicated and no error bars 
shown. 
7.7 Data-mining for potential drug leads. 
7.7.1 Virtual screening of the eIF4E cap-binding site with LIDAEUS. 
The full-length human eIF4E structure complexed to m7GTP (1IPB) solved by Tomoo 
et a1 7 was used as the structural template for virtual screening runs. All waters and 
ligand molecules must be removed. A program called MAPSITE is used to generate 
map sites that LIDAEUS 8 uses in the initial stages of docking. MAPSITE requires a 
mol2 file of the ligand specifying where to make the site points and a PDB of the protein 
under study. Default parameters were used to run MAPSITE. The mo12 file produced 
by MAPSITE was then converted to a .clu file using the mol2clu utility program. The 
parameters of the pose.dat file, which controls the tolerance of the fit to the site points 
generated, was also maintained at the default settings. LIDAEUS 8 was then run and the 
top 250 best scoring compounds retained. 
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7.7.2 ISISBase searching for analogous quaternary ammonium ions to N7 in 
rn7GTP. 
ISISBase was used to search for compounds within the ACD (Available Chemical 
Database) by designing template ring systems that contained a charged nitrogen and then 
using the similarity search option to search for potential compounds. Levels of 
similarity specified in the search ranged from 30% to 50%. 
7.8 Synthesis of ligand cap-analogues and verification with mass spectrometry. 
7.8.1 Materials. 
Guanosine 5'-monophosphate, quinolene, isoquinolene and benzothiazole were ordered 
from Sigma-Aldrich, Ltd. All alkyl and aryl halides were also bought from Sigma-
Aldrich, Ltd. All chemical were of reagent grade or higher quality. 
7.8.2 Synthesis of cap-analogues. 
The 7-substituted GMP cap analogues were synthesized from GMP (Na, 0.28mM) and 
the corresponding alkyl halide (1mM) by the general method described earlier 910 
Reactants were incubated at room temperature for 48 h in 5m1 of DMSO, or in the case 
of quinolene, isoquinolene and benzothiazole in dichioromethane (DCM). Upon 
completion of the reaction, acetone was added, and free halide was removed by several 
washes with ethyl ether. After each wash the sample was centrifuged and the 
supernatant decanted off. 
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7.8.3 Verification of reaction products using mass spectrometry. 
Reaction product was taken and dissolved in 90% H20 and 10% methanol and analysed 
on a single quadropole mass spectrometer (Micromass, Wyntheshawe, UK) equipped 
with a Z-spray electrospray ionisation source. The mass spectrometer has a m/z range of 
up to 3500. Samples were injected directly into the source using a Harvard Model 22 
syringe at a flow rate of 20tL min - '. The conditions used to obtain mass spectra of the 
reaction products were capillary voltage, 3.5kV; cone voltage, 45V;source block 
temperature, 60°C; desolvation temperature, 90°C; extraction voltage, 4V; RF lens, 0.3V. 
Spectra were acquired in positive ion mode over a m/z range of 100 to 1000 with scan 
time of 5s. The ESI spectra shown in this work and those used for measurements of the 
intensities of ion peaks were subjected to background subtraction and were smoothed. 
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